

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
13 December 2001 (13.12.2001)

PCT

(10) International Publication Number
WO 01/94627 A2

(51) International Patent Classification⁷: **C12Q 1/68**

(21) International Application Number: **PCT/IB01/01213**

(22) International Filing Date: **8 June 2001 (08.06.2001)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
0014009.5 **8 June 2000 (08.06.2000) GB**

(71) Applicant (for all designated States except US): **DEV-GEN NV [BE/BE]**; Technologiepark 9, B-9052 Zwijnaarde (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **VERWAERDE, Philippe [FR/FR]**; 72, résidence Du Château D'Eau, F-59960 Neuville En Ferrain (FR). **BOGAERT, Thierry [BI/BE]**; Wolvendreef 26g, B-8500 Kortrijk (BE).

(74) Agents: **BALDOCK, Sharon, Claire et al.**; Boulton Wade Tennant, Verulam Gardens, 70 Gray's Inn Road, London WC1X 8BT (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG)
- of inventorship (Rule 4.17(iv)) for US only

Published:

- without international search report and to be republished upon receipt of that report
- with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **ASSAY TECHNIQUES BASED ON GROWTH STAGE DEPENDENT EXPRESSION INC. ELEGANS**

(57) Abstract: This invention is directed to new methods to perform assays with nematodes, and more particularly with microscopic nematodes such as *C. elegans*. In particular, the invention provides methods based on the use of growth-stage specific promoters to drive growth-stage specific gene expression.

WO 01/94627 A2

BEST AVAILABLE COPY

Assay techniques based on growth stage dependent expression in *C. elegans*.

This invention is directed to new methods to perform assays with nematodes, and more particularly with microscopic nematodes such as *C. elegans*.

5 The assay techniques described herein may *inter alia* be used for a variety of purposes, such as the discovery and development of compounds for pharmaceutical, veterinary and/or agrochemical use, the selection and isolation of mutant nematode strains, and may also be used for the specific expression of desired amino acid sequences, such as polypeptides and/or proteins, at various growth stages of the
10 nematodes, among others.

Other aspects, embodiments, applications and advantages of the present invention will become clear from the further description hereinbelow.

General techniques and methodology for performing *in vivo* assays using the nematode worm *Caenorhabditis elegans* (*C. elegans*) - i.e. as a model organism for
15 higher multicellular animals - have been described in the art, most notably in the following applications by applicant: PCT/EP99/09710 (published on 15 June 2000 as WO 00/34438); PCT/EP99/04718 (published on January 15, 2000 as WO/00/01846); PCT/IB00/00575 (published on October 26, 2000 as WO 00/63427); PCT/IB00/00557 (published on October 26, 2000 as WO 00/63425); PCT/IB00/00558 (published on
20 October 26, 2000 as WO 00/63426); as well as for instance PCT/US98/10080 (published on 19-11-1998 as WO 98/51351), PCT/US99/13650, PCT/US99/01361 (published on 29-07-1999 as WO99/37770), and PCT/EP00/05102.

As described in these applications, one of the main advantages of assays involving the use of *C. elegans* is that such assays can be carried out in multi-well plate
25 format (with each well usually containing a sample of between 2 and 100 worms) and - also because of this - may also be carried out in an automated fashion, i.e. using suitable robotics (as are described in the aforementioned applications and/or as may be commercially available). This makes assays involving the use of *C. elegans* ideally suited for the screening of libraries of chemical compounds, in particular at medium to high
30 throughput. Such automated screens may for instance be used in the discovery and/or development of new compounds (e.g. small molecules and/or small peptides) for pharmaceutical, veterinary or agrochemical/pesticidal (e.g. insecticidal and/or nematocidal) use.

Some other advantages associated with the use of *C.elegans* as a model organism (e.g. in the assay techniques referred to above) include, but are not limited to:

- *C. elegans* has a short life-cycle of about 3 to 4 days.

This not only means that these nematodes (and suitable mutants, transgenics and/or stable lines thereof) can be cultivated/generated quickly and in high numbers, but also allows assays using *C.elegans* to test, in a relatively short period of time and at high throughput, the nematode worms over one or more, and up to all, stages of life/development, and even over one or more generations. Also, because of this short life span, in *C.elegans* based-assays, compounds may be tested over one or more, and up to essentially all, stages of development, without any problems associated with compound stability and/or (bio)availability;

- *C. elegans* is transparent, allowing -with advantage- for visual or non-visual inspection of internal organs and internal processes, and also the use of markers such as fluorescent reporter proteins, even while the worms are still alive. Also, as further mentioned below, such inspection may be carried out in automated fashion using suitable equipment such as plate readers;
- *C.elegans* is a well-established and well-characterized model organism. For example, the genome of *C.elegans* has been fully sequenced, and also the complete lineage and cell interactions (for example of synapses) are known. In addition, *C.elegans* has full diploid genetics, and is capable of both sexual reproduction (e.g. for crossing) as well as reproduction as a self-fertilizing hermaphrodite. All this may provide many advantages, not only for the use of *C.elegans* in genetic and/or biological studies, but also for the use of *C.elegans* in the discovery, development and/or pharmacology of (candidate) drugs for human or animal use.
- Techniques for transforming, handling, cultivating, maintaining and storing (e.g. as frozen samples, which offers great practical advantages) *C. elegans* are well established in the art, for instance from the handbooks referred to below. For example, *C.elegans* may be used as a one or more samples with essentially fully isogenic genotype(s).

Generally, in the assays described above, the nematodes are incubated in suitable vessel or container - such as a compartment or well of a multi-well plate - on a suitable medium (which may be a solid, semi-solid, viscous or liquid medium, with liquid and viscous media usually being preferred for assays in multi-well plate format). The nematodes are then contacted with the compound(s) to be tested, e.g. by adding the

compound to the medium containing the worms. After a suitable incubation time (i.e. sufficient for the compound to have its effect - if any - on the nematodes), the worms are subjected to a suitable detection technique, i.e. to measure/determine a signal that is representative for the influence of the compound(s) to be tested on the nematode worms, which may then be used as a measure for the activity of the compound(s) in the in vivo assay. Often, such a signal will be based on and/or derived from (changes in) at least one biological, phenotypical, behavioural and/or biochemical property of the worm, such as drinking, pharynx pumping, movement, egg laying, mating or defecation (vide for instance PCT/IB00/00575). These properties are also generally referred to as
10 "(biological) read outs" of or for the assay.

Often, in particular for automated assays, such a detection technique involves a non-visual detection method (as further described in the applications mentioned above), such as measurement of fluorescence or another optical method, measurement of a particular marker (either associated with worms or associated with the medium) such as
15 an autonomous fluorescent proteins (AFP) for example green fluorescent protein (GFP), aequorin, alkaline phosphatase, luciferase, Beta-glucoronidase, Beta-lactamase, Beta-galactosidase, acetohydroxyacid, chloramphenicol acetyl transferase, horse radish peroxidase, nopaline synthase, or octapine synthase. For example, for automated assays carried out in multi-well plates, so called (multi-well) "plate readers" may be used
20 for detecting/measuring such a signal.

For a further description of the above and other assay techniques involving the use of nematodes as a model organism, reference is made to the prior art, such as the applications by applicant referred to above.

For general information on *C.elegans* and techniques for handling this nematode worm, reference is made to the standard handbooks, such as W.B. Wood et al., "*The nematode Caenorhabditis elegans*", Cold Spring Harbor Laboratory Press (1988) and
25 D.L. Riddle et al., "*C. ELEGANS II*", Cold Spring Harbor Laboratory Press (1997), and *Caenorhabditis elegans*, Modern Biological analysis of an organism: ed. by H. Epstein and D. Shakes, Methods in Cell Biology, Vol 48, 1995

30 Although the assay techniques described in the prior art mentioned above demonstrate the usefulness of *C. elegans* in a range variety of *in vivo* assays and for a variety of different purposes, there is an ever continuing need to develop further *C.elegans* based assays, in order to further broaden and expand the applicability of this model organism in drug discovery, development, testing and pharmacology.

The present invention provides such assay techniques, which, in addition to the advantages described hereinbelow, again have all the general advantages associated with the use of *C.elegans* as already described above.

In particular, the invention provides such assays, which are based on (changes
5 in) growth and/or development of the nematode as the biological read out.

The invention is *inter alia* based on the fact that the nematodes used show a number of very distinct stages of development, e.g. from egg to the subsequent development stages referred to as embryonic (early, mid, late), L1, L2, L3 and L4, respectively, to adult. In addition, and mainly depending on environmental factors such
10 as the absence of food, temperature, population and/or certain pheromones, the nematodes may optionally go into a specific and very distinctive stage called the "dauer-state" (which, although an optional stage of development, for the purposes of the present application is also considered a stage of life/development of the nematode).

Thus, more in particular, the present invention provides assay techniques which
15 have been specifically designed to make use of such transition(s) by *C.elegans* from a first stage of development to another (i.e. second, and usually subsequent) stage of development as a biological read out.

The invention is also based on the fact that certain genes within the genome of the nematodes are expressed only during some of these stages of development of the
20 nematodes, but not during some other stages. This is essentially because the promoters associated with these genes drive the expression of these genes in a manner that is dependent on the stage of development.

Some non-limiting examples of such "*development-dependent*" promoters, as well as the specific stage(s) of development in which they drive expression of their
25 associated gene(s), are mentioned in Table 1 below. Others may be found in the handbooks referred to above.

Table 1: Promoters with growth stage dependent expression in <i>C. elegans</i>		
glp-1	Very early embryonic stage	WBG* 13(2):22 (1feb, 1994)
unc-54	Mid-late embryonic stage	WBG 13(2):22 (1feb, 1994)
myo-2	Mid-late embryonic stage- adult	WBG 13(2):22 (1feb, 1994)
vit-2	Adult	WBG 13(2):22 (1feb, 1994)
lin-28	Embryonic-late L2	WBG 14(5):56 (1feb, 1997)
lin-4	Late L1-adult	<i>C.elegans</i> II :501-518
lin-14	Late embryonic- mid L1	WBG 11(3):46
col-7	L4-early adult	WBG (11)4:61
col-19	L4-early adult	WBG (11)4:61
col-17	Late embryonic-L3	WBG (11)4:61
ctl-1	Dauer	Nature 399:162-166
sod-3	Dauer	FASEB 13: 1385-1393

WBG*: worm breeders gazette

5 One promoter of particular interest for the purposes of the present invention is the vit-2 promoter, which specifically induces expression in the adult stage of the worm, and does so in a very stringent manner. The regulation and gene expression of the vitellogenin gene of *C. elegans* designated vit-2 promoter is well known, and the promoter region has been analyzed in detail. (MacMorris et al., Mol. Cell. Biol., 1992, 12:1652-1662; MacMorris et al., Mol. Cell. Biol., 1994, 14:484-491; Greenspoon et al.,
 10 worm breeder's gazette, 1988, 10:25).

In the present invention, the "development-dependent" promoters referred to above are used to provide transgenic (strains of) nematode worms, which strains can be used in the assay techniques of the invention.

15 Thus, although promoters that may provide for development-dependant expression in *C.elegans*, as well as transgenic *C.elegans* lines that use such promoters for development-dependant expression in *C.elegans* have been described in the art, so far, such promoters and transgenes have not yet been used in the art in (the design of)

assay techniques, in particular in (the design of) automated, high-throughput assay techniques.

Generally, to accomplish the present invention, the inventors have constructed transgenic nematodes which contain a growth stage dependent promoter operationally
5 linked to a marker gene, and have used this transgenic nematode to develop assays which can be configured for a high throughput setting. The speed of growth or the passage in one of the growth stages which is monitored by the expression of the marker gene which is only expressed in a specific growth stage is then the criteria for selection. Mutant nematodes, and chemically treated nematodes are known to show growth delay,
10 or even growth stage growth arrest. So this method allows for the selection of nematodes which growth faster or slower than the reference nematode. Particular descriptions and examples below are included to clarify this new method.

Thus, in a first aspect, the invention relates to a method for determining the influence of at least one exogenous factor on the development and/or growth of a
15 sample of nematode worms, said method comprising:

a) providing a sample of nematode worms,

which nematode worms contain a marker gene operably linked to a promoter,
which promoter is capable of driving the expression of the marker gene in
the nematode worms such that the marker gene is not expressed in at
20 least a first development stage of the nematodes, but is expressed in at
least a second development stage of the nematodes (different from the
first life stage);

b) exposing said sample of nematode worms to at least one exogenous factor;

c) maintaining/cultivating said sample of nematode worms in a suitable medium,
25 optionally over one or more life stages and/or generations;

d) subjecting the sample of nematode worms to at least one detection technique that is
capable of detecting the signal generated by the marker gene (if expressed).

The nematodes used are preferably from the genus *Caenorhabditis*, such as
Caenorhabditis briggsae or *Caenorhabditis elegans*.

30 The sample of nematodes may comprise any suitable number of worms,
depending on the size of the container/vessel used. Usually, the sample will comprise
between 2 and 500, in preferably between 3 and 300, more preferably between 5 and
200, even more preferably between 10 and 100 nematodes. When the assay is carried
out in multi-well plate format, each well usually contains between 15 and 75 worms, such

as 20 to 50 worms. Although not preferred, it is not excluded that a sample may consist of a single worm.

Usually, each such individual sample of worms will consist of worms that - at least at the start of the assay - are essentially the same, in that they are of the same strain, in that they contain the same mutation(s), in that they are essentially of an isogenic genotype, in that they show essentially the same phenotype(s), in that they are essentially "synchronised" (i.e. at essentially the same stage of development; it should however be noted that this stage of development may - and usually will - change during the course of the assay), in that they have been grown/cultivated in essentially the same way, and/or in that they have been grown under and/or exposed to essentially the same conditions, factors or compounds, including but not limited to pheromones, gene suppression (such as by RNAi), gene- or pathway-inducing factors or (small) molecules, and/or gene- or pathway-inhibiting factors or (small) molecules, and/or mutagenesis. However, in its broadest sense, the invention is not limited thereto.

In step a), when the sample of nematodes is initially provided, it is preferably such that the nematodes are essentially all in the first development stage.

Preferably said first development stage is such that it precedes the second development stage, in which said first development stage and said second development stage may or may not be separated (i.e. in time) by one or more further, intermediate development stages. For example, the first development stage may be L1, and the second development stage may be adult, with L2, L3, and L4 being intermediate development stages.

Preferably, the first development stage is chosen from eggs, an embryonal stage, L1, L2, L3, L4, or dauer; with eggs, embryonal stages, L1, L2 and dauer being particularly preferred, and L1 being the most preferred.

The second development stage is preferably a development stage subsequent to the first development stage (which may also be, if the first stage is dauer, any stage following escape from dauer) and is preferably chosen from L4, adult or dauer, and more preferably from adult or dauer, dependant on the choice of the first development stage. However, as can also be seen from Table 2 below, which lists some preferred combinations of first development stage, second development stage and promoter, the invention is not limited strictly thereto.

Table 2: some preferred combinations of first development stage, second development stage and promoter.

Promoter	First stage	Second stage
glp-1	L1, L2, L3, L4, dauer, (adults)	very early embryonic stage (eggs)
unc-54	L1, L2, L3, L4, dauers, (adults)	mid-late embryonic stage (eggs)
myo-2	Very early eggs	mid-late embryonic stage-adult
vit-2	Eggs, L1, L2, L3, (L4, dauer)	Adult
lin-28	L4, dauer, adult (L3)	Embryonic-late L2
lin-4	Eggs	late L1-adult
lin-14	L3, L4, adult, dauer, (L2)	late embryonic- mid L1
col-7	Eggs, L1, L2, dauer, (L3)	L4-early adult
col-19	Eggs, L1, L2, dauer, (L3)	L4-early adult
col-17	Adult, dauer, (L4)	Late embryonic-L3
ctl-1	Eggs, L1, (L2, L3, L4, adult)	Dauer
sod-3	Eggs, L1, (L2, L3, L4, adult)	Dauer

5

In the assays of the invention, the nematodes may be kept in or on any suitable medium, including but not limited to solid and semi-solid media - but are preferably kept in a suitable liquid or viscous medium (e.g. with a viscosity at the temperature of the assay that is equal to a greater than the viscosity of M9 medium, as measured by a suitable technique, such as an Ubbelohde, Ostwald and/or Brookfield viscosimeter).

10

Generally, suitable media for growing/maintaining nematode worms will be clear to the skilled person, and include for example the media generally used in the art, such

as M9 (10 X M9 buffer: 30 g KH_2PO_4 , 75.212 g $\text{Na}_2\text{HPO}_4 \cdot 2\text{H}_2\text{O}$, 50 g NaCl, 10 ml 1M MgSO_4 , add up to 1 L), S-buffer (5.9 g NaCl, 50 ml 1M KH_2PO_4 , 1ml 5g/L cholesterol, add up to 1 L), and the further media described in the applications and handbooks mentioned hereinabove.

5 The medium may further contain all factors, compounds and/or nutrients as may be required for the survival, maintenance and/or growth of the worms. For this, reference is again made to the prior art, such as the applications and handbooks referred to above. The medium may also contain a suitable source of food for the worms such as bacteria, for example a suitable strain of *E.coli* in a suitable amount, e.g. between 0.001 and 10
10 % (w/v), preferably between 0.01 and 1%, more preferably between 0.1 and 0.2 %, such as about 0.125 % w/v. In one specific embodiment, further described below, said bacteria may also contain or express a double stranded RNA (construct), intended for specific gene down regulation in the nematode worm, e.g. by means of RNA-interference (vide PCT/EP99/04718)

15 The assay may be carried out at a suitable temperature, which may for example be a temperature of between 10°C and 30 °C, preferably between 20°C and 27 °C, such as 21, 22, 23, 24, 25 or 26°C, depending on the specific strain used. The temperature may be kept essentially constant during the course of the assay, and/or may be varied, e.g. within the ranges indicated above.

20 In the method of the invention, the sample of nematodes can be kept - e.g. maintained, grown or incubated - in any suitable vessel or container, but is preferably kept in a well of a multi-well plate, such as a standard 6, 24, 48, 96, 384, 1536, or 3072 well-plate (in which each well of the multi-well plate may contain a separate sample of worms, which may be the same or different). Such plates and general techniques and
25 apparatus for maintaining/ handling nematode worms in such multi-well plate format are well known in the art, for instance from the applications mentioned hereinabove.

 The method/assay of the invention is preferably carried out in an automated fashion, e.g. using the equipment and techniques described in the applications mentioned above.

30 In the invention, a nematode strain is used that contains a marker gene that is operably linked to a promoter, which promoter is capable of driving the expression of the marker gene in the nematode worm(s) such that the marker gene is not expressed in at least a first development stage of the nematodes, but is expressed in at least a second development stage of the nematodes (different from the first development stage).

As already indicated hereinabove, such promoters are also referred to herein as "development-dependent" promoters, and some preferred examples have been given above.

A particularly preferred development-dependent promoter is the vit-2 promoter.
5 An operational fusion of a DNA sequence (gene, cDNA) with the vit-2 promoter allows for the expression of this DNA sequence in the adult stage of *C. elegans*, and not in the other life stages of *C. elegans* such as the L1, L2, L3, and L4 larvae stages and the dauer stages.

In the present disclosure, two or more nucleotide sequences, such as a promoter
10 and a marker gene, are considered "operably linked" when they are in a functional relationship with each other. For instance, the development-dependent promoter is considered "operably linked" to the marker gene if said promoter is able to initiate or otherwise control/regulate the transcription and/or the expression of said marker gene, in particular in a development-dependent manner (and in which said marker gene should
15 be understood as being "under the control of" said promoter). Generally, when two nucleotide sequences are operably linked, they will be in the same orientation and usually also in the same reading frame. They will usually also be essentially contiguous, although this may also not be required.

The marker gene may be any gene which, upon expression in *C. elegans* - i.e.
20 under the control of the development-dependent promoter - provides a signal that can be detected, e.g. visually or preferably by the automated, non-visual detection techniques referred to above.

For example, the marker gene may be chosen from green fluorescent protein, beta-galactosidase, beta-lactamase, luciferase, acetohydroxyacid synthase, alkaline
25 phosphatase, beta-glucuronidase, chloramphenicol acetyltransferase, horseradish peroxidase, nopaline synthase and/or octopine synthase. Other suitable marker genes will be clear to the skilled person, and are for instance described in the applications referred to above.

In a specific embodiment, the gene may be a toxic gene, e.g. a gene that
30 encodes a gene product that is toxic (e.g. lethal) to the nematode. Thus, another application of the invention consists in the conditional expression of putative toxic genes, and in the conditional expression genes, to be expressed in specific growth stage in nematodes such as *C. elegans*. When toxic genes are expressed in nematode at any growth stage, and surely in the early development of the nematode, this will have

dramatic influences on the further development and vitality of the nematode. It may be opportune to express such genes in a particular growth phase of the worm, such as the L1, L2, L3, L4, adult or dauer stages. Such transgenic nematodes have more chance to survive the expression of the toxic gene and may be used for further analysis, for instance in a HTS assay, screening for compounds, mutants, etc. Some preferred, but non-limiting examples of such toxic genes are ataxin, alpha-synuclein, ubiquitin, the tau gene, the huntington gene, the best macular dystrophy gene product, unc-53; others are mentioned in the applications referred to above.

The nematode strain used in the invention may generally be provided by transforming a suitable nematode strain with a nucleotide sequence that comprises the marker gene under the control of the development-dependent promoter. Preferably, said nucleic acid sequence is in the form of a genetic construct, which may be DNA or RNA (and are preferably double-stranded DNA) and which is preferably in a form suitable for transformation of the nematode strain used. For example, it may be in the form of a construct that, upon transformation, is integrated in the genomic DNA of the nematode, and/or may be in a form suitable for independent replication, maintenance and/or inheritance in the nematode. Preferably, the construct is also such that it is capable of independent replication, maintenance and/or inheritance in the (micro-) organism used for cloning, such as *E. coli*. For instance, said genetic construct may be in the form of a plasmid, vector, viron or transposon.

The genetic construct(s) used in the invention may further contain - i.e. besides the nucleotide sequences encoding the development-dependent promoter and the marker gene - one or more further suitable elements of genetic constructs known per se, including but not limited to selection markers and/or elements that may facilitate or increase (the rate of) transformation or integration. These and other suitable elements for such genetic constructs will be clear to the skilled person, also from the applications referred to above.

The constructs of the invention can be provided in a manner known per se, which will generally involve techniques such as restricting and linking nucleic acids/nucleic acid sequences, as will be clear to the skilled person. Reference is made to the standard handbooks, such as Sambrook et al, "Molecular Cloning: A Laboratory Manual" (2nd.ed.), Vols. 1-3, Cold Spring Harbor Laboratory Press (1989) and F. Ausubel et al, eds., "Current protocols in molecular biology", Green Publishing and Wiley Interscience, New York (1987). The nucleic acids encoding the development-dependent promoters

and marker genes used in the invention have been described in the art and can be provided in the manner described therein.

The nematodes may be transformed with the constructs in any suitable manner, such as micro-injection or ballistic transformation, for which reference is made to the handbooks referred to above, as well as for instance in PCT/EP99/01903 (published as WO 99/49066)

The nematode strain that is transformed with the nucleotide sequence encoding the marker gene/development-dependent promoter - i.e. to provide a nematode strain useful in the assay of the invention - is not particularly limited, and may for instance be any nematode strain known per se, such as wildtype, N2 or hawaiian (CB4856, Hodgkin et al., Genetics146:149-164, 1997). Also, specific mutant nematode strains or lines and transgenic strains or lines may be used which are particularly suited/adapted for transformation and/or the specific transformation technique used, or if they are desired in the assay.

In one embodiment, before use in the present assays, the nematodes are subjected to random or specific mutagenesis. Thereupon, the different strains resulting from the mutagenesis may be tested in the assay(s) of the invention, and optionally may be compared to the original strain and/or to a(nother) reference strain. This may be done with and/or without exposure to the exogenous factor(s) and may for instance be used to identify genes and/or mutations that influence the development and/or growth of the nematodes, and/or to identify genes and/or mutations which alter or influence the response of the nematodes (i.e. with respect to development and growth) to the exogenous factors. For example, when a mutation in a gene leads to a marked change in development and/or growth (as determined using the assay(s) of the invention), or leads to a markedly different response to the exogenous compound(s), it may be concluded that said gene is involved in development or growth and/or in the response of the nematode to the exogenous factor(s). In this way, the assays of the invention may for instance be used to determine the function of (known or unknown) genes (for instance as part of a functional genomics program) and/or to determine the mode of action of the exogenous factor(s).

In step b), a sample of nematodes containing the marker gene under the control of the development-dependent promoter is exposed to the exogenous factor(s) to be tested. This may be carried out while the nematodes in the sample are (still) in the first stage of development, and/or in any subsequent stage(s) of development. Preferably,

however, the sample of nematodes is exposed to the at least one exogenous factor in at least one stage of development which precedes the second stage of development (however, it should be noted that the invention does not exclude that the sample of nematodes is still in contact with the exogenous factor(s) while the nematodes transit into and/or are in the second stage of development).

For example, the nematodes may be exposed to the exogenous factor(s) in only a single stage of development (such as only in the first stage or only in a subsequent stage that precedes the second development stage), in two or more stages (which may include the first stage, any subsequent stage(s) and/or the second stage), or essentially continuously throughout the duration of the assay.

Thus, generally, the nematodes may be exposed to the exogenous factor(s) during a time of 1 minute up to the entire life (cycle) of the nematodes, and/or to the duration of the assay. Usually, a contact time of between 5 minute and 110 hours, preferably between 10 minutes and 80 hours will be preferred.

The total time for the assay will preferably be such that it is sufficient to allow at least one of the nematodes in the sample to transit from the first development stage into a subsequent development stage, and more preferably sufficient to allow at least one of the nematode worms in the sample to enter from the development stage into the second development stage, optionally via any (further) intermittent stages of development

For example, in step c), the sample of nematode worms may be maintained/cultivated for a time such that at least 1%, preferably at least 5%, of the nematode worms present in the sample enter from the first development stage into at least one other/further development stage.

Also, for example, in step c), the sample of nematode worms may be maintained/cultivated for a time such that at least 1%, preferably at least 5%, of the nematode worms present in the sample enter from the first development stage into the second development stage.

Often, the total time for the assay will be at least such that it would allow at least one of the nematode worms present in a reference sample - i.e. a sample not containing any exogenous factor(s) - to enter from the first development stage into the second development stage, optionally via any (further) intermittent stages of development.

For example, for assays from the following first development stage to the following second development stage, the total time of the assay can be as follows: from eggs to adults: 45 to 110 hours; from L1 to adults: 30 to 80 hours; from eggs to L1: 13 to

30 hours; from L1 to L2: 13 to 25 hours; from L2 to L3: 8 to 20 hours; from L3 to L4: 8 to 15 hours; from L4 to adult: 8 to 25 hours; for assays involving dauer as the first or second stage: between 8 and 72 hours (depending on the strain used, temperature and food quality, nematodes will generally enter the L1 growth stage between 13 and 30 hours, the L2 growth stage between 24 and 55 hours, the L3 growth stage between 30 and 70 hours, the L4 growth stage between 38 and 85 hours, and the adult stage between 45 and 110 hours, starting from eggs).

During the duration of the assay, the sample may be subjected to the - preferably non-visual - detection method for determining/measuring the expression of the marker gene essentially continuously during the entire duration of the assay, essentially continuously during one part of the duration of the assay (usually the latter part, when the nematodes are considered likely to enter the second stage of development, e.g. during the last 24, 12, or even 6 hours of the duration of the assay), at regular intervals, or any combination thereof.

In the assays of the invention, each individual sample of nematode worms will generally be exposed to a single exogenous factor to be tested, at a single amount or concentration; with different samples (e.g. as present in the different wells of the multi-well plate used) being exposed either to different concentrations of the same factor (e.g. to establish a dose response curve for said factor), to one or more different factors (e.g. in the case of compounds for instance are part of a chemical library and/or of a chemical class or series, such as a series of closely related structural analogues; or in case of a library or series of dsRNA constructs for RNAi), or both (e.g. to the same and/or different factors at different concentrations).

It is also within the scope of the invention to expose the (sample of) nematodes to two or more factors - at essentially the same time or sequentially (e.g. with an intermediate washing step) - for example to determine whether the two factors have an effect which is the same or different from both the factors separately (e.g. to provide a synergistic effect or an inhibitory or competitive effect).

Furthermore, it is within the scope of the invention to use one or more reference samples, e.g. samples without any factor(s) present, and/or with a predetermined amount of a reference factor. The invention also includes the use, in an assay, of two or more samples of nematode worms of different strains (e.g. each containing a marker gene under the control of a (different) development-dependent promoter), e.g. to compare (the effect of the factors(s) to be tested on) said different strains.

In one specific embodiment, which is referred to herein as an "FPTP-type assay", each sample of a series of two or more essentially similar samples of nematode worms (e.g. containing the same development-dependant promoter, preferably the same marker gene - although this is not strictly required - and preferably comprised of worms in the same stage of development) is exposed, in essentially the same manner (e.g. time and conditions, but optionally at different concentrations), to (a) different exogenous factor(s), and optionally to one or more reference factors. Thereupon, the order in which the nematodes present in each of these samples enter the second development stage is determined, i.e. by determining the order in which the samples of the series show expression of the marker gene (i.e. which sample shows the expression of the marker gene first, second, third, etc.). Inter alia, this allows the different factors present in each of the samples to be compared and/or ranked according to their influence on the development/growth of the nematode, and also compared to the reference factor(s). This for instance allows the identification of factors with an influence on the nematodes comparable to, or even improved compared to, the influence of the reference factors. Generally, such FPTP-assays will involve determining the (possible) expression of the marker gene in the series of samples essentially continuously, at least during the last 36, 24, 12, or 6 hours of the assay.

Thus, in a specific embodiment, the invention relates to a method for determining the influence of at least a first exogenous factor on the development and/or growth of a sample of nematode worms, said method comprising:

- a) providing at least a first and a second sample of nematode worms, in which the nematode worms in each sample contain a marker gene operably linked to a promoter,
 - 25 which promoter is capable of driving the expression of the marker gene in the nematode worms such that the marker gene is not expressed in at least a first development stage of the nematodes, but is expressed in at least a second development stage of the nematodes (different from the first life stage);
- 30 b) exposing at least said first sample of nematode worms to said first one exogenous factor;
- c) maintaining/cultivating said samples of nematode worms in a suitable medium, optionally over one or more life stages and/or generations;

- d) subjecting the samples of nematode worms to at least one detection technique that is capable of detecting the signal generated by the marker gene (if expressed);
- e) determining the time required for the first sample of nematode worms to show expression of the marker gene (as determined by the signal detected for the first sample in step b)), and preferably also determining the time required for the second sample of nematode worms to show expression of the marker gene (as determined by the signal detected for the second sample in step b)); and/or comparing the time required for the first sample of nematode worms to show expression of the marker gene with the time required for the second sample of nematode worms to show expression of the marker gene.

In one aspect, the second sample of nematode worms will be a reference sample, e.g. a sample of worms that is not exposed to any exogenous factor, or to a known reference factor. The second sample may also be exposed to a second exogenous factor, e.g. to compare the first and the second factor.

Generally, as already indicated above, the assay according to this aspect of the invention will involve the use/testing of a series of samples, e.g. more than 5, preferably more than 10, such as about 6, 24, 48, 96, 384, 1536, or 3072 (i.e. essentially the number of wells of a multi-well plate), each sample being exposed to a different factor and/or to a different concentration of factor (including any reference samples), and the samples than being ranked as described above.

Usually, to allow for a good comparison between the samples/factors, all samples will be essentially similar (as described above) and cultivated/maintained in an essentially similar manner. These FPTP-assays may further be carried out in essentially the manner described herein.

In all the assays described above, the exogenous factor may be any factor the influence of which on the growth/development of nematode worms is to be tested. The exogenous factors may for instance be chosen from small compounds (as defined below), small peptides (as defined below), factors which induce or suppress specific pathways in the worm, factors which induce or suppress (the expression of) specific genes in the worm (such as dsRNAi for RNA-interference), polypeptide and/or proteins, or extracts from natural products (such as plants, animals, fungi, bacteria), amino acids and derivatives, hormones and derivatives, nucleic acids and derivatives.

For the purposes of the present disclosure, a "small molecule" generally means a molecular entity with a molecular weight of less than 1500, preferably less than 1000.

This may for example be an organic, inorganic or organometallic molecule, which may also be in the form of a suitable salt, such as a water-soluble salt.

The term "small molecule" also covers complexes, chelates and similar molecular entities, as long as their (total) molecular weight is in the range indicated above.

5 In a preferred embodiment, such a "small molecule" has been designed according, and/or meets the criteria of, at least one, preferably at least any two, more preferably at least any three, and up to all of the so-called Lipinski rules for drug likeness prediction (vide Lipinski *et al.*, *Advanced Drug Delivery Reviews* 23 (1997), pages 3-25). As is known in the art, small molecules which meet these criteria are particularly suited
10 (as starting points) for the (design and/or) development of drugs (e.g) for human use, e.g. for use in (the design and/or compiling of) chemical libraries for (high throughput screening), (as starting points for) hits-to-leads chemistry, and/or (as starting points for) lead development.

In a preferred embodiment, such a "small molecule" has been designed
15 according, and/or meets the criteria of, at least one, preferably at least any two, more preferably at least any three, and up to all of the so-called Lipinski rules for rational drug design (vide Lipinski *et al.*, *Advanced Drug Delivery Reviews* 23 (1997), pages 3-25). As is known in the art, small molecules which meet these criteria are particularly suited (as starting points for) the design and/or development of drugs (e.g) for human use

20 Also, for these purposes, the design of such small molecules (as well as the design of libraries consisting of such small molecules) preferably also takes into account the presence of pharmacophore points, for example according to the methods described by I. Muegge *et al.*, *J. Med. Chem.* 44, 12 (2001), pages 1-6 and the documents cited herein.

25 The term "small peptide" generally covers (oligo)peptides that contain a total of between 2 and 35, such as for example between 3 and 25, amino acids (e.g. in one or more connected chains, and preferably a single chain). It will be clear that some of these small peptides will also be included in the term small molecule as used herein, depending on their molecular weight.

30 Thus, the methods of the invention may in particular be used to test and/or screen (libraries of) such small molecules and/or peptides, in the manner as further outlined herein.

According to another embodiment, the exogenous factor is a factor that suppresses or enhances the expression of one or more genes in the nematodes used. In

one preferred example, this factor may be a dsRNA, which may be used for gene suppression in accordance with well-known RNA-interference techniques. Such dsRNA may for instance be provided to the nematode worms in the manner described in PCT/EP99/04718 (published as WO 00/01846) or PCT/US98/27233 (published as WO 99/32619), e.g. by injection of dsRNA or by feeding of bacteria containing/expressing the dsRNA to the nematode. In this latter embodiment, for example, the effect(s) of the suppression of one or more gene(s) on the growth or development of the nematode worms and/or on the response of other exogenous factors, may be determined.

The nematodes may be exposed to the exogenous factor in any suitable manner, such as by incorporating the exogenous factor in the medium in which the nematode worms are grown/maintained or by incorporating the nematode worms in the food of the nematodes (e.g. in the case of dsRNA for RNAi purposes).

The nematode worms may take up the exogenous factor in any suitable manner, such as by drinking, feeding, soaking, pharynx pumping, or in any other suitable way, e.g. either through (a part of) the gastrointestinal tract, the cuticle and/or through openings in the cuticle, and either through an active or passive uptake mechanism, or any combination thereof.

When the exogenous factor is a compound, it will usually be used in step b) at a concentration of between 0.1 nanomolar and 100 milimolar, preferably between 1 nanomolar and 50 milimolar, more preferably between 10 nanomolar and 10 milimolar, even more preferably between 100 nanomolar and 5 milimolar, in particular between 1 micromolar and 1 milimolar, even more particular between 10 micromolar and 600 micromolar, most particular between 20 micromolar and 500 micromolar, such as about 30 micromolar for compound selection screens and about 300 micromolar for compound resistance screens.

For dsRNA, suitable amounts will be as described in the PCT/EP99/04718 (published as WO 00/01846) or PCT/US98/27233 (published as WO 99/32619).

The assay techniques of the invention may be used for several different applications, some non-limiting examples of which will now be further described.

A first application is to identify and select chemical entities that may be used in the development of pharmaceutical products, veterinary products, and pesticides. In this respect, it should also be noted that the invention may not just be used to identify exogenous factors (such as compounds) which directly influence development and/or growth, but also compounds which influence other behavioural, biological, phenotypical

and/or biochemical processes which in turn influence growth and/or development, such as metabolic processes, feeding/drinking behaviour and/or (other) processes which are controlled by the central nervous system or other nerve cells.

Thus, the invention may also be used to identify compounds which may influence
5 metabolic processes and neuron-controlled processes, not just in nematodes, but also in higher animals including humans and other mammals, for which the nematode is used as a model organism. Thus, the assays of the invention may be used in the discovery and/or development of pharmaceuticals and/or veterinary products.

Also, exogenous factors such as compounds which, in the assays of the
10 invention, retard growth and/or development may find use in the development of novel insecticides or other pesticides (including but not limited to nematocides).

Another application is to identify and select new mutants, and further on isolating the genes which are mutated. This genes and the proteins they encode for are then considered as putative target genes and/or members of biochemical pathways. In a
15 specific variant of this objective, mutants are selected that show resistance to a chemical compound, and once again the final objective is to isolate the mutated gene.

A third possible application is related to the isolation of genes, and the proteins they encode for by dsRNA inhibition (RNAi). The isolated genes and the proteins they encode for are considered as putative target genes, members of biochemical pathways,
20 resistance.

In the development and performance of HTS assays with nematodes, the synchronicity of the animals is of major importance, i.e. nematodes used in the assay need to be at the same growth stage. Although several methods have been developed to grow a culture of nematodes at the same speed, while they are in the same growth
25 stage, aberrations are usual. The present invention also offers a solution to this problem. As the nematodes described in this invention express marker genes at a certain growth stage, the nematodes in a culture at the same growth stage can easily be detected and isolated prior to the HTS assay. Moreover several machines are presently available that allow to select automatically nematodes which have common features (such as
30 expressing a green fluorescent proteins). An example of such machine, generally designated as a worm dispensers or FANS (Fluorescence Activated Nematode Sorter), is provided by UBI (Union, Biometrica, USA). The methods allows the inventors to select nematodes which are in a specific growth stage, such growth stage may for example be, eggs, L1, L2, L3, L4, Adult or dauer growth stage.

In another aspect, the invention relates to the use of a (sample of at least one) nematode worm, which nematode worm contains a marker gene operably linked to a promoter, which promoter is capable of driving the expression of the marker gene in the nematode worms such that the marker gene is not expressed in at least a first
5 development stage of the nematodes, but is expressed in at least a second development stage of the nematodes (different from the first life stage), in a method or assay for determining the influence of at least one exogenous factor on the development and/or growth on a nematode worm.

In a particular aspect, the invention relates to the use of a (sample of at least
10 one) nematode worm in an FFTP assay as described above.

The invention will now be further illustrated by means of the following non-limiting Figures and Examples. The Figures show:

- Figure 1: Nucleotide sequence of pGQ1
- Figure 2: Nucleotide sequence of PCLUC6
- 15 - Figure 3: Nucleotide sequence of pGQ2
- Figure 4: Nucleotide sequence of pGN156
- Figure 5: Nucleotide sequence of pGQ3
- Figure 6: Nucleotide sequence of pGQ4
- Figure 7: Nucleotide sequence of the vit-2 promoter/NLS as present plasmid
20 pPM143
- Figure 8: Schematic drawing of pGN156
- Figure 9: Schematic drawing of pGQ1
- Figure 10: Schematic drawing of pGQ2
- Figure 11: Schematic drawing of pCLUC6
- 25 - Figure 12: Schematic drawing of pGQ3
- Figure 13: Schematic drawing of pGQ4
- Figure 14 : Stage specific expression of LacZ (C. elegans harboring pGN156) after one hour of probe addition.
- Figure 15 : Stage specific expression of LacZ (C. elegans harboring pGN156) after
30 two hours of probe addition.
- Figure 16: Stage specific expression of LacZ (C. elegans harboring pGN156) after three hours of probe addition.
- Figure 17: Expression of LacZ in function of the number of nematodes (C. elegans harboring pGN156).

- Figure 18: Fluorescence activity of adult nematodes (*C. elegans* UG1513) in flat bottom wells in function of the number of wells
- Figure 19 : Fluorescence activity of adult nematodes (*C. elegans* UG1513) in U-Shaped wells in function of the number of wells

5

Strain *C. elegans* UG1353 (pGN156) is deposited under accession number: "LMBP 5719CB", at the Belgian Coordinated Collection of Microorganisms (BCCM), Laboratorium voor molecular Biology-plasmidencollectie (LMBP) University of Ghent, K.L. Ledeganckstraat 35, 9000 Ghent, Belgium, according to the Budapest treaty of 28 April 1977 on the international recognition of the deposit of microorganisms for the purpose of patent procedures.

10

Examples:

- 15 Example 1: Construction of plasmids which allow for the expression of markers in a specific growth stage.

1) Construction of pGQ1 (ctl-1::GFP vector) (Figure 1, 9)

- 20 PCR was performed on genomic DNA isolated from *C. elegans* wild-type strain N2 under standard conditions with following primers:

oGQ1:

5'AAACTGCAGCCAATGCATTGGAAGAGATATTTTGC GCGTCAAATATGTTTTGTGT
CC3'

- 25 oGQ2:

5'CGCGGATCCGGCCGATTCTCCAGCGACCG3'

The PCR fragment was isolated and cloned as a PstI/BamHI fragment in pDW2020, resulting in pGQ1.

- 30 2) Construction of pGQ2 (ctl-2::luciferase vector) (Figure 3, 10)

PCR was performed on genomic DNA isolated from *C. elegans* wild-type strain N2 under standard conditions with following primers:

oGQ3:

5'CCAGGCCTGAGATATTTTGC GCGTCAAATATGTTTGTGTCC3'

oGQ4:

5'CGGAGCTCCGATTGGATGTGGTGAGCAGG3'

The PCR fragment was isolated and cloned as a *Stu*I/*Sac*I fragment in pCluc6, resulting in pGQ2.

3) Construction of pGQ3 (*sod-3*::GFP vector) (figure 5, 12)

PCR was performed on genomic DNA isolated from *C. elegans* wild-type strain N2 under standard conditions with following primers:

oGQ7: 5'GCAGAATTTGCAAAACGAGCAGGAAAGTC3'

oGQ6: 5'TTGCGCGCCAAAGCCTTAATAGTGTCCATCAGC3'

The PCR fragment was isolated and cloned as a *Pst*I/*Asc*I fragment in pDW2020, resulting in pGQ3.

4) Construction of pGQ4 (*sod-3*::luciferase vector) (Figure 6, 13)

PCR was performed on genomic DNA isolated from *C. elegans* wild-type strain N2 under standard conditions with following primers:

oGQ7: 5'GCAGAATTTGCAAAACGAGCAGGAAAGTC3'

oGQ8: 5'CTGAGCTCGGCTTAATAGTGTCCATCAGC3'

The PCR fragment was isolated and cloned as a *Pst*I/*Cac*III fragment in pCluc6, resulting in pGQ4.

5) Construction of pCluc6 (*vit-2*::Luciferase vector) (Figure 2, 11)

PCR was performed on genomic DNA isolated from *C. elegans* wild-type strain N2 under standard conditions with following primers:

vit-2F: 5'CCCCCAAGCTTCCATGTGCTAGCTGAGTTTCATCATGTCC3'

vit-2R: 5'CCCCCAAGCTTGGCTGAACCGTGATTGG3'

The PCR fragment was isolated and cloned as a *Hind*III fragment in pCluc2, resulting in pCluc6.

6) Construction pGN156 (vit-2::lacZ vector) (Figure 4, 8)

The LacZ fragment of pPD95.4 (Fire et al, Gene Gene. 1990 Sep 14;93(2):189-98) was isolated as a SfuI/Spel fragment and cloned in pPM143 (MacMorris et al., Gene expression vol. 3 no. p27, 1993) digested with the same enzymes, resulting in vector pGN156.

10 Example 2: Construction of *C. elegans* nematodes harboring the plasmids described above, and construction of stable integrated lines.

Each of the vectors was injected into *C. elegans* nematode worms using standard techniques as described in one of the references above. All the constructed transgenic strains showed the desired marker gene expression pattern, in a heritable way. Stable integrated line were constructed, an example is given for the integration of pGN156 (vit-2::lacZ):

- 1) *C. elegans* wild-type N2 nematodes have been injected with various concentrations of pGN156, reference and selection plasmid pGR6 (myo2::GFP), and carrier DNA (pUC18)
- 2) A good heritable strain was selected from the injection with 25ng pGN156, 5ng pGR6, 80 ng pUC18. Approximately 60 animals were gamma-irradiated (3000rad; 16x16 cm², 50 cm, 82.2 min) after which each worm was placed on a single plate and allowed to growth for offspring growth. Approximately 560 F1 offspring worms expressing GFP were placed each on a single plate, and allowed to grow. From The F2 generation, worms were again placed on single plates, and finally the F3 generation was checked for its GFP expression. The strains were then out-crossed with wild-type strain N2 to eliminate undesirable mutations, and checked for LacZ expression.
- 3) 6 selected nematodes, wherein pGN156 is integrated, were grown. From each culture, 10 nematodes were placed in the well of a 96 well plate, 25 µl M9 buffer (see above), 25 µl 60% ice cold Methanol, and 50 µl 20mM C12FDG probe (molecular probes) was added, the wells were further incubated for 2h at 37°C and

fluorescence was measured in a plate reader with following settings: ex/em:
485nm/535nm

- 4) One of the six strains showed high viability, strong GFP expression and relatively high LacZ expression and was selected for further analysis

5

This strain, designated *C. elegans* UG1353 (pGN156) is deposited under accession number: "LMBP 5719CB", at the Belgian Coordinated Collection of Microorganisms (BCCM), Laboratorium voor molecular Biology-plasmidencollectie (LMBP) University of Ghent, K.L. Ledeganckstraat 35, 9000 Ghent, Belgium, according to the Budapest treaty of 28 April 1977 on the international recognition of the deposit of microorganisms for the purpose of patent procedures.

10

Example 3: LacZ-staining of an increasing number of *C. elegans* UG1353 (pGN156)

- 15 Transgenic nematodes, in various quantities per well, were dispensed using a worm dispenser: Copas 250NF (UBI), and the volume was added up to 35µL with M9 buffer. 35 µL C12FDG (molecular probes) and 35 µL 45% methanol was added. The wells were further incubated for at least 1h at 37°C. Fluorescence was measured with a Wallac Victor2 plate reader at ex/em: 485 nm/535 nm.
- 20 As shown in figure 18 and figure 19, the expression pattern of the transgenic nematodes is stable, which is clear from the linear increase of fluorescence versus a linear increase of nematodes in the wells.

Example 4: LacZ staining of *C. elegans* harboring pGN156 at various growth stages.

- 25 The expression pattern in function of the growth stage was measured. *C. elegans* harboring pGN156 was grown at various growth stages. Approximately 35 nematodes at various growth stages were placed in the wells of a microtiter plate. Each well contains only nematodes at a defined growth stage, being L1, L2-L3, L4, young adults, adults and older adults. M9 medium is added to a final volume of 35 µL.
- 30 35 µL 45% methanol and 35 µL 60 µM probe is added. Two probes have been tested:
- 1) Fluorescein di-beta-D-galactopyranoside (FDG) (Molecular Probes)
 - 2) ImaGene green TM C12FDG (FDG) (Molecular Probes)

The probe was incubated for different time intervals (1 to 5 hours) at 37°C, after which the plates are cooled down to 30°C prior to measurement.

Measurement of fluorescence was performed described above. The results are shown in figures 14, 15, and 16, and clearly show that the marker gene under the control of the vit-2 promoter is only expressed at the adult growth stage.

Further more linear relationship has also been tested between the number of worms added to the well and the fluorescence measured. Essential this has been performed in the same way as described above. Figure 17 shows the results, and the clear linearity between the number of nematodes and the fluorescence.

Example 5: Constructing mutant strains harboring the integrates pGN156

The integrated pGN156 in *C. elegans* UG1353 can be crossed in any desired mutant available (as provided by the references above, or by the CGC, university of Minnesota, St.-Paul) , or in any mutant newly created. As an example the integrated line has been crossed in a Daf-2 mutant line.

Strain UG1353 was crosses with a Wild-type male (N2) resulting in heterozygote males and hermaphrodites. A daf-2 (m41) strain was crossed with the herterozygote strain isolated above. From the offspring, the GFP expressing nematodes were isolated, and allowed self-fertilization, once again, L4 stage nematodes were isolated which express GFP, and the nematodes were placed at 25°C to allow o form dauers. Dauers were isolated and further incubated at 15°C. The offspring was analysed and nematodes which have a 100% GFP expressing offspring are isolated for further analysis. These analysed nematodes are homozygote for both the integration of PGN156 and for daf-2 (mp41)

Example 6: Screening for compounds that affect dauer formation using the daf-2 (PNZ156) nematodes of the example above.

The *C. elegans* daf-2 (pNZ156) nematodes were synchronized, and approximately 50 nematodes at the L1 stage were placed in each well of a 96 well plate. S medium was added as well as *E. coli* as described above to a final volume of 50 µL. Compound was

added at a final concentration of 30 μ L and the nematodes were allowed to grow between 22°C and 25°C for approximately 4 days, dependent on the temperature chosen.

Methanol and probe was then added as described in the examples above to allow the detection of the expression of the LacZ marker, and the wells were further incubated for 1 hour to overnight as described above, after which the fluorescence was measured, as described above.

At a temperature higher than 22°C this strain enters the dauer stage, at which stage no vit-2 expression, and hence no LacZ expression can be observed. Compounds which allow the nematode to bypass the dauer stage, and hence allows the nematodes to grow till the adult stage, will result in the expression of lacZ. Hence, fluorescence is detected in the wells where nematodes have been grown till at least the adult stage, hereby selecting a compound that affects dauer formation.

Example 7: selection of synchronized worms

Example 8: selection of mutants

Chemical mutagenesis has been described extensively in *C. elegans*, Modern biological analysis of an organism, Methods in Cell Biology, Vol 48. Transposon mutagenesis has been described in WO 00/73510 (PCT/US00/40091). In general, the desired mutated nematodes are selected which have a desired phenotype by microscopy. When these mutagenesis techniques are performed with transgenic strains harboring a marker gene such as GFP under the control of a growth stage specific promoter, this allows for a faster and automated selection.

In Short:

Approximately 1000000 eggs of a strain harboring a marker gene under the regulation of a growth stage dependent promoter (such as vit-2::GFP) are grown till L4-young adult stage after which they are treated with the mutagen. They are allowed to grow further on plates (approximately 25.000 worms per plate). The nematodes are washed off the plates with M9 buffer, while the eggs (harboring the mutants) are allowed to grow further. The L1 offspring is then washed off and filtered using a 20 μ M nylon membrane (millipore).

The L1 nematodes (F1) contain the desired dominant mutants. Depending on the desired phenotype, between 2 and 50 worms are then placed in the wells of a 96 well plate, and allowed to grow further. The plates are placed into a plate reader at various time intervals (approximately every 12 hours) to check the growth speed. As mutants are
5 known to have a slower growth speed, selection can be made automatically the mutants that grow slower or selected for further analysis.

To select for recessive mutants, the L1 nematodes (F1) are allowed to grow further, and the resulting young adults are placed (approximately 500 per plate) on plates.

The eggs are isolated as above and allowed to grow further till L1 stage (F2) prior to the
10 dispensing of the nematodes into the wells, as described above. The selection occurs as described for the F1 generation.

Example 9: Selection in resistance genetics

A particular kind of mutants to be selected, are those mutants who show resistance to a
15 compound. The addition of an active compound to a nematode results mainly in growth delay, growth arrest, lethality, and/or paralysis. Analogous as in the assay described above, mutant nematodes can be isolated that are resistant to the compound. Such mutant can be selected as the mutants will overcome the induction of the phenotype induced by the compound, and hence grow faster than the non-mutated nematodes.
20 The mutagenesis is performed as described above, while the assay and the outcome is different. In the well plates, where the L1 nematodes are allowed to grow, the compound is added. The concentration is dependent on the compound and may be between 10 μ M and 350 μ M, preferably 100 μ M. As such compound resistance mutants will grow faster than the non-mutated nematodes, selection of the desired mutants occurs by selecting
25 the nematodes that show firstly expression, which also has been done automatically.

Example 10: Growth monitoring in RNAi screens

Analogous to the mutagenesis methods above, dsRNA inhibition can be performed. The principle of HTS RNAi has been described in WO 00/01846, Nematodes can be fed
30 by bacteria that express high amounts of dsRNA. Such RNA crosses the gut barrier, and enters the cells of *C. elegans* performing its RNA inhibitory action.
In short:

Approximately 3 to 5 L1 synchronized nematodes (harboring a marker gene under the regulation of stage specific promoter) are placed in the wells of a microtiter plate, in

which also *E. coli* bacteria are present that express high levels of dsRNA. The nematodes are allowed to grow, and those are selected that show lethality, growth delay, growth arrest, etc, which can automatically be measured as these nematodes will not enter the growth stage that allows the expression of the marker gene. The assay to
5 select for the desired *E. coli* (harboring dsRNA expression of the gene of interest) is essential the same as the assay described above for mutagenesis.

In addition, a compound that induced growth delay, growth arrest, paralysis, or lethality can be added to the wells, at appropriate concentrations as described above. RNAi action on the nematode can induce resistance to such compound, analogous as has
10 been described above for compound resistance selection. Also in this case, the nematodes are selected that overcome the phenotype induced by the compound, as they will grow faster than the nematodes that have not acquired resistance by the RNAi. As the nematodes harbor a functional promoter marker fusion, such as *vit-2::GFP*, only the nematodes that grow (fast), will express the marker, and hence can be selected.

CLAIMS

1. Method for determining the influence of at least one exogenous factor on the development and/or growth of a sample of nematode worms, said method comprising:

- 5 a) providing a sample of nematode worms,
in which said nematode worms contain a marker gene operably linked to a promoter,
which promoter is capable of driving the expression of the marker gene in the nematode worms such that the marker gene is not expressed in at
10 least a first development stage of the nematodes, but is expressed in at least a second development stage of the nematodes (different from the first life stage);
b) exposing said sample of nematode worms to at least one exogenous factor;
c) maintaining/cultivating said sample of nematode worms in a suitable medium,
15 optionally over one or more life stages and/or generations;
d) subjecting the sample of nematode worms to at least one detection technique that is capable of detecting the signal generated by the marker gene (if expressed).

2. Method for determining the influence of at least a first exogenous factor on the development and/or growth of a sample of nematode worms, said method comprising:

- 20 a) providing at least a first and a second sample of nematode worms,
in which the nematode worms in each sample contain a marker gene operably linked to a promoter,
which promoter is capable of driving the expression of the marker gene in
25 the nematode worms such that the marker gene is not expressed in at least a first development stage of the nematodes, but is expressed in at least a second development stage of the nematodes (different from the first life stage);
b) exposing at least said first sample of nematode worms to said first one exogenous
30 factor;
c) maintaining/cultivating said samples of nematode worms in a suitable medium, optionally over one or more life stages and/or generations;
d) subjecting the samples of nematode worms to at least one detection technique that is capable of detecting the signal generated by the marker gene (if expressed);

e) determining the time required for the first sample of nematode worms to show expression of the marker gene (as determined by the signal detected for the first sample in step b)), and preferably also determining the time required for the second sample of nematode worms to show expression of the marker gene (as determined by the signal detected for the second sample in step b)); and/or comparing the time required for the first sample of nematode worms to show expression of the marker gene with the time required for the second sample of nematode worms to show expression of the marker gene.

10 3. Method according to claim 2, in which the second sample of nematode worms is not exposed to any exogenous factor.

 4. Method according to claim 2, in which the second sample of nematode worms is exposed to a second exogenous factor.

15 5. Method according to any of the preceding claims, in which nematodes used are preferably from the genus *Caenorhabditis*, such as from *Caenorhabditis briggsae* or *Caenorhabditis elegans*.

20 6. Method according to claim any of the preceding claims, in which the first development stage is chosen from eggs, an embryonal stage, L1, L2 and dauer.

 7. Method according to claim any of the preceding claims, in which the first development stage is L1.

25 8. Method according to claim any of the preceding claims, in which the first development stage is chosen from L4, adult or dauer.

 9. Method according to any of the preceding claims, in which the promoter
30 chosen from any one of the following promoters: *gpl-1*, *unc-54*, *myo-2*, *lin-28*, *lin-4*, *lin-14*, *col-7*, *col-19*, *col-17*, *ctl-1*, *sod-3*, *vit-2*.

 10. Method according to any of the preceding claims, in which the promoter is the *vit-2* promoter.

11. Method according to any of the preceding claims, in which marker gene is chosen from green fluorescent protein, beta-galactosidase, beta-lactamase, luciferase, acetohydroxyacid synthase, alkaline phosphatase, beta-glucuronidase, chloramphenicol acetyltransferase, horseradish peroxidase, nopaline synthase and/or octapine synthase.

12. Method according to any of the preceding claims, in which marker gene encodes a gene product that is toxic (e.g. lethal) to the nematode.

13. Method according to any of the preceding claims, in which step d) is carried out using a non-visual detection technique.

14. Method according to any of the preceding claims, which is carried out in multi-well plate format.

15. Method according to any of the preceding claims, which is carried out in an automated fashion.

16. Method according to any of the preceding claims, in which the at least one exogenous factor is at least one small compound or at least one small peptide.

17. Method according to any of the preceding claims, in which the at least one exogenous factor is a double stranded RNA sequence, suitable or intended for suppression the expression of at least one nucleotide sequence in the nematode worm by means of RNA interference.

18. Method according to any of the preceding claims, in which the nematode worms have been subjected to mutagenesis prior to use in step a).

19. Use of a (sample of at least one) nematode worm, which nematode worm contains a marker gene operably linked to a promoter, which promoter is capable of driving the expression of the marker gene in the nematode worms such that the marker gene is not expressed in at least a first development stage of the nematodes, but is expressed in at least a second development stage of the nematodes (different from the

first life stage), in a method or assay for determining the influence of at least one exogenous factor on the development and/or growth on a nematode worm.

20. Use according to claim 19, in which nematodes used are preferably from the
5 genus *Caenorhabditis*, such as from *Caenorhabditis briggsae* or *Caenorhabditis elegans*.

21. Use according to claim 19 or 20, in which the promoter chosen from any one
of the following promoters: gpl-1, unc-54, myo-2, lin-28, lin-4, lin-14, col-7, col-19, col-17,
10 ctl-1, sod-3, vit-2.

22. Use according to any of claims 19-21, in which the promoter is the vit-2
promoter.

15 23. Use according to any of claims 19-22, in which the marker gene is chosen
from green fluorescent protein, beta-galactosidase, beta-lactamase, luciferase,
acetohydroxyacid synthase, alkaline phosphatase, beta-glucuronidase, chloramphenicol
acetyltransferase, horseradish peroxidase, nopaline synthase and/or octapine synthase.

20 24. Use according to any of claims 19-22, in which the marker gene encodes a
gene product that is toxic (e.g. lethal) to the nematode.

1/27

FIG. 1. Nucleotide sequence of pGQ1

ATGACCATGA TTACGCCAAG CTTGCATGCC TGCAGCCAAT GCATTGGAAG
 AGATATTTTG CGCGTCAAAT ATGTTTTGTG TCCCCGTAAT ATTTTTTTAA
 ATCAAATTC ACATTTTAAC CATAAAAAAC TCTTTCAAAA GTGTAATTTT
 CTACGCAAAA ATGCCGTTTCG GATGAAAAAT TACTTTTGAA AAACAACTC
 GAAACTACGG TACGCAAAAA AGTACATCGG TGTTTGCACA TAAGTGAAAA
 CAATGTTGTT TTTTGTAAAT TAAAATCGAT TAATTTTTTT TCCCGGAAAA
 CAAAAACGTT TTCAGCGTGG ATTTCTATTG TTTCTTGCCT AAAAAAAT
 TATTTACCAA TTTTAAACGA TAATTTCCAC GAATTTTCGC CATTAATCTC
 TCGATTTTGT TGATTCTTGA CTCCGAGCAA TCTCTCCGGT TTTCGCAAAAC
 GATTATATTA TTTATTTGTT TTCCTTTTCA GTGCCGATTC TCGGAAATTC
 AACAGTAAAT CTTCAAATG CCAATGCTTC CCCACATGGT CAATCTAAGT
 GAGTTTCTTT GTTACAAAAT ACACGTGATG TCAGATTGTC TCATTTCCGT
 TTGATCTACG TAGATCTACA AAAAATGCGG GAATTGAGCC GCAGAGTTCT
 CAACTGCTTT CGCATGGTTA AGAACGTGCG GACGTCAAAT TGTTTTGGGC
 AAAAAATCCC GCATTTTTTG TAGATCAAAC CGTAATGGGA CAGTCTGGCA
 CCACGTGACT ATATATTTTT AGCGGTCAAC GACACAAAAC CCGGACCAAT
 GGCTGAGGAT CAGCTGAAAG CTTATAGAGA TAGAAATCAG GTGAGAAAAA
 TCAATTTTCT CGATTTTCTT CGCAATTTAT ATAAAACTG ATTTTCCAG
 GAACCCACC TGCTCACCAC ATCCAATGGA GCTCCGATCT ACTCGAAGAC
 CGCCGTGCTC ACCGCCGAC GACGTGGTCC AATGCTAATG CAGGACATCG
 TTTATATGGA CGAGATGGCT CATTTGATC GTGAACGCAT CCCGGAGCGT
 GTCGTCCATG CCAAAGGTGG TGGTGCTCAT GGATACTTCG AGGTCACCCA
 TGACATCACC AAGTACTGTA AGGCCGATAT GTTCAACAAG GTCGGAACAA
 AGACACCACT TCTCGTTCGT TTTTCAACGG TCGCTGGAGA ATCGCCGGA
 TCCCCGGGAT TGGCCAAAGG ACCCAAAGGT ATGTTTCGAA TGATACTAAC
 ATAACATAGA ACATTTTTCAG GAGGACCCTT GGCTAGCGTC GACGGTACCA
 TGGGGCGCGC CATGAGTAAA GGAGAAGAAC TTTTCACTGG AGTTGTCCCA
 ATTCTTGTTG AATTAGATGG TGATGTTAAT GGGCACAAAT TTTCTGTCAG
 TGGAGAGGGT GAAGGTGATG CAACATACGG AAAACTTACC CTTAAATTTA
 TTTGCACTAC TGGAAACTA CCTGTTCCAT GGGTAAGTTT AAACATATAT
 ATACTAACTA ACCCTGATTA TTTAAATTTT CAGCCAACAC TTGTCCTAC
 TTTCTGTTAT GGTGTTCAAT GCTTCTCGAG ATACCCAGAT CATATGAAAC
 GGCATGACTT TTTCAAGAGT GCCATGCCCG AAGGTTATGT ACAGGAAAGA
 ACTATATTTT TCAAAGATGA CGGGAACCTAC AAGACACGTA AGTTTAAACA
 GTTCGGTACT AACTAACCCT ACATATTTAA ATTTTCAGGT GCTGAAGTCA
 AGTTTGAAGG TGATACCTTT GTTAATAGAA TCGAGTTAAA AGGTATTGAT
 TTTAAAGAAG ATGGAAACAT TCTTGACAC AAATTGGAAT ACAACTATAA
 CTCACACAAT GTATACATCA TGGCAGACAA ACAAAGAAT GGAATCAAAG
 TTGTAAGTTT AAACCTGGAC TTACTAACTA ACGGATTATA TTTAAATTTT
 CAGAACTTCA AAATTAGACA CAACATTGAA GATGGAAGCG TTCAACTAGC
 AGACCATTAT CAACAAAATA CTCCAATTGG CGATGGCCCT GTCCTTTTAC
 CAGACAACCA TTACCTGTCC ACACAATCTG CCCTTTCGAA AGATCCCAAC
 GAAAAGAGAG ACCACATGGT CCTTCTTGAG TTTGTAACAG CTGCTGGGAT
 TACACATGGC ATGGATGAAC TATACAAATA GGGCCGGCCG AGCTCCGCAT
 CGGCCGCTGT CATCAGATCG CCATCTCGCG CCCGTGCCTC TGACTTCTAA
 GTCCAATTAC TCTTCAACAT CCTACATGC TCTTCTCCC TGTGCTCCCA
 CCCCCTATTT TTGTTATTAT CAAAAAACT TCTTCTTAAT TTCTTTGTTT
 TTTAGCTTCT TTTAAGTCAC CTCTAACAAT GAAATTGTGT AGATTCAAAA
 ATAGAATTAA TTCGTAATAA AAAGTCGAAA AAAATTGTGC TCCCTCCCCC

2/27

FIG. 1 (CONTINUED 1).

CATTAAATAAT AATTCTATCC CAAAATCTAC ACAATGTTCT GTGTACACTT
 CTTATGTTTT TTTACTTCT GATAAATTTT TTTTGAAACA TCATAGAAAA
 AACCGCACAC AAAATACCTT ATCATATGTT ACGTTTCAGT TTATGACCGC
 AATTTTTATT TCTTCGCACG TCTGGGCCTC TCATGACGTC AAATCATGCT
 CATCGTGAAA AAGTTTTGGA GTATTTTTGG AATTTTTCAA TCAAGTGAAA
 GTTTATGAAA TTAATTTTCC TGCTTTTGCT TTTTGGGGGT TTCCCTATT
 GTTTGTCAAG AGTTTCGAGG ACGGCGTTTT TCTTGCTAAA ATCACAAGTA
 TTGATGAGCA CGATGCAAGA AAGATCGGAA GAAGGTTTGG GTTTGAGGCT
 CAGTGGAAGG TGAGTAGAAG TTGATAATTT GAAAGTGGAG TAGTGTCTAT
 GGGGTTTTTG CCTTAAATGA CAGAATACAT TCCCAATATA CCAAACATAA
 CTGTTTCCTA CTAGTCGGCC GTACGGGCCC TTTCGTCTCG CGCGTTTCGG
 TGATGACGGT GAAAACCTCT GACACATGCA GTCCTCCGGAG ACGGTCACAG
 CTTGTCTGTA AGCGGATGCC GGGAGCAGAC AAGCCCGTCA GGGCGCGTCA
 GCGGGTGTG GCGGGTGTG GGGCTGGCTT AACTATGCGG CATCAGAGCA
 GATTGTACTG AGAGTGCACC ATATGCGGTG TGAAATACCG CACAGATGCG
 TAAGGAGAAA ATACCGCATC AGGCGGCCTT AAGGGCCTCG TGATACGCCCT
 ATTTTTATAG GTTAATGTCA TGATAATAAT GGTTTCTTAG ACGTCAGGTG
 GCACTTTTCG GGGAAATGTG CGCGGAACCC CTATTTGTTT ATTTTTCTAA
 ATACATTCAA ATATGTATCC GTCATGAGA CAATAACCTT GATAAATGCT
 TCAATAATAT TGAAAAAGGA AGAGTATGAG TATTCAACAT TTCCGTGTCTG
 CCCTTATTCC CTTTTTTGCG GCATTTTGCC TTCCTGTTTT TGCTCACCCA
 GAAACGCTGG TGAAAGTAAA AGATGCTGAA GATCAGTTGG GTGCACGAGT
 GGGTTACATC GAACTGGATC TCAACAGCGG TAAGATCCTT GAGAGTTTTT
 GCGCGAAGA ACGTTTTCCA ATGATGAGCA CTTTTAAAGT TCTGCTATGT
 GCGCGGTAT TATCCCGTAT TGACGCCGGG CAAGAGCAAC TCGGTCGCGG
 CATACACTAT TCTCAGAATG ACTTGTTTGA GTACTACCA GTCACAGAAA
 AGCATCTTAC GGATGGCATG ACAGTAAGAG AATTATGCAG TGCTGCCATA
 ACCATGAGTG ATAACACTGC GGCCAACCTA CTTCTGACAA CGATCGGAGG
 ACCGAAGGAG CTAACCGCTT TTTTGACAAA CATGGGGGAT CATGTAACCT
 GCCTTGATCG TTGGGAACCG GAGCTGAATG AAGCCATACC AAACGACGAG
 CGTGACACCA CGATGCCTGT AGCAATGGCA ACAACGTTGC GCAAACATTT
 AACTGGCGAA CTACTTACTC TAGCTTCCCG GCAACAATTA ATAGACTGGA
 TGGAGGCGGA TAAAGTTGCA GGACCACTTC TGCGCTCGGC CCTTCCGGCT
 GGCTGGTTTT TTGCTGATAA ATCTGGAGCC GGTGAGCGTG GGTCTCGCGG
 TATCATTGCA GCACTGGGGC CAGATGGTAA GCCCTCCCGT ATCGTAGTTA
 TCTACACGAC GGGGAGTCAG GCAACTATGG ATGAACGAAA TAGACAGATC
 GCTGAGATAG GTGCCCTACT GATTAAGCAT TGGTAACTGT CAGACCAAGT
 TTAATCATAT ATACTTTAGA TTGATTAAA ACTTCATTTT TAATTTAAAA
 GGATCTAGGT GAAGATCCTT TTTGATAATC TCATGACCAA AATCCCTTAA
 CGTGAGTTTT CGTTCCACTG AGCGTCAGAC CCCGTAGAAA AGATCAAAGG
 ATCTTCTTGA GATCCTTTTT TTCTGCGCGT AATCTGCTGC TTGCAAACAA
 AAAAACCAAC GCTACCAGCG GTGGTTTGTT TGCCGGATCA AGAGCTACCA
 ACTCTTTTTC CGAAGGTAAC TGGCTTCAGC AGAGCGCAGA TACCAAATAC
 TGTCCTTCTA GTGTAGCCGT AGTTAGGCCA CCACTTCAAG AACTCTGTAG
 CACCGCCTAC ATACCTCGCT CTGCTAATCC TGTTACCAGT GGCTGCTGCC
 AGTGCGGATA AGTCGTGTCT TACCGGGTTG GACTCAAGAC GATAGTTACC
 GGATAAGGCG CAGCGGTCGG GCTGAACGGG GGGTTCGTGC ACACAGCCCA
 GCTTGAGCGG AACGACCTAC ACCGAACCTGA GATACCTACA GCGTGAGCAT
 TGAGAAAGCG CCACGCTTCC CGAAGGGAGA AAGGCGGACA GGTATCCGGT
 AAGCGGCAGG GTCGGAACAG GAGAGCGCAC GAGGGAGCTT CCAGGGGGAA
 ACGCCTGGTA TCTTTATAGT CTTGTCGGGT TTCGCCACCT CTGACTTGAG

3/27

FIG. 1 (CONTINUED 2).

CGTCGATTTT TGTGATGCTC GTCAGGGGGG CGGAGCCTAT GGAAAAACGC
CAGCAACGCG GCCTTTTAC GGTTCCTGGC CTTTGTCTGG CCTTTGCTC
ACATGTTCTT TCCTGCGTTA TCCCCTGATT CTGTGGATAA CCGTATTACC
GCCTTTGAGT GAGCTGATAC CGCTCGCCGC AGCCGAACGA CCGAGCGCAG
CGAGTCAGTG AGCGAGGAAG CGGAAGAGCG CCCAATACGC AAACCGCCTC
TCCCCGCGCG TTGGCCGATT CATTAAATGCA GCTGGCACGA CAGGTTTCCC
GACTGGAAAG CGGGCAGTGA GCGCAACGCA ATTAATGTGA GTTAGCTCAC
TCATTAGGCA CCCCAGGCTT TACACTTTAT GCTTCCGGCT CGTATGTTGT
GTGGAATTGT GAGCGGATAA CAATTCACA CAGGAACAG CT

4/27

FIG. 2. Nucleotide sequence of PCLUC6

```

ATGACTGCTC CAAAGAAGAA GCGTAAGGTA CCGGTAGAAA AAATGGAAGA
CGCCAAAAAC ATAAAGAAAG GCCCGGCGCC ATTCTATCCG CTGGAAGATG
GAACCGCTGG AGAGCAACTG CATAAGGCTA TGAAGAGATA CGCCCTGGTT
CCTGGAACAA TTGCTTTTAC AGATGCACAT ATCGAGGTGG ACATCACTTA
CGCTGAGTAC TTCGAAATGT CCGTTCGGTT GGCAGAAGCT ATGAAACGAT
ATGGGCTGAA TACAAATCAC AGAATCGTCG TATGCAGTGA AAACCTCTCTT
CAATTCTTTA TGCCGGTGTT GGGCGCGTTA TTTATCGGAG TTGCAGTTGC
GCCCGCGAAC GACATTTATA ATGAACGTGA ATTGCTCAAC AGTATGGGCA
TTTCGCAGCC TACCGTGCTG TTCGTTTCCA AAAAGGGGTT GCAAAAAATT
TTGAACGTGC AAAAAAAGCT CCCAATCATC CAAAAAATTA TTATCATGGA
TTCTAAAACG GATTACCAGG GATTTCAGTC GATGTACACG TTCGTCACAT
CTCATCTACC TCCCGGTTTT AATGAATACG ATTTTGTGCC AGAGTCCTTC
GATAGGGACA AGACAATTGC ACTGATCATG AACTCCTCTG GATCTACTGG
TCTGCCTAAA GGTGTCGCTC TGCCTCATAG AACTGCCTGC GTGAGATTCT
CGCATGCCAG AGATCCTATT TTTGGCAATC AAATCATTCC GGATACTGCG
ATTTTAAGTG TTGTTCATT CCATCACGGT TTTGGAATGT TTACTACACT
CGGATATTTG ATATGTGGAT TTCGAGTCGT CTTAATGTAT AGATTTGAAG
AAGAGCTGTT TCTGAGGAGC CTTCAGGATT ACAAGATTCA AAGTGCCTG
CTGGTGCCAA CCCTATTCTC CTTCTTCGCC AAAAGCACTC TGATTGACAA
ATACGATTTA TCTAATTTAC ACGAAATTGC TTCTGGTGGC GCTCCCTCT
CTAAGGAAGT CGGGGAAGCG GTTGCCAAGA GGTTCATCT GCCAGGTATC
AGGCAAGGAT ATGGGCTCAC TGAGACTACA TCAGCTATTC TGATTACACC
CGAGGGGGAT GATAAACCGG GCGCGGTCGG TAAAGTTGTT CCATTTTTTG
AAGCGAAGGT TGTGGATCTG GATACCGGGA AAACGCTGGG CGTTAATCAA
AGAGGCGAAC TGTGTGTGAG AGGTCCATG ATTATGTCCG GTTATGTAAA
CAATCCGGA GCGACCAACG CCTTGATTGA CAAGGATGGA TGGCTACATT
CTGGAGACAT AGCTTACTGG GACGAAGACG AACACTTCTT CATCGTTGAC
CGCTGAAGT CTCTGATTAA GTACAAAGGC TATCAGGTGG CTCCCGCTGA
ATTGGAATCC ATCTTGCTCC AACACCCCAA CATCTTCGAC GCAGGTGTCTG
CAGGTCTTCC CGACGATGAC GCCGGTGAAC TTCCCGCCGC CGTTGTTGTT
TTGGAGCACG GAAAGACGAT GACGGAAAAA GAGATCGTGG ATTACGTCCG
CAGTCAAGTA ACAACCGCGA AAAAGTTGCG CGGAGGAGTT GTGTTTGTGG
ACGAAGTACC GAAAGGTCTT ACCGGAAAAA TCGACGCAAG AAAAAACAGA
GAGATCCTCA TAAAGGCCAA GAAGGGCGGA AAGATCGCCG TGTAATTTCTA
GGAATPCCAA CTGAGCGCCG GTCGCTACCA TTACCAACTT GTCTGGTGTG
AAAAATAATA GGGGCCGCTG TCATCAGAGT AAGTTTAAAC TGAGTTCTAC
TAACTAACGA GTAATATTTA AATTTTCAGC ATCTCGCGCC CGTGCCCTCTG
ACTTCTAAGT CCAATTACTC TTCAACATCC CTACATGCTC TTTCTCCCTG
TGCTCCACCC CCTATTTTT GTTATTATCA AAAAACTTC TTCTTAATTT
CTTTGTTTTT TAGCTTCTTT TAAGTCACCT CTAACAATGA AATTGTGTAG
ATTCAAAAAT AGAATTAATT CGTAATAAAA AGTCGAAAAA AATTGTGCTC
CCTCCCCCCA TTAATAATAA TTCTATCCCA AAATCTACAC AATGTTCTGT
GTACACTTCT TATGTTTTTT TTAATTCTGA TAAATTTTTT TTGAAACATC
ATAGAAAAAA CCGCACACAA AATACCTTAT CATATGTTAC GTTTCAGTTT
ATGACCGCAA TTTTATTTC TTCGCACGTC TGGGCCTCTC ATGACGTCAC
ATCATGCTCA TCGTGAAAAA GTTTTGGAGT ATTTTGGGAA TTTTTCATC
AAGTGAAAGT TTATGAAATT AATTTTCCTG CTTTTGCTTT TTGGGGGTTT
CCCCTATTGT TTGTCAAGAG TTTGAGGAC GCGTTTTTTC TTGCTAAAAA
CACAAGTATT GATGAGCACG ATGCAAGAAA GATCGGAAGA AGGTTTGGGT

```

5/27

FIG. 2 (CONTINUED 1).

TTGAGGCTCA GTGGAAGGTG AGTAGAAGTT GATAATTTGA AAGTGGAGTA
GTGTCTATGG GGTTTTTGCC TTAAATGACA GAATACATTC CCAATATACC
AAACATAACT GTTTCCTACT AGTCGGCCGT ACGGGCCCTT TCGTCTCGCG
CGTTTCGGTG ATGACGGTGA AAACCTCTGA CACATGCAGC TCCCGGAGAC
GGTCACAGCT TGTCTGTAAG CGGATGCCGG GAGCAGACAA GCCCGTCAGG
GCGCGTCAGC GGGTGTTCGG GGGTGTTCGG GCTGGCTTAA CTATGCGGCA
TCAGAGCAGA TTGTACTGAG AGTGCACCAT ATGCGGTGTG AAATACCGCA
CAGATGCGTA AGGAGAAAAT ACCGCATCAG GCGGCCCTAA GGGCCTCGTG
ATACGCCTAT TTTTATAGGT TAATGTCATG ATAATAATGG TTTCTTAGAC
GTCAGGTGGC ACTTTTCGGG GAAATGTGCG CGGAACCCCT ATTTGTTTAT
TTTTCTAAAT ACATTCAAAT ATGTATCCGC TCATGAGACA ATAACCTGA
TAAATGCTTC AATAATATTG AAAAAGGAAG AGTATGAGTA TTCAACATT
CCGTGTCGCC CTTATTCCCT TTTTTCGGC ATTTTGCCTT CCTGTTTTG
CTCACCAGCA AACGCTGGTG AAAGTAAAAG ATGCTGAAGA TCAGTTGGGT
GCACGAGTGG GTTACATCGA ACTGGATCTC AACAGCGGTA AGATCCTTGA
GAGTTTTTCG CCCGAAGAAC GTTTTCCAAT GATGAGCACT TTTAAAGTTC
TGCTATGTGG CGCGGTATTA TCCCGTATTG ACGCCGGGCA AGAGCAACTC
GGTCGCCGCA TACACTATTG TCAGAATGAC TTGGTTGAGT ACTCACCAGT
CACAGAAAAG CATCTTACGG ATGGCATGAC AGTAAGAGAA TTATGCAGTG
CTGCCATAAC CATGAGTGAT AACACTGCGG CCAACTTACT TCTGACAACG
ATCGGAGGAC CGAAGGAGCT AACCCTTTT TTGCACAACA TGGGGGATCA
TGTAATCGC CTTGATCGTT GGGAAACCGA GCTGAATGAA GCCATACCAA
ACGACGAGCG TGACACCAG ATGCCTGTAG CAATGGCAAC AACGTTGCGC
AAACTATTAA CTGGCGAACT ACTTACTCTA GCTTCCCGG AACAATTAAT
AGACTGGATG GAGGCGGATA AAGTTGCAGG ACCACTTCTG CGCTCGGCCC
TTCCGGCTGG CTGGTTTATT GCTGATAAAT CTGGAGCCGG TGAGCGTGGG
TCTCGCGGTA TCATTGCAGC ACTGGGGCCA GATGGTAAGC CCTCCCGTAT
CGTAGTTATC TACACGACGG GGAGTCAGGC AACTATGGAT GAACGAAATA
GACAGATCGC TGAGATAGGT GCCTCACTGA TTAAGCATTG GTAAGTGTCA
GACCAAGTTT ACTCATATAT ACTTTAGATT GATTTAAAAC TTCATTTTA
ATTTAAAAGG ATCTAGGTGA AGATCCTTTT TGATAATCTC ATGACCAAAA
TCCCTTAACG TGAGTTTTTCG TTCCACTGAG CGTCAGACCC CGTAGAAAAG
ATCAAAGGAT CTTCTTGAGA TCCTTTTTTT CTGCGCGTAA TCTGCTGCTT
GCAAACAAA AAACCACCGC TACCAGCGGT GGTGTTGTTG CCGGATCAAG
AGCTACCAAC TCCTTTTCCG AAGGTAAC TGCTTCAGCAG AGCGCAGATA
CCAAATACTG TCCTTCTAGT GTAGCCGTAG TTAGGCCACC ACTTCAAGAA
CTCTGTAGCA CCGCCTACAT ACCTCGCTCT GCTAATCCTG TTACAGTG
CTGCTGCCAG TGGCGATAAG TCGTGTCTTA CCGGGTTGGA CTCAAGACGA
TAGTTACCGG ATAAGGCGCA GCGGTCGGGC TGAACGGGGG GTTCGTGCAC
ACAGCCCAGC TTGGAGCGAA CGACCTACAC CGAACTGAGA TACCTACAGC
GTGAGCATTG AGAAAGCGCC ACGCTTCCCG AAGGGAGAAA GCGGACAGG
TATCCGGTAA GCGGCAGGGT CGGAACAGGA GAGCGCACGA GGGAGCTTCC
AGGGGGAAAC GCCTGGTATC TTTATAGTCC TGTCGGGTTT CGCCACCTCT
GACTTGAGCG TCGATTTTTG TGATGCTCGT CAGGGGGGCG GAGCCTATGG
AAAAACGCCA GCAACGCGGC CTTTTTACGG TTCTTGGCCT TTTGCTGGCC
TTTTGCTCAC ATGTTCTTTC CTGCGTTATC CCCTGATTCT GTGGATAACC
GTATTACCGC CTTTGAGTGA GCTGATACCG CTCGCCGAG CCGAACGACC
GAGCGCAGCG AGTCAGTGAG CGAGGAAGCG GAAGAGCGCC CAATACGCAA
ACCGCCTCTC CCGCGCGGTT GGCCGATTCA TTAATGCAGC TGGCACGACA
GGTTTCCCGA CTGGAAAGCG GGCAGTGAGC GCAACGCAAT TAATGTGAGT
TAGCTCACTC ATTAGGCACC CCAGGCTTTA CACTTTATGC TTCCGGCTCG

6/27

FIG. 2 (CONTINUED 2).

TATGTTGTGT GGAATTGTGA GCGGATAACA ATTCACACA GGAAACAGCT
ATGACCATGA TTACGCCAAG CTGTAAGTTT AAACATGATC TTACTAACTA
ACTATTCTCA TTTAAATTTT CAGAGCTTAA AAATGGCTGA AATCACTCAC
AACGATGGAT ACGCTAACAA CTTGGAAATG AAATAAGCTT GCATGCCTGC
AGGCCTTGGT CGACTCTAGA GGATCAAACG GTATTACTTG AAACAATTTA
GTTATATGTT TAGAACCCCT CATTCAAAT TAATAGACAG GGCTCTCACC
GAATGTTGCA ATTTGTTTCT GATAAGGGTC ACAAAGCGGA GCGAATGCTT
GAATGTGTCC ATCAATGAGC TTATCAATGC GCTAAAACGC TATAACTTCC
ATATGAAGTC AATCGAACAT ATGTCAATCT TTAGCCGTAT ATAAAGGTGC
ACTGAAAACA GTCCAATCAC GGTTCAAGCA TGAGGTCGAT CCCCAGCCGG
GATTGGCCAA AGGACCCAAA GGTATGTTTC GAATGATACT AACATAACAT
AGAACATTTT CAGGAGGACC CTTGGAGGGT ACCGGGGATT GGCCAAAGGA
CCCAAAGGTA TGTTTCGAAT GATACTAACA TAACATAGAA CATTTTCAGG
AGGACCCTTG CTTGGAGGGT ACCGAGCTCA GAAAAA

7/27

FIG. 3. Nucleotide sequence of pGQ2

```

ATGACTGCTC CAAAGAAGAA GCGTAAGGTA CCGGTAGAAA AAATGGAAGA
CGCCAAAAAC ATAAAGAAAG GCCCGGCGCC ATTCTATCCG CTGGAAGATG
GAACCGCTGG AGAGCAACTG CATAAGGCTA TGAAGAGATA CGCCCTGGTT
CCTGGAACAA TTGCTTTTAC AGATGCACAT ATCGAGGTGG ACATCACTTA
CGCTGAGTAC TTCGAAATGT CCGTTCGGTT GGCAGAAGCT ATGAAACGAT
ATGGGCTGAA TACAAATCAC AGAATCGTCG TATGCAGTGA AAACCTCTCT
CAATTCTTTA TGCCGGTGTT GGGCGCGTTA TTTATCGGAG TTGCAGTTGC
GCCCGCGAAC GACATTTATA ATGAACGTGA ATTGCTCAAC AGTATGGGCA
TTTCGCAGCC TACCGTGGTG TTCGTTTCCA AAAAGGGGTT GCAAAAAAAT
TTGAACGTGC AAAAAAAGCT CCCAATCATC CAAAAAATTA TTATCATGGA
TTCTAAAACG GATTACCAGG GATTTAGTC GATGTACACG TTCGTCACAT
TTCATCTACC TCCCGGTTTT AATGAATACG ATTTTGTGCC AGAGTCCTTC
GATAGGGACA AGACAATTGC ACTGATCATG AACTCCTCTG GATCTACTGG
TCTGCCTAAA GGTGTCGCTC TGCCTCATAG AACTGCCTGC GTGAGATTCT
CGCATGCCAG AGATCCTATT TTTGGCAATC AAATCATTCC GGATACTGCC
ATTTTAAGTG TTGTTCCATT CCATCACGGT TTTGGAATGT TTAACACT
CGGATATTTG ATATGTGGAT TTCGAGTCGT CTTAATGTAT AGATTTGAAG
AAGAGCTGTT TCTGAGGAGC CTTGAGGATT ACAAGATTCA AAGTGCCTG
CTGGTGCCAA CCCTATTCTC CTTCTTCGCC AAAAGCACTC TGATTGACAA
ATACGATTTA TCTAATTTAC ACGAAATTGC TTTGTTGGC GCTCCCTCT
CTAAGGAAGT CGGGGAAGCG GTTGCCAAGA GGTTCATCT GCCAGGTATC
AGGCAAGGAT ATGGGCTCAC TGAGACTACA TCAGCTATTC TGATTACACC
CGAGGGGGAT GATAAACCAG GCGCGGTCGG TAAAGTTGTT CCATTTTTTG
AAGCGAAGGT TGTGGATCTG GATACCGGGA AAACGCTGGG CGTTAATCAA
AGAGGCGAAC TGTGTGTGAG AGGTCTATG ATTATGTCCG GTTATGTA
CAATCCGGA GCGACCAACG CCTTGATTGA CAAGGATGGA TGGTACATT
CTGGAGACAT AGCTTACTGG GACGAAGACG AACACTTCTT CATCGTTGAC
CGCCTGAAGT CTCTGATTAA GTACAAAGGC TATCAGGTGG CTCCCGCTGA
ATTGGAATCC ATCTTGCTCC AACACCCCAA CATCTTCGAC GCAGGTGTCG
CAGGTCTTCC CGACGATGAC GCCGGTGAAC TTCCCGCCGC CGTTGTTGTT
TTGGAGCACG GAAAGACGAT GACGGAAAAA GAGATCGTGG ATTACGTCG
CAGTCAAGTA ACAACCGCGA AAAAGTTGCG CGGAGGAGTT GTGTTTGTGG
ACGAAGTACC GAAAGGTCCT ACCGGAAGAC TCGACGCAAG AAAAATCAGA
GAGATCCTCA TAAAGGCCAA GAAGGGCGGA AAGATCGCCG TGTAATTCTA
GGAATTCCAA CTGAGCGCCG GTCGCTACCA TTACCAACTT GTCTGGTGTC
AAAAATAATA GGGGCCGCTG TCATCAGAGT AAGTTTAAAC TGAGTTCTAC
TAACTAACGA GTAATATTTA AATTTTCAGC ATCTCGCGCC CGTGCCTCTG
ACTTCTAAGT CCAATTACTC TTCAACATCC CTACATGCTC TTTCTCCCTG
TGCTCCCACC CCCTATTTTT GTTATTATCA AAAAAACTTC TTCTTAATTT
CTTTGTTTTT TAGCTTCTTT TAAGTCACCT CTAACAATGA AATTGTGTAG
ATTCAAAAAT AGAATTAATT CGTAATAAAA AGTCGAAAAA AATTGTGCTC
CCTCCCCCCA TTAATAATAA TTCTATCCCA AAATCTACAC AATGTTCTGT
GTACACTTCT TATGTTTTTT TTAATTCTGA TAAATTTTTT TTGAAACATC
ATAGAAAAAA CCGCACACAA AATACCTTAT CATATGTTAC GTTTCAGTTT
ATGACCGCAA TTTTATTTTC TTCGCACGTC TGGGCCTCTC ATGACGTCAA
ATCATGCTCA TCGTGAAAAA GTTTTGGAGT ATTTTGGAA TTTTCAATC
AAGTGAAAGT TTATGAAATT AATTTTCCTG CTTTGTCTTT TTGGGGGTTT
CCCCTATTGT TTGTCAAGAG TTTGAGGAC GCGGTTTTTC TTGCTAAAAA
CACAAGTATT GATGAGCAGC ATGCAAGAAA GATCGGAAGA AGGTTTGGGT

```


8/27

FIG. 3(Continued 1).

```

TTGAGGCTCA GTGGAAGGTG AGTAGAAGTT GATAATTTGA AAGTGGAGTA
GTGTCTATGG GGTTTTTGCC TTAAATGACA GAATACATTG CCAATATACC
AAACATAACT GTTTCCTACT AGTCGGCCGT ACGGGCCCTT TCGTCTCGCG
CGTTTCGGTG ATGACGGTGA AAACCTCTGA CACATGCAGC TCCCGGAGAC
GGTCACAGCT TGTCTGTAAG CGGATGCCGG GAGCAGACAA GCCCGTCAGG
GCGCGTCAGC GGGTGTTGGC GGGTGTCGGG GCTGGCTTAA CTATGCGGCA
TCAGAGCAGA TTGTACTGAG AGTGCACCAT ATGCGGTGTG AAATACCGCA
CAGATGCGTA AGGAGAAAT ACCGCATCAG GCGGCCCTAA GGGCCTCGTG
ATACGCCTAT TTTTATAGGT TAATGTCATG ATAATAATGG TTTCTTAGAC
GTCAGGTGGC ACTTTTCGGG GAAATGTGCG CGGAACCCCT ATTTGTTTAT
TTTTCTAAAT ACATTCAAAT ATGTATCCGC TCATGAGACA ATAACCCTGA
TAAATGCTTC AATAATATTG AAAAAGGAAG AGTATGAGTA TTCAACATTT
CCGTGTCGCC CTTATTCCCT TTTTTCGGC ATTTTCCTT CCTGTTTTTG
CTCACCCAGA AACGCTGGTG AAAGTAAAAG ATGCTGAAGA TCAGTTGGGT
GCACGAGTGG GTTACATCGA ACTGGATCTC AACAGCGGTA AGATCCTTGA
GAGTTTTTCG CCCGAAGAAC GTTTTCCAAT GATGAGCACT TTTAAAGTTC
TGCTATGTGG CGCGGTATTA TCCCGTATTG ACGCCGGGCA AGAGCAACTC
GGTCGCCGCA TACACTATTC TCAGAATGAC TTGGTTGAGT ACTCACCAGT
CACAGAAAAG CATCTTACGG ATGGCATGAC AGTAAGAGAA TTATGCAGTG
CTGCCA'AAC CATGAGTGAT AACACTGCGG CCAACTTACT TCTGACAACG
ATCGGAGGAC CGAAGGAGCT AACCGCTTTT TTGCACAACA TGGGGGATCA
TGTAACTCGC CTTGATCGTT GGGAACCGGA GCTGAATGAA GCCATACCAA
ACGACGAGCG TGACACCACG ATGCCTGTAG CAATGGCAAC AACGTTGCGC
AAACTATTAA CTGGCGAACT ACTTACTCTA GCTTCCCGGC AACAA'TTAA
AGACTGGATG GAGGCGGATA AAGTTGCAGG ACCACTTCTG CGCTCGGCC
TTCCGGCTGG CTGGTTTATT GCTGATAAAT CTGGAGCCGG TGAGCGTGGG
TCTCGCGGTA TCATTGCAGC ACTGGGGCCA GATGGTAAGC CCTCCCGTAT
CGTAGTTATC TACACGACGG GGAGTCAGGC AACTATGGAT GAACGAAATA
GACAGATCGC TGAGATAGGT GCCTCACTGA TTAAGCATTG GTAAC'TGTC
GACCAAGTTT ACTCATATAT ACTTTAGATT GATTTAAAAC TTCATTTTAA
ATTTAAAAGG ATCTAGGTGA AGATCCTTTT TGATAATCTC ATGACCAAAA
TCCCTTAACG TGAGTTTTCG TTCCACTGAG CGTCAGACCC CGTAGAAAAG
ATCAAAGGAT CTTCTTGAGA TCCTTTTTTT CTGCGCGTAA TCTGCTGCTT
GCAAAACAAA AAACCACCGC TACCAGCGGT GGTTTGTTTG CCGGATCAAG
AGCTACCAAC TCTTTTTCG AAGGTAAGT GCTTCAGCAG AGCGCAGATA
CCAAATACTG TCCTTCTAGT GTAGCCGTAG TTAGGCCACC ACTTCAAGAA
CTCTGTAGCA CCGCCTACAT ACCTCGCTCT GCTAATCCTG TTACCAGTGG
CTGCTGCCAG TGGCGATAAG TCGTGTCTTA CCGGGTTGGA CTCAAGACGA
TAGTTACCGG ATAAGGCGCA GCGTCGGGC TGAACGGGGG GTTCGTGCAC
ACAGCCCAGC TTGGAGCGAA CGACCTACAC CGAACTGAGA TACCTACAGC
GTGAGCATTG AGAAAGCGCC ACGCTTCCCG AAGGGAGAAA GGCGGACAGG
TATCCGGTAA GCGGCAGGGT CGGAACAGGA GAGCGCACGA GGGAGCTTCC
AGGGGGAAC GCCTGGTATC TTTATAGTCC TGTCGGGTTT CGCCACCTCT
GACTTGAGCG TCGATTTTGG TGATGCTCGT CAGGGGGGCG GAGCCTATGG
AAAAACGCCA GCAACGCGGC CTTTTTACGG TTCCTGGCCT TTTGCTGGCC
TTTTGCTCAC ATGTTCTTTC CTGCGTTATC CCCTGATTCT GTGGATAACC
GTATTACCGC CTTTGAGTGA GCTGATACCG CTCGCCGAG CCGAACGACC
GAGCGCAGCG AGTCAGTGAG CGAGGAAGCG GAAGAGCGCC CAATACGCAA
ACCGCCTCTC CCCGCGCGTT GGCCGATTCA TTAATGCAGC TGGCACGACA
GGTTTCCCGA CTGGAAAGCG GGCAGTGAGC GCAACGCAAT TAATGTGAGT
TAGCTCACTC ATTAGGCACC CCAGGCTTTA CACTTTATGC TTCCGGCTCG

```

9/27

FIG. 3 (CONTINUED 2).

TATGTTGTGT GGAATTGTGA GCGGATAACA ATTCACACA GGAAACAGCT
ATGACCATGA TTACGCCAAG CTGTAAGTTT AAACATGATC TTACTAACTA
ACTATTCTCA TTTAAATTTT CAGAGCTTAA AAATGGCTGA AATCACTCAC
AACGATGGAT ACGCTAACAA CTTGGAAATG AAATAAGCTT GCATGCCTGC
AGGCCTGAGA TATTTTGGCG GTCAAATATG TTTTGTGTCC CCGTAATATT
TTTTTAAATC AAATTCACA TTTTAACCAT AAAAACTCT TTCAAAAGTG
TAATTTTCTA CGCAAAAATG CCGTTCGGAT GAAAAATTAC TTTTGAAAAA
CAAACCTCGAA ACTACGGTAC GCAAAAAAGT ACATCGGTGT TTGCACATAA
GTGAAAACAA TGTGTGTTTT TTGTAATTAA AATCGATTAA TTTTTTTTCC
CGGAAAACAA AAACGTTTTT AGCGTGGATT TCTATTGTTT CTTGCGTAAA
AAAAAATTAT TTACCAATTT TAAACGATAA TTTCCACGAA TTTTCGCCAT
TAATCTCTCG ATTTTGTGTA TTCTTGACTC CGAGCAATCT CTCCGGTTTT
CGCAAACGAT TATATTATTT ATTTGTTTTT CTTTTTCAGTG CCGATTCTCG
GAAATTCAAC AGTAAATCTT CAAAATGCCA ATGCTTCCCC ACATGGTCAA
TCTAAGTGAG TTTCTTTGTT ACAAATACA CGTGATGTCA GATTGTCTCA
TTTCGGTTTG ATCTACGTAG ATCTACAAAA AATGCGGGAA TTGAGCCGCA
GAGTTCTCAA CTGCTTTCGC ATGGTTAAGA ACGTGCGGAC GTCAAATTGT
TTTGGGCAAA AATTCCCACA TTTTTTGTAG ATCAAACCGT AATGGGACAG
TCTGGCACCA CGTGACTATA TATTTTTAGC GGTCAACGAC ACAAACCCG
GACCAATGGC TGAGGATCAG CTGAAAGCTT ATAGAGATAG AAATCAGGTG
AGAAAAATCA ATTCAGCGA TTTTCTTCGC AATTTATATA AAAACTGATT
TTTCCAGGAA CCCACCTGC TCACCACATC CAATCGGAGC TCAGAAAAA

10/27

FIG. 4. Nucleotide sequence of pGN156

agcttgcatgcctgcagggtcgactctagaggatcaaactgtattacttgaaacaatttagttatatgttta
gaacccctcattcaaaattaatagacagggtctcaccgaatgttgcaatttgtttctgataagggtcacaa
agcggagcgaatgcttgaatgtgtccatcaatgagcttatcaatgcgctaaaacgctataacttccatga
agtcaatcgaacatatgtcaatctttagccgtatataaagggtgcactgaaaacagtcgaatcacggttcagc
catgaggtcgatccccggcgggattggccaaaggacccaaaggtatgtttcgaatgataactaacataacat
agaacattttcaggaggacccttggagggtaccggtgggtgaagaccagaaacagcacctcgaactgagccg
cgatattgccagcggtttcaacgcgctgtatggcgagatcgatcccgtcggtttacaacgctcgtagctggga
aaacccctggcggttacccaacttaatcgcttcgagcacatccccctttcgccagctggcgtaatagcgaaga
ggcccgacccgatcgcccttcccaacagttgcgaaggttaagtttaaacagatccataactaacttgttc
tgacataattttcagcttgaatggcgaatggcgctttgcctggtttccggcaccagaagcgggtgccggaag
ctggctggagtgcgatcttctgaaggccgatactgtcgtcgtcccctcaaactggcagatgcacggttacga
tgccccatctacaccaacgtaacctatcccattaccggtcaatccgcggtttgttcccacggagaatccgac
gggttgttactcgctcacatttaattgttgatgaaagctggctacaggaaggccagacgcgaattattttga
tggcggttaactcggcggtttcatctgtggtgcaacggggcgctgggtcggttacggccaggttaagtttaata
gttgataactaactaacaagatctgattaattttcaggacagtcggttgcgctctgaatttgacctgagcgc
atttttacgcgcgggagaaaaccgcctcgcggtgatggtgctgcgttgagtgacggcagttatctggaaga
tcaggatatgtggcggatgagcggcattttccgctgacgtctcgttgcgtgcataaaccgactacacaaatcag
cgatttccatgtttgccactcgctttaaagatgatttctccgcgctgtactggaggctgaagtcaggttaag
tttaaacaggatcttactaactaacatgctaactgaattttcagatgtgcggcgagttgcgtgactacct
acgggtaacagtttctttatggcagggtgaaacgcaggtcgccagcggcaccgcgctttcggcggtgaaat
tatcgatgagcgtggtggttatgccgatcgctcacactacgtctgaacgtcgaaaacccgaaactgtggag
cgccgaaatcccgaatctctatcgctgcggtggttgaactgcacaccgcgcagcggcacgctgattgaagcaga
agcctgcgatgtcggtttccgcgagggtgcggattgaaaatggtctgctgctgctgaacggcaagccgttgc
gattcgaggcggttaaccgtcacgagcatcatcctctgcattggtcaggtcatggtgagcagacgatggtgca
ggatgtaagtttaaaactattcgttactaactaactttaaactttaaattttcagatcctgctgatgaagca
gaacaactttaacgcggtgcgctgttcgcattatccgaaccatccgctgtggtacacgctgtgcgacctga
cgccctgtatgtggtggatgaagccaatattgaaacccacggcatggtgccaatgaatcgcttgaccgatga
tccgcgctggctaccggcgatgagcgaacgcgtaacgcgaatggtgcagcgcgatcgtaatcacccgagtg
gatcatctggtcgctgggaatggtaagtttaaacagttgaataactaactaacggagatctttgaaattttc
agaatcaggccacggcgtaatcacgacgcgctgtatcgctggatcaaactctgcgatccttccgcggcggt
gcagtatgaaggcggcgagccgacaccacggccaccgatattattgcccgatgtacgcgcgctggatga
agaccagcccttcccgctgtgcccgaatggtccatcaaaaaatggctttcgctacctggagagacgcgccc
gctgattctttgcgaggtaagtttaacagaactctactaactaacacattagatcctaattttcagtagc
tcacgcatgggcaacagtccttggcggtttcgctaaatactggcaggcggtttcgctcagtatccccgtttaca
ggcggttctgcttggactgggtggatcagtcgctgattaaatatgatgaaaacggcaacccgtggtcggc
ttacggcggtgattttggcgatacgcgaacgatcgccagttctgtatgaacggtctggtctttgccgaccg
cacgcgcatccagcgtaagtttaaaacaataacctaactaactaacgtagataatttaaattttcaggctgac
ggaagcaaaacaccagcagcagtttttccagttccgtttatccgggcaaacatcgaagtaccagcgaata
cctgttccgctcatagcgataacgagctcctgcactggatggtggcgctggatggttaagccgctggcaagcg
tgaagtgcctctggatgtcgctccacaaggtaaacagttgattgaactgcctgaactaccgcagccggagag
cgccgggcaactctggctcacagtacgcgtagtgaaccgaacgcgacccgatggtcagaagccgggacat
cagcgcatggcagcagtgagggttaagtttaacaagatcctactaactaactctacattgatgaattttcag
actggcggaacacctcagtgtagcgtccccgcgctccacgcatcccgcatctgaccaccagcgaaat
ggatttttgcacgagctgggttaataagcgttggcaatttaaccgccagtcaggctttctttcacagatgtg
gattggcgataaaaaaactgctgacgccgctgcgcgatcagttcaccgctgcaccgctggataaacgacat
tggcgtaagtgaagcgaccgcattgaccctaacgcctgggtcggttaagtttaacaaagttgtaactaacta
acgaagatcttgataattttcagaacgctggaaggcggcgccattaccaggccgaagcagcgttgttgca
gtgcacggcagatacacttgcgtgatgcggtgctgattacgaccgctcacgcgtggcagcatcaggggaaac
cttattttatcagccggaaaacctaccggattgatggttagtggtcaaatggcgattaccggttgatgttgaagt

H/27

FIG. 4 (CONTINUED).

ggcgagcgatacacccgcatccggcgcggtattggcctgaactgccagctggcgaggtagcagagcggttaa
ctggctcggtattagggccgcaagaaaactatcccgaccgcttactgccgctgttttgaccgctgggtatc
gccattgtcagacatgtagtaagtttaacttgatagtactaactaacatgtttcatttaaattttcagtac
cccgtagctcttcccgagcgaaaacggctcgctgcgggacgcgcaattgaattatggccacaccagtg
gcgcgcgacttccagttcaacatcagccgtacagtaacagcaactgatggaaaccagccatcgccatct
gctgcacgcggaagaaggcacatggctgaatatcgacgggttccatatggggattggtggcgacgactcctg
gagcccgctcagtatcgccggaattccaactgagcgccggtcgctaccattaccaactgtctggtgtcaaaa
ataatagggggcgctgtcatcagagtaagtttaactgagttctactaactaacagagtaataatttaaat
cagcatctcgcccgctgcctctgacttctaagtccaattactcttcaacatccctacatgctctttctccc
tgtgctcccacccctatttttgttattatcaaaaaaacttcttcttaatttctttgttttttagcttcttt
taagtacaccttaacaatgaaattgtgtagattcaaaaaatagaatttaattcgtaataaaaaagtcgaaaaaa
ttgtgctccctccccccatttaataataattctatccccaaatctacacaatgttctgtgtacacttcttatg
tttttttacttctgataaatttttttgaacatcatagaaaaaacgcacacaaaataccttatcatatg
ttacgtttcagtttatgaccgcaatttttatttcttcgcacgtctgggctctcatgacgtcaaatcatgct
catcgtgaaaaagttttggagtatttttgaatttttcaatcaagtgaagtttatgaaatttaatttctctg
cttttgctttttgggggtttccctattgtttgtcaagagtttcgaggacgcggttttcttctgtaaaatca
caagttgatgagcacgatgcaagaaagatcggaagaaggtttgggtttgaggtcagtggaaggtgagta
gaagttgataaattgaaagtgagtagtgtctatgggggttttgccttaaatgacagaatacattcccaata
taccacataactgtttcctactagtcggccgtacggggccctttcgtctcgcggtttcgtgtgacggt
gaaaacctctgacacatgcagctcccgagacggtcacagcttgcctgtaagcggtatgccgggagcagacaa
gcccgtcagggcgcgctcagcggtgttgccgggtgtcggggtggtggttaactatcgggcatcagagcagatt
gtactgagagtgaccatatgcggtgtgaaataccgcacagatgcgtaaggagaaaaataccgcacagggcg
ccttaaggccctcgtgatacgcctatttttataggttaattgtcatgataataatggtttcttagacgtcagg
tggcacttttcggggaaatgtgcgcggaacccctattgtttatttttctaaatacattcaaatatgtatcc
gctcatgagacaataaccctgataaattgcttcaataattgaaaaaggaagagtagtagtattcaacattt
ccgtgtcgcccttattcccttttttgcggcattttgccttctgttttgcctcaccagaaacgctggtgaa
agtataagatgctgaagatcagttgggtgcacgagtggttacatcgaactggatctcaacagcggttaagat
ccttgagagttttcgccccgaagaacgttttccaatgatgagcacttttaagttctgctatgtggcgcggt
attatcccgatttgacgcgggcaagagcaactcggctcgccgatacactattctcagaatgacttggttga
gtactcaccagtcacagaaaagcatcttacggatggcatgacagtaagagaattatgcagtgctgccataac
catgagtgataacactgcggccaacttacttctgacaacgatcgaggagaccgaaggagctaaccgcttttt
gcacaacatgggggatcatgtaactgccttgactggttggaacccgagctgaatgaagccataccaaacga
cgagcgtgacaccacgatgcctgtagcaatggcaacaacgttgcgcaactattaactggcgaactacttac
tctagcttcccggaacaattaatagactggatggaggcgataaagttgcaggaccacttctgcgctcggc
ccttccggctgggtggtttattgctgataaattctggagccggtgagcgtgggtctcgcggtatcattgcagc
actggggccagatggtaagccctcccgatcgtagttatctacacgacggggagtcaggcaactatggatga
acgaaatagacagatcgctgagataggtgcctcactgattaagcattggtaactgtcagaccaagtttactc
atatatacttttagattgatttaaaacttcatttttaatttaaaaggatctaggtgaagatccttttgataa
tctcatgacaaaaatcccttaacgtgagtttctgctccactgagcgtcagaccccgtagaaaagatcaaagg
atcttcttgagatccttttttctgcgcgtaattctgctgcttgcaacaaaaaaaccaccgctaccagcggt
ggtttggttgccggatcaagagctaccaactcttttccgaaggttaactggcttcagcagagcgagataacc
aaatactgtccttctagtgtagccgtagtttaggccaccacttcaagaactctgtagcacccgctacatacct
cgctctgctaactcctgttaccagtggtgctgctgccaagtgccgataaagtcgtgtcttaccgggttgactcaag
acgatagttaccggataaaggcgacggtcgggctgaacggggggttcgtgcacacagccagcttggagcg
aacgacctacaccgaactgagatactacagcgtgagcattgagaaaagccacgcttcccgagggaagaaa
ggcgacaggtatccggttaagcggcaggtcggaacaggagagcgacgagggagcttccaggggaaacgc
ctggtatctttatagtcctgtcggtttcgccacctctgacttgagcgtcgatttttgtgatgctcgtcagg
ggggcgagcctatggaaaaacgccagcaacggcgcccttttacggttcttggccttttgcgtggccttttgc
tcacatgttcttctcgttatccctgattctgtggataaaccgtattaccgcctttgagtgagctgatac
cgctcgccgacgccaacgaccgagcgacgagtcagtgagcgaggaagcggaagagcgccaataacgcaa
accgctctccccgcgcttgccgattcattaatgcagctggcagcagaggtttcccgactggaaagcggt
cagtgagcgcaacgcaattaatgtgagtttagctcactcattaggcaccacaggtttacactttatgcttcc
ggctcgtatgtgtgtggaattgtgagcggaataacaatttcacacaggaacagctatgaccatgattacgc
ca

12/27

FIG. 5. Nucleotide sequence of pGQ3

```

CGCGCCATGA GTAAAGGAGA AGAACTTTTC ACTGGAGTTG TCCCAATTCT
TGTTGAATTA GATGGTGATG TTAATGGGCA CAAATTTTCT GTCAGTGGAG
AGGGTGAAGG TGATGCAACA TACGGAAAAC TTACCCCTAA ATTTATTTGC
ACTACTGGAA AACTACCTGT TCCATGGGTA AGTTTAAACA TATATATACT
AACTAACCTT GATTATTTAA ATTTTCAGCC AACACTTGTC ACTACTTTCT
GTTATGGTGT TCAATGCTTC TCGAGATACC CAGATCATAT GAAACGGCAT
GACTTTTTCA AGAGTGCCAT GCCCGAAGGT TATGTACAGG AAAGAAGTAT
ATTTTTCAAA GATGACGGGA ACTACAAGAC ACGTAAGTTT AAACAGTTCG
GTACTAACTA ACCATACATA TTTAAATTTT CAGGTGCTGA AGTCAAGTTT
GAAGGTGATA CCCTTGTTAA TAGAATCGAG TTAAAAGGTA TTGATTTTAA
AGAAGATGGA AACATTCTTG GACACAAATT GGAATACAAC TATAACTCAC
ACAATGTATA CATCATGGCA GACAAACAAA AGAATGGAAT CAAAGTTGTA
AGTTTAAACT TGGACTTACT AACTAACGGA TTATATTTAA ATTTTCAGAA
CTTCAAAATT AGACACAACA TTGAAGATGG AAGCGTTCAA CTAGCAGACC
ATTATCAACA AAATACTCCA ATTGGCGATG GCCCTGTCTT TTTACCAGAC
AACCATTACC TGTCCACACA ATCTGCCCTT TCGAAAGATC CCAACGAAAA
GAGAGACCAC ATGGTCCTTC TTGAGTTTGT AACAGCTGCT GGGATTACAC
ATGGCATGGA TGAATATAC AAATAGGGCC GGCCGAGCTC CGCATCGGCC
GCTGTCATCA GATCGCCATC TCGCGCCCGT GCCTCTGACT TCTAAGTCCA
ATTACTCTTC AACATCCCTA CATGCTCTTT CTCCCTGTGC TCCCACCCCC
TATTTTGTGT ATTATCAAAA AAACCTCTTC TTAATTTCTT TGTTTTTTAG
CTTCTTTTAA GTCACCTCTA ACAATGAAAT TGTGTAGATT CAAAAATAGA
ATTAATTCGT AATAAAAAGT CGAAAAAAT TGTGCTCCCT CCCCCATTA
ATAATAATTC TATCCCAAAA TCTACACAAT GTTCTGTGTA CACTTCTTAT
GTTTTTTTTT CTTCGTGATA ATTTTTTTTG AAACATCATA GAAAAAACCG
CACACAAAAT ACCTTATCAT ATGTTACGTT TCAGTTTATG ACCGCAATTT
TTATTTCTTC GCACGTCTGG GCCTCTCATG ACGTCAAATC ATGCTCATCG
TGAAAAAGTT TTGGAGTATT TTTGGAATTT TTCAATCAAG TGAAAGTTTA
TGAAATTAAT TTTCTGCTT TTGCTTTTGG GGGGTTTCCC CTATTGTTTG
TCAAGAGTTT CGAGGACGGC GTTTTTCTTG CTAAAATCAC AAGTATTGAT
GAGCACGATG CAAGAAAGAT CGGAAGAAGG TTTGGGTTTG AGGCTCAGTG
GAAGGTGAGT AGAAGTTGAT AATTTGAAAG TGGAGTAGTG TCTATGGGGT
TTTTGCCTTA AATGACAGAA TACATTCCCA ATATACCAA CATAACTGTT
TCCTACTAGT CGGCCGTACG GGCCCTTTCG TCTCGCGCGT TCGGTGATG
ACGGTGAAAA CCTCTGACAC ATGCAGCTCC CGGAGACGGT CACAGCTTGT
CTGTAAGCGG ATGCCGGGAG CAGACAAGCC CGTCAGGGCG CGTCAGCGGG
TGTTGGCGGG TGTCGGGGCT GGCTTAACTA TGCGGCATCA GAGCAGATTG
TACTGAGAGT GCACCATATG CGGTGTGAAA TACCGCACAG ATGCGTAAGG
AGAAAATACC GCATCAGGCG GCCTTAAGGG CCTCGTGATA CGCCTATTTT
TATAGGTTAA TGTCATGATA ATAATGGTTT CTTAGACGTC AGGTGGCACT
TTTCGGGGAA ATGTGCGCGG AACCCTTATT TGTTTATTTT TCTAAATACA
TTCAAATATG TATCCGCTCA TGAGACAATA ACCCTGATAA ATGCTTCAAT
AATATTGAAA AAGGAAGAGT ATGAGTATTC AACATTTCCG TGTCGCCCTT
ATTCCCTTTT TTGCGGCATT TTGCCTTCCT GTTTTTGCTC ACCCAGAAAC
GCTGGTGAAA GTAAAAGATG CTGAAGATCA GTTGGGTGCA CGAGTGGGTT
ACATCGAACT GGATCTCAAC AGCGGTAAGA TCCTTGAGAG TTTTCGCCCC
GAAGAAGGTT TTCCAATGAT GAGCACTTTT AAAGTTCTGC TATGTGGCGC
GGTATTATCC CGTATTGACG CCGGGCAAGA GCAACTCGGT CGCCGCATAC
ACTATTCTCA GAATGACTTG GTTGAGTACT CACCAGTCAC AGAAAAGCAT

```

13/27

FIG. 5 (CONTINUED 1).

CTTACGGATG GCATGACAGT AAGAGAATTA TGCAGTGCTG CCATAACCAT
 GAGTGATAAC ACTGCGGCCA ACTTACTTCT GACAACGATC GGAGGACCGA
 AGGAGCTAAC CGCTTTTTTG CACAACATGG GGGATCATGT AACTCGCCTT
 GATCGTTGGG AACC GGAGCT GAATGAAGCC ATACCAAACG ACGAGCGTGA
 CACCACGATG CCTGTAGCAA TGGCAACAAC GTTGC GCAA CTATTAAGTG
 GCGAACTACT TACTCTAGCT TCCCGGCAAC AATTAATAGA CTGGATGGAG
 GCGGATAAAG TTGCAGGACC ACTTCTGCGC TCGGCCCTTC CGGCTGGCTG
 GTTTATTGCT GATAAATCTG GAGCCGGTGA GCGTGGGTCT CGCGGTATCA
 TTGCAGCACT GGGGCCAGAT GGTAAAGCCCT CCCGTATCGT AGTTATCTAC
 ACGACGGGGA GTCAGGCAAC TATGGATGAA CGAAATAGAC AGATCGCTGA
 GATAGGTGCC TCACTGATTA AGCATTGGTA ACTGTCAGAC CAAGTTTACT
 CATATATACT TTAGATTGAT TTAAGACTTC ATTTTAAAT TAAAGGATC
 TAGGTGAAGA TCCTTTTTGA TAATCTCATG ACCAAATCC CTTAACGTGA
 GTTTTCGTTT CACTGAGCGT CAGACCCCGT AGAAAAGATC AAAGGATCTT
 CTGAGATCC TTTTTTCTG CGCGTAATCT GCTGCTTGCA AACAAAAAAA
 CCACCGCTAC CAGCGGTGGT TTGTTTGCCG GATCAAGAGC TACCAACTCT
 TTTCCGAAG GTAAGTGGCT TCAGCAGAGC GCAGATACCA AATACTGTCC
 TTCTAGTGTA GCCGTAGTTA GGCCACCACT TCAAGAACTC TGTAGCACC
 CCTACATACC TCGCTCTGCT AATCCTGTTA CCAGTGGCTG CTGCCAGTGG
 CGATAAGTCG TGCTTTACCG GGTTGGACTC AAGACGATAG TTACCGGATA
 AGGCGCAGCG GTCGGGCTGA ACGGGGGGTT CGTGACACACA GCCCAGCTTG
 GAGCGAACGA CCTACACCGA ACTGAGATAC CTACAGCGTG AGCATTGAGA
 AAGCGCCACG CTTCGGAAG GGAGAAAGGC GGACAGGTAT CCGGTAAGCG
 GCAGGGTCGG AACAGGAGAG CGCACGAGGG AGCTCCAGG GGGAAACGCC
 TGGTATCTTT ATAGTCTGTG CGGGTTTCGC CACCTCTGAC TTGAGCGTCG
 ATTTTGTGA TGCTCGTCAG GGGGGCGGAG CCTATGGAAA AACGCCAGCA
 ACGCGGCCCT TTTACGGTTC CTGGCCTTTT GCTGGCCTTT TGCTCACATG
 TTCTTCTCTG CGTTATCCCC TGATTCTGTG GATAACCGTA TTACCGCCTT
 TGAGTGAGCT GATACCGCTC GCCGCAGCCG AACGACCGAG CGCAGCGAGT
 CAGTGAGCGA GGAAGCGGAA GAGCGCCCAA TACGCAAAAC GCCTCTCCCC
 GCGCGTTGGC CGATTCAATTA ATGCAGCTGG CACGACAGGT TTCCCGACTG
 GAAAGCGGGC AGTGAGCGCA ACGCAATTAA TGTGAGTTAG CTCACTCATT
 AGGCACCCCA GGCTTTACAC TTTATGCTTC CGGCTCGTAT GTTGTGTGGA
 ATTTGTAGCG GATAACAATT TCACACAGGA AACAGCTATG ACCATGATTA
 CGCCAAGCTT GCATGCCCTG AGTGATTCAG AGAGGTTGAG AATTATTTTC
 AAAAACATTC AATGTTTTCC CTTGGAGTGA CTATGCAAT ATGAAAATGT
 TTTCCAAAAA TATTTGGATG CCCTGATAAA AAGTAGGTGA AATTTCCGAG
 GGGAACATCA TATTAATG TTGAATTTT AGAAGAAATG GAAATGTTTG
 TCGGTGGTAT GCTCGAATAT TTGAGATATT ATATATTTAC TGTTAAATCC
 GAAATTTTG ACAACCGAA AAAATTTGTG TCGAAATACT ACATTTTCGA
 TAACACAAAG GTACTTCCAT AACACTTATA AAAACTGTTT GACTATCTTA
 ATTGTGTTTC CATGAAGGTA TTGTGAATAT TTTTGACAAA CTGATAGAAT
 TTTTCAGGAA AAAAATCCA AGAATAAACA TTTTCAGAA TTTGAAGTTT
 CTAATGGCTG ATTAATAAAA CAAAGTTATA CAACTATTCA AAGCAGTTGC
 TCAATCTGGC ATTTTCTTGT GTTTTTTTTT GAATATTTCA TCAGCAAGAT
 GTTGATAATT TTGTGTTAAT TCTAATTGTT TTCTACAATT TTTCAAACCG
 AAAATTGACC TTTGACTTTG TTTACTTTGT TCTCGTGGGT TAAGTGTCA
 CTGATTTCTA TTGCTGTTGA TGAGGTCTTT GATCAATTT GTATTGTTTT
 TATACTGCAT ATTGCTTCAA TTCTAAATCA TCTAATATAT TGTCAAACAA
 CTTCTTGT TTTTTTTCAT TCAAACTTC TGCAAAAACG TTCTCTTAAC
 AAAGGTTTAC ACAACAATC TCCTCTCCAT CTCTTTCTCT CAACAACAAT

14/27

FIG. 5 (CONTINUED 2).

GTGCTGGCCT TGCATGTTTG CCAGTGCGGG TTGTTTACGC GTTTTCAAGA
TTTTTGGTCT CCTATCTAAC GTCCCGAAAT GCATTTTTTC CTTTCATTTG
GTTTTTTTCT GTTCGAGAAA AGTGACCGTT TGTCAAATCT TCTAATTTTC
AGTGAATAAA ATGCTGCAAT CTACTGCTCG CACTGCTTCA AAGCTTGTTT
AACCGGTTGC GGGGTAAGTC AAAATGAAAT TTTCGTTTAA AAATTGGTTT
TTTTTGGTAT TATAGATAAA ACTTATACCA AAACAAAACA TATTTAGAAA
AACTTTAATA GAGAATAATT GTTTAATAAT TAATTTTTGC AAGCTCCTTT
TAAATTAAGA CATCTAAAAC AGTTTTCAGC TTGATTGTTT TAATGGTTTA
GAAAGCAATA TTTGTATTTT GTGTTAAACT GAAAATATCT AGGAAATACT
ACTTTTAAAA TATTTGAAAC TTGAAATTTT AAAATTCCAA ATAATTTTAC
TCATTTCCCTA AAGTGTTTGA GTATTTGTAT CCTGTGCTGA CACCGAAATG
TTCTCAATTT TGGAAAAAAA AGATTTTAT CCGTATCTTC AGTCTTACAA
TTTTTTTTCAC CTTTTTTTTT ATTTCAGAGT TCTCGCCGTC CGCTCCAAGC
ACACTCTCCC AGATCTCCCA TTCGACTATG CAGATTTGGA ACCTGTAATC
AGCCATGAAA TCATGCAGCT TCATCATCAA AAGCATCATG CCACCTACGT
GAACAATCTC AATCAGATCG AGGAGAACT TCACGAGGCT GTTTCGAAAG
GTTTTTTAAT CAGAAGATTT TGAAATGAAT TTTTTTTTGT GTATATAGGG
AATCTAAAAG AAGCAATTGC TCTCCAACCA GCGCTGAAAT TCAATGGTGG
TGGACACATC AATCATTCTA TCTTCTGGAC CAACTTGGCT AAGGATGGTG
GAGAACCTTC AAAGGAGCTG ATGGACACTA TTAAGGCTTG G

15/27

FIG. 6. Nucleotide sequence of pGQ4

```

GTGATTCAGA GAGGTTGAGA ATTATTTTCA AAAACATTCA ATGTTTCC
TTGGAGTGAC TATGCAAATA TGAAATGTT TTCCAAAAT ATTTGGATGC
TGAATTTTTA GAAGAAATGG AAATGTTTGT CCGTGGTATG CTCGAATATT
TGAGATATTA TATATTTACT GTTAAATCCG AAATTTTGA CAAACGGAAA
AAATTTGTGT CGAAATACTA CATTTTCGAT AACACAAAGG TACTTCCATA
TTTAAACACA GCTTTATGAT GTAAAAGCTA TTGTGTTTCC ATGAAGGTAT
ACACTTATAA AACTGTTTG ACTATCTTAT TTCAGGAAAA AAAAATCCAA
GAATAACAT TTTTCAGAAAT TTGAACTTTC TAATGGCTGA TTAATAAAAC
AAAGTTATAC AACTATTCAA AGCAGTTGCT CAATCTGGCA TTTTCTTG
TTTTTTTTTG AATATTTTAT CAGCAAGATG TTGATAATTT TGTGTTAATT
CTAATTGTTT TCTACAATTT TTCAAACCGA AAATTGACCT TTGACTTTGT
TTACTTTGTT CTCGTGGGTT AACTGTTTAC TGATTTCTAT TGCTGTTGAT
GAGGTCTTTG ATCAAATTTG TATGTGTTTT ATACTGCATA TTGCTTCAAT
TCTAAATCAT CTAATATATT GTCAAACAAC TTCTGTGTTT TTTTTCATT
CAAAACTTCT GCAAAAACGT TCTCTTAACA AAGGTTTACA CAACAACCT
CCTCTCCATC TCTTTCTCTC AACAACAATG TGCTGGCCTT GCATGTTTGC
CAGTGCGGGT TGTTTACGCG TTTTCAAGAT TTTTGGTCTC CTATCTAACG
TCCCGAAATG CATTTTTTCC TTTTATTGTT TTTTCTCTG TTCGAGAAAA
GTGACCGTTT GTCAAATCTT CTAATTTTCA GTGAATAAAA TGCTGCAATC
TACTGCTCGC ACTGCTTCAA AGCTTGTTC ACCGGTTGCG GGGTAAGTCA
AAATGAAATT TTCGTTTAAA AATTGGTTTT TTTTGGTATT ATAGATAAAA
CTTATACCAA AACAAAACAT ATTTAGAAAA ACTTTAATAG AGAATAATTG
TTAATAAATT AATTTTTGCA AGCTCCTTTT AAATTAAGAC ATCTAAAACA
GTTTTCAGCT TGATTGTTTT AATGGTTTAG AAAGCAATAT TTGTATTTG
TGTTAAACTG AAAATATCTA GGAAATACTA CTTTAAAAAT ATTTGAAACT
TGAAATTTTA AAATCCAAA TAATTTTACT CATTTCTTAA AGTGTGTTGAG
TATTTGTATC CTGTGCTGAC ACCGAAATGT TCTCAATTTT GGAAAAAAA
GATTTTTATC CGTATCTTCA GTCTTACAAT TTTTTCACC TTTTTCATC
TTTCAGAGTT CTCGCCGTCC GCTCCAAGCA CACTCTCCCA GATCTCCCAT
TCGACTATGC AGATTTGGAA CCTGTAATCA GCCATGAAAT CATGCAGCTT
CATCATCAAA AGCATCATGC CACCTACGTG AACAATCTCA ATCAGATCGA
GGAGAAACTT CACGAGGCTG TTTCGAAAAG TTTTAAATC AGAAGATTTT
GAAATGAATT TTTTTTTTGG TATATAGGGA ATCTAAAAGA AGCAATTGCT
CTCCAACCAG CGCTGAAATT CAATGGTGGT GGACACATCA ATCATTCTAT
CTTCTGGACC AACTTGGCTA AGGATGGTGG AGAACCTTCA AAGGAGCTGA
TGGACACTAT TAAGCCGAGC TCAGAAAAAA TGACTGCTCC AAAGAAGAAG
CGTAAGGTAC CGGTAGAAAA AATGGAAGAC GCCAAAAACA TAAAGAAGG
CCCGGCGCCA TTCTATCCGC TGGAAGATGG AACCGCTGGA GAGCAACTGC
ATAAGGCTAT GAAGAGATAC GCCCTGGTTC CTGGAACAAT TGCTTTTACA
GATGCACATA TCGAGGTGGA CATCACTTAC GCTGAGTACT TCGAAATGTC
CGTTCGGTTG GCAGAAGCTA TGAAACGATA TGGGCTGAAT ACAAATCACA
GAATCGTCGT ATGCAGTGAA AACTCTCTTC AATTCTTTAT GCCGGTGTG
GGCGCGTTAT TTATCGGAGT TGCAGTTGCG CCCGCGAAGC ACATTTATAA
TGAACGTGAA TTGCTCAACA GTATGGGCAT TTCCGAGCCT ACCGTGGTGT
TCGTTTCCAA AAAGGGGTTG CAAAAAATTT TGAACGTGCA AAAAAAGCTC
CCAATCATCC AAAAAATTAT TATCATGGAT TCTAAACGG ATTACCAGGG
ATTTCACTCG ATGTACACGT TCGTCACATC TCATCTACCT CCCGGTTTTA
ATGAATACGA TTTTGTGCCA GAGTCCTTCG ATAGGGACAA GACAATTGCA

```


16/27

FIG. 6 (CONTINUED 1).

CTGATCATGA ACTCCTCTGG ATCTACTGGT CTGCCTAAAG GTGTCGCTCT
 GCCTCATAGA ACTGCCTGCG TGAGATTCTC GCATGCCAGA GATCCTATTT
 TTGGCAATCA AATCATTCCG GATACTGCGA TTTTAAGTGT TGTTCCATTC
 CATCACGGTT TTGGAATGTT TACTACACTC GGATATTTGA TATGTGGATT
 TCGAGTCGTC TTAATGTATA GATTTGAAGA AGAGCTGTTT CTGAGGAGCC
 TTCAGGATTA CAAGATTCAA AGTGCCTGTC TGGTGCCAAC CCTATTCTCC
 TTCTTCGCCA AAAGCACTCT GATTGACAAA TACGATTTAT CTAATTTACA
 CGAAATTGCT TCTGGTGGCG CTCCCTCTC TAAGGAAGTC GGGGAAGCGG
 TTGCCAAGAG GTTCCATCTG CCAGGTATCA GGCAAGGATA TGGGCTCACT
 GAGACTACAT CAGCTATTCT GATTACACC GAGGGGGATG ATAAACCGGG
 CGCGGTGCGT AAAGTTGTTT CATTTTTTGA AGCGAAGGTT GTGGATCTGG
 ATACCGGGAA AACGCTGGGC GTTAATCAAA GAGGCGAACT GTGTGTGAGA
 GGTCTTATGA TTATGTCCGG TTATGTAAAC AATCCGGAAG CGACCAACGC
 CTTGATTGAC AAGGATGGAT GGCTACATTC TGGAGACATA GCTTACTGGG
 ACGAAGACGA ACACTTCTTC ATCGTTGACC GCCTGAAGTC TCTGATTAAG
 TACAAAGGCT ATCAGGTGGC TCCCGCTGAA TTGGAATCCA TCTTGCTCCA
 ACACCCCAAC ATCTTCGACG CAGGTGTGCG AGGTCTTCCC GACGATGACG
 CCGGTGAACT TCCCGCCGCC GTTGTGTTTT TGGAGCACGG AAAGACGATG
 ACGGAAAAAG AGATCGTGGA TTACGTGCGC AGTCAAGTAA CAACCGCGAA
 AAAGTTGCGC GGAGGAGTTG TGTTTGTGGA CGAAGTACCG AAAGGTCTTA
 CCGGAAAAC CGACGCAAGA AAAATCAGAG AGATCCTCAT AAAGGCCAAG
 AAGGGCGGAA AGATCGCCGT GTAATTCTAG GAATTCACAC TGAGCGCCGG
 TCGCTACCAT TACCAACTTG TCTGGTGTCA AAAATAATAG GGGCCGCTGT
 CATCAGAGTA AGTTTAACT GAGTTCTACT AACTAACGAG TAATATTTAA
 ATTTTCAGCA TCTCGCGCCC GTGCCTCTGA CTTCTAAGTC CAATTACTCT
 TCAACATCCC TACATGCTCT TTCTCCCTGT GCTCCCACCC CCTATTTTTG
 TTATTATCAA AAAAATTCT TCTTAATTTT TTTGTTTTTT AGCTCTTTTT
 AAGTCACCTC TAACAATGAA ATTGTGTAGA TTCAAAAATA GAATTAATTC
 GTAATAAAAA GTCGAAAAAA ATTGTGCTCC CTCCTCCCAT TAATAATAAT
 TCTATCCCAA AATCTACACA ATGTTCTGTG TACACTTCTT ATGTTTTTTT
 TACTTCTGAT AAATTTTTTT TGAAACATCA TAGAAAAAC CGCACACAAA
 ATACCTTATC ATATGTTACG TTTCAGTTTA TGACCGCAAT TTTTATTTCT
 TCGCACGTCT GGGCCTCTCA TGACGTCAA TCATGCTCAT CGTGAAAAAG
 TTTTGGAGTA TTTTGGAAAT TTTTCAATCA AGTGAAAGTT TATGAAATTA
 ATTTTCCTGC TTTTGCTTTT TGGGGGTTTC CCTATTGTT TGTCAGAGT
 TTCGAGGACG GCGTTTTTCT TGCTAAAATC ACAAGTATTG ATGAGCACGA
 TGCAAGAAAG ATCGGAAGAA GGTGTTGGTT TGAGGCTCAG TGGAAGGTGA
 GTAGAAGTTG ATAATTTGAA AGTGGAGTAG TGTCTATGGG GTTTTTGCCT
 TAAATGACAG AATACATTCC CAATATACCA AACATAACTG TTTCTACTA
 GTCGGCCGTA CGGGCCCTTT CGTCTCGCGC GTTTCGGTGA TGACGGTGAA
 AACCTCTGAC ACATGCAGCT CCCGGAGACG GTCACAGCTT GTCTGTAAGC
 GGATGCCGGG AGCAGACAAG CCCGTCAGGG CGCGTCAGCG GGTGTTGGCG
 GGTGTCGGGG CTGGCTTAAC TATGCGGCAT CAGAGCAGAT TGTACTGAGA
 GTGCACCATA TGCGGTGTGA AATACCGCAC AGATGCGTAA GGAGAAAATA
 CCGCATCAGG CGGCCTTAAG GGCCTCGTGA TACGCTATT TTTTATAGTT
 AATGTCATGA TAATAATGGT TTCTTAGACG TCAGGTGGCA CTTTTCGGGG
 AAATGTGCGC GGAACCCCTA TTTGTTTATT TTTCTAAATA CATTCAAATA
 TGTATCCGCT CATGAGACAA TAACCTGAT AAATGCTTCA ATAATATTGA
 AAAAGGAAGA GTATGAGTAT TCAACATTTT CGTGTGCGCC TTATTCCCTT
 TTTTGC GGCA TTTTGCCTTC CTGTTTTTGC TCACCCAGAA ACGCTGGTGA
 AAGTAAAAGA TGCTGAAGAT CAGTTGGGTG CACGAGTGGG TTACATCGAA

17/27

FIG. 6 (CONTINUED 2).

CTGGATCTCA ACAGCGGTAA GATCCTTGAG AGTTTTTCGCC CCGAAGAACG
TTTTCCAATG ATGAGCACTT TTAAAGTTCT GCTATGTGGC GCGGTATTAT
CCCGTATTGA CGCCGGGCAA GAGCAACTCG GTCGCCGCAT ACACTATTCT
CAGAA TGACT TGGTTGAGTA CTCACCAGTC ACAGAAAAGC ATCTTACGGA
TGGCATGACA GTAAGAGAAT TATGCAGTGC TGCCATAACC ATGAGTGATA
ACACTGCGGC CAACTTACTT CTGACAACGA TCGGAGGACC GAAGGAGCTA
ACCGCTTTTT TGCACAACAT GGGGGATCAT GTAACTCGCC TTGATCGTTG
GGAACCGGAG CTGAATGAAG CCATACCAAA CGACGAGCGT GACACCACGA
TGCCTGTAGC AATGGCAACA ACGTTGCGCA AACTATTAAC TGGCGAACTA
CTTACTCTAG CTTCCCGGCA ACAATTAATA GACTGGATGG AGGCGGATAA
AGTTGCAGGA CCACTTCTGC GCTCGGCCCT TCCGGCTGGC TGGTTTATTG
CTGATAAATC TGGAGCCGGT GAGCGTGGGT CTCGCGGTAT CATGTCAGCA
CTGGGGCCAG ATGGTAAGCC CTCCCGTATC GTAGTTATCT ACACGACGGG
GAGTCAGGCA ACTATGGATG AACGAAATAG ACAGATCGCT GAGATAGGTG
CCTCACTGAT TAAGCATTGG TAACTGTCAG ACCAAGTTTA CTCATATATA
CTTTAGATTG ATTTAAACT TCATTTTAA TTTAAAGGA TCTAGGTGAA
GATCCTTTTT GATAATCTCA TGACCAAAAT CCCTAACGT GAGTTTTCGT
TCCACTGAGC GTCAGACCCC GTAGAAAAGA TCAAAGGATC TTCTTGAGAT
CCTTTTTTTC TGCGCGTAAT CTGCTGCTTG CAAACAAAAA AACCACCGCT
ACCAGCGGTG GTTTGTTTGC CGGATCAAGA GCTACCAACT CTTTTCCGA
AGGTAACCTG CTTACAGCAGA GCGCAGATAC CAAATACTGT CCTTCTAGTG
TAGCCGTAGT TAGGCCACCA CTTCAAGAAC TCTGTAGCAC CGCCTACATA
CCTCGCTCTG CTAATCCTGT TACCAAGTGC TGCTGCCAGT GGCATAAGT
CGTGTCTTAC CGGGTTGGAC TCAAGACGAT AGTTACCGGA TAAGGCGCAG
CGGTCGGGCT GAACGGGGGG TTCGTGCACA CAGCCCAGCT TGGAGCGAAC
GACCTACACC GAACTGAGAT ACCTACAGCG TGAGCATTGA GAAAGCGCCA
CGCTTCCCGA AGGGAGAAAG GCGGACAGGT ATCCGGTAAG CGGCAGGGTC
GGAACAGGAG AGCGCACGAG GGAGCTTCCA GGGGAAACG CCTGGTATCT
TTATAGTCCT GTCGGGTTTC GCCACCTCTG ACTTGAGCGT CGATTTTGT
GATGCTCGTC AGGGGGGCGG AGCCTATGGA AAAACGCCAG CAACGCGGCC
TTTTTACGGT TCCTGGCCTT TTGCTGGCCT TTTGCTCACA TGTTCTTTCC
TGCGTTATCC CCTGATTCTG TGGATAACCG TATTACCGCC TTTGAGTGAG
CTGATACCGC TCGCCGCAGC CGAACGACCG AGCGCAGCGA GTCAGTGAGC
GAGGAAGCGG AAGAGCGCCC AATACGCAAA CCGCCTCTCC CCGCGCGTTG
GCCGATTCTA TAATGCAGCT GGCACGACAG GTTCCCGAC TGGAAAGCGG
GCACTGAGCG CAACGCAATT AATGTGAGTT AGCTCACTCA TTAGGCACCC
CAGGCTTTAC ACTTTATGCT TCCGGCTCGT ATGTTGTGTG GAATTGTGAG
CGGATAACAA TTTCACACAG GAAACAGCTA TGACCATGAT TACGCCAAGC
TGTAAGTTTA AACATGATCT TACTAACTAA CTATTCTCAT TTAATTTTC
AGAGCTTAAA AATGGCTGAA ATCACTCACA ACATGGATA CGCTAACAA
TTGGAAATGA AATAAGCTTG CATGCCTGCA


18/27

FIG. 7. Nucleotide sequence of the vit-2 promoter/NLS

ATGTTTAGAA CCCCTCATTC AAAATTAATA GACAGGGGCTC TCACCGAATG TTGCAATTTG
TTTCTGATAA GGGTCACAAA GCGGAGCGAA TGCTTGAATG TGTCCATCAA TGAGCTTATC
AATGCGCTAA AACGCTATAA CTTCCATATG AAGTCAATCG AACATATGTC AATCTTTAGC
CGTATATAAA GGTGCACTGA AAACAGTCCA ATCACGGTTC AGCCATGAGG TCGATCCCCG
GCCGGGATTG GCCAAAGGAC CCAAAGGTAT GTTTCGAATG ATACTAACAT AACATAGAAC
ATTTTCAGGA GGACCCTTGG AGGGTACCGG GGATTGGCCA AAGGACCCAA AGGTATGTTT
CGAATGATAC TAACATAACA TAGAACATTT TCAGGAGGAC CCTTGCTTGG AGGGTACCGA
GCTCAGAAAA AATGACTGCT CCAAAGAAGA AGCGTAAGGT ACCGGTAGAA AAA


19/27

FIG. 8. Schematic drawing of pGN156




20/27

FIG. 9. Schematic drawing of pGQ1




21/27

FIG. 10. Schematic drawing of pGQ2




22/27

FIG. 11. Schematic drawing of pCLUC6




23/27

FIG. 12. Schematic drawing of pGQ3



24/27

FIG. 13. Schematic drawing of pGQ4



25/27

FIG. 14.





FIG. 15.



26/27

FIG. 16.





FIG. 17.



27/27

FIG. 18.





FIG. 19.



SEQUENCE LISTING

<110> DEVGEN NV

<120> VIT-2 PROMOTER CONSTRUCTS

<130> SCB/57946/001

<140>

<141>

<160> 7

<170> PatentIn Ver. 2.0

<210> 1

<211> 5442

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Plasmid pGQ1

<400> 1

```
atgaccatga ttacgccaaag cttgcatgcc tgcagccaat gcattggaag agatattttg 60
cgcgtaaaat atgttttgtg tccccgtaat atttttttaa atcaaatttc acatttttaac 120
cataaaaaaac tctttcaaaa gtgtaatttt ctacgcaaaa atgccgttcg gatgaaaaat 180
tacttttgaa aaacaaactc gaaactacgg tacgcaaaaa agtacatcgg tgtttgacac 240
taagtgaaaa caatgttggt tttttgtaat taaaatcgat taattttttt tcccggaaaa 300
caaaaacggt ttacagcgtg atttctattg tttcttgctg aaaaaaaaat tattttacca 360
ttttaaacga taattttccac gaattttcgc cattaatctc tcgattttgt tgattcttga 420
ctccgagcaa tctctccggt tttcgcaaac gattatatta tttatttgtt ttccttttca 480
gtgccgatcc tcggaaattc aacagtaaat cttcaaaatg ccaatgcttc cccacatggg 540
caatctaagt gagtttcttt gttacaaaat acacgtgatg tcagattgtc tcatttcggg 600
ttgatctacg tagatctaca aaaaatgcgg gaattgagcc gcagagttct caactgcttt 660
cgcatgggta agaagcgtgcg gacgtcaaat tgttttgggc aaaaattccc gcattttttg 720
tagatcaaac cgtaatggga cagtcctggc ccacgtgact atatatattt agcgggtcac 780
gacacaaaaa ccggaccaat ggctgaggat cagctgaaag cttatagaga tagaaatcag 840
gtgagaaaaa tcaatttcag cgattttctt cgcaatttat ataaaaactg atttttccag 900
gaaccccacc tgctcaccac atccaatgga gctccgatct actcgaagac cgccgtgctc 960
accgccggac gacgtggtcc aatgctaatt caggacatcg tttatatgga cgagatggct 1020
catttcgatc gtgaacgcat cccggagcgt gtcgtccatg ccaaaggtgg tgggtgctcat 1080
ggatacttcg aggtcaccac tgacatcacc aagtactgta aggccgatat gttcaacaag 1140
gtcggaaaaa agacaccact tctcgttcgt ttttcaacgg tcgctggaga atcggccgga 1200
tccccgggat tggccaaagg acccaaagggt atgtttcgaa tgatactaac ataacataga 1260
acattttcag gaggaccctt ggctagcgtc accgttacca tggggcgcg catgagtaaa 1320
ggagaagaac ttttcactgg agttgtccca attcttggtg aattagatgg tgatgttaat 1380
gggcacaaat tttctgtcag tggagagggt gaagggtgat caacatacgg aaaacttacc 1440
cttaaattta tttgcactac tggaaaacta cctgttccat gggttaagtt aaacatatat 1500
atactaacta accctgatta tttaaatttt cagccaacac ttgtcactac tttctgttat 1560
ggtgttcaat gcttctcgag ataccagat catatgaaac ggcatgactt tttcaagagt 1620
gccatgcccg aaggttatgt acaggaaaga actatatatt tcaaagatga cgggaactac 1680
aagacacgta agtttaaaaca gttcgggtact aactaaccat acatatttaa attttcaggt 1740
gctgaagtca agtttgaagg tgataccctt gttaatagaa tcgagttaaa aggtattgat 1800
tttaaagaag atggaaacat tcttgacac aaattggaat acaactataa ctcacacaat 1860
gtatacatca tggcagacaa acaaaagaat ggaatcaaag ttgtaagttt aaacttgga 1920
ttactaacta acggattata tttaaatttt cagaacttca aaattagaca caacattgaa 1980
```

gatggaagcg ttcaactagc agaccattat caacaaaata ctccaattgg cgatggccct 2040
 gtccttttac cagacaacca ttacctgtcc acacaatctg ccttttcgaa agatcccaac 2100
 gaaaagagag accacatggt ccttcttgag tttgtaacag ctgctgggat tacacatggc 2160
 atggatgaac tatacaaata gggccggccg agctccgcat cggccgctgt catcagatcg 2220
 ccatctcgcg cccgtgcctc tgacttctaa gtccaattac tcttcaacat ccctacatgc 2280
 tctttctccc tgtgctccca cccctatttt ttgttattat caaaaaaact tcttcttaat 2340
 ttctttgttt tttagcttct ttttaagtcac ctctaacaat gaaatttgtt agattcaaaa 2400
 atagaattaa ttcgtaataa aaagtgcgaaa aaaatttgtc tccctccccc cattaataat 2460
 aattctatcc caaaatctac acaatgttct gtgtacactt cttatgtttt ttttacttct 2520
 gataaatttt ttttgaaaca tcatagaaaa aaccgcacac aaaatacctt atcatatgtt 2580
 acgtttcagt ttatgaccgc aatttttatt tcttcgcacg tctgggcctc tcatgacgtc 2640
 aaatcatgct catcgtagaa aagttttgga gtatttttg aatttttcaa tcaagtgaag 2700
 gtttatgaaa ttaattttcc tgcttttgct ttttgggggt ttcccctatt gtttgcagg 2760
 agtttcgagg acggcggttt tcttgctaaa atcacaagta ttgatgagca cgatgcaaga 2820
 aagatcgga gaaggttttg gtttgaggct cagtggaaag tgagtagaag ttgataattt 2880
 gaaagtggag tagtgtctat ggggtttttg ccttaaatga cagaatacat tcccaatata 2940
 ccaaacataa ctgtttccta ctagtccggc gtacggggcc tttcgtctcg cgcgtttcgg 3000
 tgatgacggt gaaaacctct gacacatgca gctcccgag acggtcacag cttgtctgta 3060
 agcggtatgcc gggagcagac aagcccgta gggcgctca gcggtgttg gcggtgtcg 3120
 gggctggctt aactatgcgg catcagagca gattgtactg agagtgcacc atatgcggtg 3180
 tgaaataccg cacagatgcg taaggagaaa ataccgcac agggcgccct aaggcgctcg 3240
 tgatacgctt atttttatag gttaatgtca tgataataat ggtttcttag acgtcagggtg 3300
 gcacttttgc gggaaatgtg cgcggaaccc ctatttgggt atttttctaa atacattcaa 3360
 atatgtatcc gctcatgaga caataaccct gataaatgct tcaataatat tgaaaaagga 3420
 agagtatgag tattcaacat ttccgtgtcg ccttatttcc cttttttgcg goattttgcc 3480
 ttctgttttt tgctaccca gaaacgctgg tgaaagtaaa agatgctgaa gatcagtttg 3540
 gtgcacgagt gggttacatc gaactggatc tcaacagcgg taagatcctt gagagttttc 3600
 gccccgaaga acgttttcca atgatgagca cttttaaagt tctgctatgt ggcgcggtat 3660
 tatccgtat tgacgccggg caagagcaac tcggtcgccg catacactat tctcagaatg 3720
 acttggttga gtactacca gtcacagaaa agcatcttac ggtggcatg acagtaagag 3780
 aattatgcag tgctgccata accatgagt gtaaacactg gcccaactta cttctgacaa 3840
 cgatcgagg accgaaggag ctaaccgctt ttttgacaaa catgggggat catgtaactc 3900
 gccttgatcg ttgggaaccg gagctgaatg aagccatacc aaacgacgag cgtgacacca 3960
 cgatgcctgt agcaatggca acaacgttgc gcaactatt aactggcgaa ctacttactc 4020
 tagcttcccg gcaacaatta atagactgga tggaggcgga taaagtgtgca ggaccacttc 4080
 tgcgctcgcg ccttccggct ggctgggtta ttgctgataa atctggagcc ggtgagcgtg 4140
 ggtctcgcg tatcattgca gcaactgggc agatggtaa gccctcccgt atcgtagtta 4200
 tctacacgac ggggagtcag gcaactatgg atgaacgaaa tagacagatc gctgagatag 4260
 gtgcctcact gattaagcat tggttaactgt cagaccaagt ttactcatat atactttaga 4320
 ttgattttaaa acttcatttt taatttataa ggaactaggt gaagatcctt tttgataatc 4380
 tcatgaccaa aatcccttaa cgtgagtttt cgttccactg agcgtcagac cccgtagaaa 4440
 agatcaaaag atcttcttga gatccttttt ttctgcgctg aatctgctgc ttgcaaaaa 4500
 aaaaaccacc gctaccagcg gtggtttgtt tgccggatca agagctacca actctttttc 4560
 cgaaggtaac tggttcagc agagcgcaga taccataac tgtccttcta gtgtagccgt 4620
 agttaggcca cacttcaag aactctgtag caccgcctac atacctcgt ctgctaattc 4680
 tgttaccagt ggctgctgcc agtggcgata agtctgtct taccgggttg gactcaagac 4740
 gatagttacc ggataaggcg cagcgtcgg gctgaacgg gggttcgtgc acacagccca 4800
 gcttgagcgc aacgacctac accgaactga gatacctaca gcgtgagcat tgagaaagcg 4860
 ccacgcttcc cgaagggaga aaggcggaca ggtatccggt aagcggcagg gtcggaacag 4920
 gagagcgcac gagggagctt ccagggggaa acgcctggt tctttatagt cctgtcgggt 4980
 ttcgccacct ctgacttgag cgtcgatttt tgtgatgctc gtcagggggg cggagcctat 5040
 ggaaaaacgc cagcaacgcg gcctttttac ggttcctggc cttttgctgg ccttttgcctc 5100
 acatgttctt tctgcgtta tcccctgatt ctgtggataa ccgtattacc gcctttgagt 5160
 gagctgatac cgctcgccgc agccgaacga ccgagcgcag cgagtcagtg agcgaggag 5220
 cggaagagcg cccaatacgc aaaccgcctc tccccgcgcg ttggccgatt cattaatgca 5280
 gctggcacga caggtttccc gactgaaaag cgggcagtga gcgcaacgca attaatgtga 5340
 gttagctcac tcattaggca cccaggtt tacactttat gcttccggct cgtatgttgt 5400

gtggaattgt gagcgataa caatttcaca caggaaacag ct

5442

<210> 2

<211> 5686

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Plasmid pCLUC6

<400> 2

```

atgactgtctc caaagaagaa gcgtaaggta cggtagaaaa aaatggaaga cgccaaaaac 60
ataaagaaag gcccgcgccc attctatccg ctggaagatg gaaccgctgg agagcaactg 120
cataaggcta tgaagagata cgccctgggt cctggaacaa ttgcttttac agatgcacat 180
atcgagggtg acatcactta cgctgagtac ttcgaaatgt ccgttcgggt ggcagaagct 240
atgaaacgat atgggctgaa tacaatcac agaatcgtcg tatgcagtga aaactctctt 300
caattcttta tgccgggtgt gggcgcggtt tttatcggag ttgcagttgc gcccgcgaa 360
gacatttata atgaacgtga attgctcaac agtatgggca tttcgcagcc taccgtggtg 420
ttcgtttcca aaaaggggtt gcaaaaaatt ttgaacgtgc aaaaaagct cccaatcatc 480
caaaaatta ttatcatgga ttctaaaacg gattaccagg gatttcagtc gatgtacacg 540
ttcgtcacat ctcacttacc tcccggtttt aatgaatacg attttgtgcc agagtccttc 600
gatagggaca agacaattgc actgatcatg aactcctctg gatctactgg tctgcctaaa 660
ggtgtcgtct tgccctcatg aactgcctgc gtgagattct cgcagccag agatcctatt 720
tttggaatc aaatcattcc ggatactcgc attttaagt ttgttccatt ccatcacggt 780
tttggaatgt ttactacact cggatatttg atatgtggat ttcgagtcgt cttaatgtat 840
agatttgaa aagagctgtt tctgaggagc cttcaggatt acaagattca aagtgcgctg 900
ctggtgcaa ccctattctc cttcttcgcc aaaagcactc tgattgacaa atacgattta 960
tctaatttac acgaaattgc ttctggtggc gctccccctc ctaaggaagt cggggaagcg 1020
gttgccaaga ggttccatct gccaggtatc aggcaaggat atgggctcac tgagactaca 1080
tcagctattc tgattacacc cgagggggat gataaacggg gcgcggctcg taaagttgtt 1140
ccattttttg aagcgaaggt tgtggtctg gataccggga aaacgctggg cgtaaatcaa 1200
agaggcgaac tgtgtgtgag aggtcctatg attatgtccg gttatgtaaa caatccggaa 1260
gcgaccaacg ccttgattga caaggatgga tggctacatt ctggagacat agcttactgg 1320
gacgaagacg aacacttctt catcgttgac cgcctgaagt ctctgattaa gtacaaaggc 1380
tatcagggtg ctcccgctga attggaatcc atcttgctcc aacaccccaa catcttcgac 1440
gcagggtgtc caggctcttc cgacgatgac gccgggtgaa tttcccgccg cgttgttgtt 1500
ttggagcacg gaaagacgat gacggaaaaa gagatcgtgg attacgtcgc cagtcaagta 1560
acaaccgcga aaaagtgtcg cggaggagtt gtgtttgtgg acgaagtacc gaaaggtctt 1620
accgaaaaac tcgacgcaag aaaaaacaga gagatcctca taaaggccaa gaaggcgga 1680
aagatcgccg tgtaattcta ggaattccaa ctgagcgccg gtcgctacca ttaccaactt 1740
gtctggtgtc aaaaataata ggggcccgtg tcatcagagt aagtttaaac tgagttctac 1800
taactaacga gtaatattta aattttcagc atctcgcgcc cgtgcctctg acttctaagt 1860
ccaattactc ttcaacatcc ctacatgctc tttctccctg tgctccacc ccctattttt 1920
gttattatca aaaaaacttc ttcttaattt ctttgttttt tagcttcttt taagtcacct 1980
ctaacaatga aattgtgtag attcaaaaat agaattaatt cgtaataaaa agtcgaaaaa 2040
aattgtgtct cctcccccca ttaataataa tctatccca aaatctacac aatgttctgt 2100
gtacacttct tatgtttttt ttacttctga taaatttttt ttgaaacatc atagaaaaaa 2160
ccgcacacaa aataccttat catatgttac gtttcagttt atgaccgcaa tttttatttc 2220
ttcgcacgtc tgggcctctc atgacgtcaa atcatgctca tcgtgaaaaa gttttggagt 2280
atttttgtaa tttttcaatc aagtgaaggt ttatgaaatt aattttcctg cttttgcttt 2340
ttgggggttt cccctattgt ttgtcaagag tttcaggagc gccgtttttc ttgctaaaat 2400
cacaagtatt gatgagcacg atgcaagaaa gatcggaaga aggtttgggt ttgaggctca 2460
gtggaagggt agtagaaggt gataatttga aagtggagta gtgtctatgg ggtttttgcc 2520
ttaaatgaca gaatacatc ccaatatacc aaacataact gtttcctact agtcggccgt 2580
acgggccctt tcgtctcgcg cgtttcgggt atgacggtga aaacctctga cacatgcagc 2640
tcccggagac ggtcacagct tgtctgtaag cggatgccgg gagcagacaa gcccgtcagg 2700
gcgcgtcagc ggggtgttggc ggggtgtcggg gctggcttaa ctatgcggca tcagagcaga 2760

```

```

ttgtactgag agtgcacccat atgcgggtgtg aaataccgca cagatgcgta aggagaaaaat 2820
accgcatcag gcggccttaa gggcctcgtg atacgcctat ttttataggt taatgtcatg 2880
ataataatgg tttcttagac gtcagggtggc acttttcggg gaaatgtgcg cggaaccctt 2940
atttgtttat ttttctaaat acattcaaat atgtatccgc tcatgagaca ataaccctga 3000
taaagtcttc aataatattg aaaaaggaag agtatgagta ttcaacattt ccgtgtcgcc 3060
cttattccct tttttgcggc attttgcctt cctgtttttg ctcaccacaga aacgctggtg 3120
aaagtaaaag atgctgaaga tcagttgggt gcacgagtg gttacatcga actggatctc 3180
aacagcggta agatccttga gaggtttctc cccgaagaac gttttccaat gatgagcact 3240
tttaaagttc tgctatgtgg cgcggtatta tcccgtattg acgccgggca agagcaactc 3300
ggtcgcccga tacactattc tcagaatgac ttggttgagt actcaccagt cacagaaaag 3360
catcttacgg atggcatgac agtaagagaa ttatgcagtg ctgccataac catgagtgat 3420
aacactgcgg ccaacttact tctgacaacg atcggaggac cgaaggagct aaccgctttt 3480
ttgcacaaca tgggggatca tgtaactcgc cttgatcgtt gggaaccgga gctgaatgaa 3540
gccataccaa acgacgagcg tgacaccacg atgcctgtag caatggcaac aacgttgcg 3600
aaactattaa ctggcgaact acttactcta gcttcccggc aacaattaat agactggatg 3660
gaggcggata aagttgcagg accacttctg cgctcggccc ttccggctgg ctggtttatt 3720
gctgataaat ctggagccgg tgagcgtggg tctcgcggta tcattgcagc actggggcca 3780
gatggtaagc cctcccgtat cgtagtattc tacacgacgg ggagtcaggc aactatggat 3840
gaacgaaata gacagatcgc tgagataggt gcctcactga ttaagcattg gtaactgtca 3900
gaccaagttt actcatatat acttttagatt gatttaaaac ttcatTTTTa atttaaaagg 3960
atctagggtga agatcctttt tgataatctc atgaccaaaa tcccttaacg tgagttttcg 4020
ttccactgag cgtcagaccc cgtagaaaaag atcaaaaggat cttcttgaga tccttttttt 4080
ctgcgcgtaa tctgctgctt gcaaacaaaa aaaccaccgc taccagcggg ggtttgtttg 4140
ccggatcaag agctaccaac tctttttccg aaggtaactg gcttcagcag agcgcagata 4200
ccaaatactg tccttctagt gtagccgtag ttaggccacc acttcaagaa ctctgtagca 4260
ccgcctacat acctcgctct gctaactctg ttaccagtgg ctgctgccag tggcgataag 4320
tcgtgtctta ccgggttgga ctcaagacga tagttaccgg ataaggcgca gcggtcgggc 4380
tgaacggggg gttcgtgcac acagcccagc ttggagcgaa cgacctacac cgaactgaga 4440
tacctacagc gtgagcattg agaaagcgcc acgcttcccg aagggagaaa ggcggacagg 4500
tatccggtaa gcggcagggg cggaacagga gagcgacga gggagcttcc agggggaac 4560
gcctggtatc tttatagtcc tgcgggtttt cgccacctct gacttgagcg tcgatttttg 4620
tgatgctcgt cagggggggc gagcctatgg aaaaacgcca gcaacgcggc ctttttacgg 4680
ttcctggcct tttgctggcc ttttgctcac atgttctttc ctgcttatc ccctgattct 4740
gtggataacc gtattaccgc ctttgagtga gctgataccg ctgcgccgag ccgaacgacc 4800
gagcgcagcg agtcagttag cgaggaagcg gaagagcgcc caatacgcaa accgcctctc 4860
cccgcgcgtt ggccgattca ttaatgcagc tggcacgaca ggtttcccga ctggaaagcg 4920
ggcagtgagc gcaacgcaat taatgtgagt tagctcactc attaggcacc ccaggcttta 4980
cactttatgc ttccggctcg tatgttgtgt ggaattgtga gcggataaca atttcacaca 5040
ggaaacagct atgacctga ttacgccaag ctgtaagttt aaacatgata ttactaacta 5100
actattctca tttaaatttt cagagcttaa aaatggctga aatcactcac aacgatggat 5160
acgctaataa cttggaaatg aaataagctt gcatgcctgc aggccttggt cgactctaga 5220
ggatcaaaact gtattacttg aaacaattta gttatatgtt tagaaccctt cattcaaaat 5280
taatagacag ggctctcacc gaatgttgca atttgtttct gataagggtc acaaagcgga 5340
gcgaatgctt gaatgtgtcc atcaatgagc ttatcaatgc gctaaaacgc tataacttcc 5400
atatgaagtc aatcgaacat atgtcaatct ttagccgtat ataaagggtc actgaaaaca 5460
gtccaatcac gtttcagcca tgaggtcgat ccccgccgg gattggccaa aggacccaaa 5520
ggtatgtttc gaatgatact aacataacat agaacatttt caggaggacc cttggagggt 5580
accggggatt ggccaaagga cccaaaggtg tgtttcgaat gataactaaca taacatagaa 5640
cattttcagg aggacccttg cttggagggt accgagctca gaaaaa 5686

```

<210> 3

<211> 6099

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Plasmid pGQ2

<400> 3

```

atgactgctc caaagaagaa gcgtaaggta ccggtagaaa aaatggaaga cgccaaaaac 60
ataaagaag gcccggcgcc attctatccg ctggaagatg gaaccgctgg agagcaactg 120
cataaggcta tgaagagata cgccctgggt cctggaacaa ttgcttttac agatgcacat 180
atcgagggtg acatcactta cgctgagtac ttcgaaatgt ccgttcggtt ggcagaagct 240
atgaaacgat atgggctgaa tacaaatcac agaatcgctg tatgcagtga aaactctctt 300
caattcttta tgccgggtgtt gggcgcggtt ttatccggag ttgcagttgc gcccgcgaaac 360
gacattttata atgaacgtga attgctcaac agtatgggca ttctgcagcc taccgtgggtg 420
ttcgtttcca aaaaggggtt gcaaaaaatt ttgaacgtgc aaaaaaagct cccaatcatc 480
caaaaaatta ttatcatgga ttctaaaacg gattaccagg gatttcagtc gatgtacacg 540
ttcgtcacat ttcatctacc tcccgggttt aatgaatacg attttggtgc agagtccttc 600
gatagggaca agacaattgc actgatcatg aactcctctg gatctactgg tctgcctaaa 660
ggtgtcgctc tgccctcatg aactgcctgc gtgagattct cgcatgccag agatcctatt 720
tttggaatc aaatcattcc ggatactgcg attttaagtg ttgttccatt ccatcacggg 780
tttggaatgt ttactacact cggatatttg atatgtggat ttcgagtcgt cttaatgtat 840
agatttgaag aagagctggt tctgaggagc cttcaggatt acaagattca aagtgcgctg 900
ctggtgccaa ccctattctc cttcttcgcc aaaagcactc tgattgacaa atacgattta 960
tctaatttac acgaaattgc ttctgggtgc gctccctct ctaaggaagt cggggaagcg 1020
gttgccaaga ggttccatct gccaggatc aggcaaggat atgggctcac tgagactaca 1080
tcagctattc tgattacacc cgagggggat gataaaccgg gcgcggctcg taaagttgtt 1140
ccattttttg aagcgaaggt tgtggatctg gataccggga aaacgctggg cgttaatcaa 1200
agaggcgaac tgtgtgtgag agtccctatg attatgtccg gttatgtaaa caatccggaa 1260
gcgaccaacg ccttgattga caagatgga tggctacatt ctggagacat agcttactgg 1320
gacgaagacg aacacttctt catcggtgac cgcctgaagt ctctgattaa gtacaaaggc 1380
tatcagggtg ctcccgtga attggaatcc atcttgctcc aacaccccaa catcttcgac 1440
gcagggtgctg caggctcttc cgacgatgac gccggtgaac ttccgcgcgc cgttgttgtt 1500
ttggagcacg gaaagacgat gacgaaaaa gagatcgtgg attacgtgc cagtcaagta 1560
acaaccgca aaaagttgcg cggaggaggt gtgtttgtgg acgaagtacc gaaaggtctt 1620
accggaaaaa tcgacgcaag aaaaatcaga gagatcctca taaaggccaa gaaggcgga 1680
aagatgcgcg tgaattcta ggaattccaa ctgagcgccg gtcgctacca ttaccaactt 1740
gtctggtgtc aaaaataata gggcgcgctg tcatcagagt aagtttaaac tgagttctac 1800
taactaacga gtaatattta aattttcagc atctcgcgcc cgtgcctctg acttctaagt 1860
ccaattactc ttcaacatcc ctacatgctc ttctccctg tgctccacc ccctattttt 1920
gttattatca aaaaacttc ttcttaattt ctttgttttt tagcttcttt taagtcacct 1980
ctaacaatga aattgtgtag attcaaaaat agaattaatt cgtaataaaa agtcgaaaaa 2040
aattgtgctc cctcccccca ttaataataa ttctatccca aaatctacac aatgttctgt 2100
gtacacttct tatgtttttt ttacttctga taaatttttt ttgaaacatc atagaaaaaa 2160
ccgcacacaa aataccttat catatgttac gtttcagttt atgaccgcaa tttttatttc 2220
ttcgacgctc tgggcctctc atgacgtcaa atcatgctca tcgtgaaaaa gttttggagt 2280
atttttggaa tttttcaatc aagtgaaggt ttatgaaatt aattttcctg cttttgcttt 2340
ttgggggttt cccctattgt ttgtcaagag ttctcaggac ggcgtttttt ttgctaaaat 2400
cacaagtatt gatgagcacg atgcaagaaa gatcggaaga aggtttgggt ttgaggctca 2460
gtggaagggt agtagaagtt gataatttga aagtggagta gtgtctatgg ggtttttgcc 2520
ttaaatgaca gaatacatcc ccaatatacc aaacataact gtttcctact agtcggccgt 2580
acgggccctt tcgtctcgcg cgtttcggtg atgacggtga aaacctctga cacatgcagc 2640
tcccggagac ggtcacagct tgtctgtaag cggatgccgg gagcagacaa gccgctcagg 2700
gcgcgtcagc ggggtgttggc ggggtgcggg gctggcttaa ctatgcggca tcagagcaga 2760
ttgtactgag agtgaccat atgcggtgtg aaataaccga cagatgcgta aggagaaaa 2820
accgcacag gcggccttaa gggcctcgtg atacgcctat ttttataggt taatgtcatg 2880
ataataatgg tttcttagac gtcagggtgc acttttcggg gaaatgtgcg cggaaccct 2940
atgtgtttat ttttctaaat acattcaa atgtatccgc tcatgagaca ataaccctga 3000
taaagtcttc aataatattg aaaaaggaa agtatgagta ttcaacattt ccgtgtcgcc 3060
cttattccct tttttgcggc attttgctt cctgtttttg ctaccccaga aacgctgggt 3120
aaagtaaaag atgctgaaga tcagttgggt gcacgagtg gttacatcga actggatctc 3180
aacagcggta agatccttga gagttttcgc cccgaagaac gttttccaat gatgagcact 3240
tttaaagttc tgctatgtgg cgcggtatta tccgctattg acgcccggga agagcaactc 3300

```

```

ggtcgcgcga tacactatc tcagaatgac ttgggtgagt actcaccagt cacagaaaag 3360
catcttacgg atggcatgac agtaagagaa ttatgcagt ctgccataac catgagtgat 3420
aacactgcgg ccaacttact tctgacaacg atcggaggac cgaaggagct aaccgctttt 3480
ttgcacaaca tgggggatca tgtaactcgc cttgatcggt gggaaccgga gctgaatgaa 3540
gccataccaa acgacgagcg tgacaccacg atgcctgtag caatggcaac aacgttgccg 3600
aaactattaa ctggcgaact acttactcta gcttcccggc aacaattaat agactggatg 3660
gaggcggata aagttgcagg accacttctg cgctcggccc ttccggctgg ctggtttatt 3720
gctgataaat ctggagccgg tgagcgtggg tctcgcggta tcattgcagc actggggcca 3780
gatggttaagc cctcccgtat cgtagttatc tacacgacgg ggagtcaggc aactatggat 3840
gaacgaaaata gacagatcgc tgagataggt gcctcactga ttaagcattg gtaactgtca 3900
gaccaagttt actcatatat acttttagatt gatttaaaac ttcattttta atttaaaagg 3960
atctaggtga agatcctttt tgataatctc atgacaaaaa ttcctttgaga tccttttttt 4020
ttccactgag cgtcagaccc cgtagaaaaa atcaaaaggat cttcttgaga tccttttttt 4080
ctgcgcgtaa tctgctgctt gcaaacaata aaaccacggc taccagcggg ggtttgtttg 4140
ccggatcaag agctaccaac tctttttccg aaggttaact gcttcagcag agcgagata 4200
cgaataactg tccttctagt gtagccgtag ttaggccacc acttcaagaa ctctgtagca 4260
ccgcctacat acctcgtctt gctaactctg ttaccagtgg ctgctgccag tggcgataag 4320
tcgtgtctta ccgggttgga ctcaagacga tagttaccgg ataaggcgca gcggtcgggc 4380
tgaacggggg gttcgtgcac acagcccagc ttggagcgaa cgacctacac cgaactgaga 4440
tacctacagc gtgagcattg agaaagcgcc acgcttcccg aaggagagaa ggcgagagg 4500
tatccggtaa gcggcagggt cggaaacagga gagcgacaga gggagcttcc agggggaaac 4560
gcctgggtatc tttatagtcc tgtcgggttt cggcacctct gacttgagcg tcgatttttg 4620
tgatgctcgt cagggggggc gagcctatgg aaaaacgcca gcaacgcggc ctttttacgg 4680
ttcctggcct tttgctggcc ttttgcacac atgttctttc ctgcttatc cctgattct 4740
gtgataaacc gtattaccgc ctttgagtga gctgataccg ctgcgcgag ccgaacgacc 4800
gagcgagcgg agtcagtgag cgaggaagcg gaagagcgcc caatacgcaa accgcctctc 4860
cccgcgcggt ggccgattca ttaatgcagc tggcacgaca gggttcccga ctggaaagcg 4920
ggcagtgagc gcaacgcaat taatgtgagt tagctcactc attaggcacc ccaggcttta 4980
cactttatgc ttccggctcg tatgttgtgt ggaattgtga gcggataaca atttcacaca 5040
ggaaacagct atgaccatga ttacgccaag ctgtaagttt aaacatgatc ttactaacta 5100
actattctca tttaaatttt cagagcttaa aaatggctga aatcactcac aacgatggat 5160
acgctaacaa cttggaaatg aaataagcct gcatgcctgc aggcctgaga tattttgcgc 5220
gtcaaatatg ttttgtgtcc ccgtaatat tttttaaatc aaatttcaca ttttaaccat 5280
aaaaaactct ttcaaaagt taattttcta cgaaaaatg ccgttcggat gaaaaattac 5340
ttttgaaaaa caaactcgaa actacggtag gcaaaaaagt acatcggtgt ttgcacataa 5400
gtgaaaacaa tgttgttttt ttgtaattaa aatcgattaa ttttttttcc cgaaaaacaa 5460
aaacgttttc agcgtggatt tctattgttt taatctctcg attttggtga ttcttgactc 5520
taaacgataa tttccacgaa ttttcgcat taatctctcg attttggtga ttcttgactc 5580
cgagcaatct ctccggtttt cgcaaacgat tatattattt atttgtttc cttttcagtg 5640
ccgattctcg gaaattcaac agtaaatctt caaaatgcca atgcttcccc acatgggtcaa 5700
tctaagttag tttctttgtt acaaaataca cgtgatgtca gattgtctca tttcggtttg 5760
atctacgtag atctacaaa aatgcgggaa ttgagccgca gagttctcaa ctgctttcgc 5820
atgggtaaga acgtgcggac gtcaaatgtt tttgggcaaa aattcccga tttttgtag 5880
atcaaacggg aatgggacag tctggcacca cgtgactata ttttttagc ggtcaacgac 5940
acaaaacccg gaccaatggc tgaggatcag ctgaaagcct atagagatag aaatcagggtg 6000
agaaaaatca atttcagcga ttttcttcgc aatttatata aaaactgatt tttccaggaa 6060
ccccacctgc tcaccacatc caatcggagc tcagaaaaa 6099

```

<210> 4

<211> 7346

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Plasmid pGN156

<400> 4

agcttgcatg	cctgcagggg	cgactctaga	ggatcaaaact	gtattacttg	aaacaattta	60
gttatatgtt	tagaaccctt	cattcaaaat	taatagacag	ggctctcacc	gaatgttgca	120
atttgtttct	gataagggtc	acaaagcgga	gcgaatgctt	gaatgtgtcc	atcaatgagc	180
ttatcaatgc	gctaaaacgc	tataacttcc	atatgaagtc	aatogaacat	atgtcaatct	240
ttagccgtat	ataaagggtg	actgaaaaca	gtccaatcac	ggttcagcca	tgagggtcgat	300
ccccggcccg	gatttgccaa	aggacccaaa	ggatatgttc	gaatgatact	aacataacat	360
agaacatttt	caggaggacc	cttggagggt	accggtgggt	gaagaccaga	aacagcacct	420
cgaactgagc	cgcgatattg	cccagcgttt	caacgcgctg	tatggcgaga	tcgatcccg	480
cgttttacaa	cgtcgtgact	gggaaaaccc	tggcgttacc	caacttaatc	gccttgacgc	540
acatccccct	ttcgccagct	ggcgtaatat	cgaagaggcc	cgcacccgat	gcccttccca	600
acagttgcga	aggtaagttt	aaacagatcc	atactaacta	acttgttctg	acataatttt	660
cagcttgaat	ggcgaatggc	gctttgcctg	gtttccggca	ccagaagcgg	tgccggaaag	720
ctggctggag	tgcgatcttc	ctgaggccga	tactgtcgtc	gtcccctcaa	actggcagat	780
gcacggttac	gatgcgcccc	tctacaccaa	cgtaacctat	ccattacgg	tcaatccgcc	840
gtttgttccc	acggagaatc	cgacgggttg	ttactcgtc	acatttaatg	ttgatgaaag	900
ctggctacag	gaaggccaga	cgcgaaattat	ttttgatggc	gttaactcgg	cgtttcatct	960
gtggtgcaac	ggcgctggg	tcggttacgg	ccaggtaagt	ttaattaagt	tgatactaac	1020
taacaaagat	ctgattaatt	ttcaggacag	tcgtttgccg	tctgaatttg	acctgagcgc	1080
atttttacgc	gccggagaaa	accgcctcgc	ggtgatggtg	ctgcgttga	gtgacggcag	1140
ttatctggaa	gatcaggata	tgtggcggat	gagcggcatt	ttccgtgacg	tctcgttgct	1200
gcataaaccg	actacacaaa	tcagcgattt	ccatgttgcc	actcgttta	atgatgattt	1260
ctcccgcgct	gtactggagg	ctgaagtcca	ggtaagtta	aacaggatct	tactaactaa	1320
catgctaaca	ctgaattttc	agatgtgcgg	cgagtgtcgt	gactacctac	gggtaacagt	1380
ttctttatgg	cagggtgaaa	cgacggctgc	cagcggcacc	gcgcctttcg	gcggtgaaat	1440
tatcgatgag	cggtgtggtt	atgccgatcg	cgtcacacta	cgtctgaacg	tcgaaaaccc	1500
gaaactgtgg	agcgccgaaa	tcccgaatct	ctatcgtcgc	gtggttgaac	tgacacccgc	1560
cgacggcacg	ctgattgaag	cagaagcctg	cgatgtcggg	ttccgcgagg	tgcggttgga	1620
aaatggtctg	ctgctgctga	acggcaagcc	gttgctgatt	cgaggcggtta	accgtcacga	1680
gcacatccct	ctgcatggtc	aggatcatgga	tgagcagacg	atggtgcagg	atgtaagttt	1740
aaactattcg	ttactaacta	actttaaaca	tttaaatttt	cagatcctgc	tgatgaagca	1800
gaacaacttt	aacgcctgct	gctgttcgca	ttatccgaac	catccgctgt	ggtagacgct	1860
gtgcgaccgc	tacggcctgt	atgtggtgga	tgaagccaat	attgaaaccc	acggcatggt	1920
gccaatgaat	cgtctgaccg	atgatccgcg	ctggctaccg	gcgatgagcg	aacgcgtaac	1980
gcgaatggtg	cagcgcgac	gtaatcacc	gagtgatgat	atctggtcgc	tggggaatgg	2040
taagtttaaa	cagttgaata	ctaactaacg	gagatctttg	aaattttcag	aatcaggcca	2100
cggcgcta	cacgacgcgc	tgtatcgtg	gatcaaatct	gtcgatcctt	cccgcccggt	2160
gcagtatgaa	ggcggcggag	ccgacacccac	ggccaccgat	attattttgc	cgatgtacgc	2220
gcgcgtggat	gaagaccagc	ccttcccggc	tgtgccgaaa	tggtccatca	aaaaatggct	2280
ttcgctac	ggagagacgc	gcccgctgat	tctttgcgag	gtaagtttaa	acagaactct	2340
actaactaac	acattagatc	ctaattttca	gtacgctcac	gcgatgggca	acagtcttgg	2400
cggtttcgct	aaatactggc	aggcgtttcg	tcagtatccc	cgtttacagg	gcggcttcgt	2460
ctgggactgg	gtggatcagt	cgctgattaa	atatgatgaa	aacggcaacc	cgtggtcggc	2520
ttacggcggt	gattttggcg	atacgccgaa	cgatcgccag	ttctgtatga	acggtctggt	2580
ctttgccgac	cgacgcgcgc	atccagcgta	agtttaaaca	ataacctact	aactaacgta	2640
gataatttaa	attttcaggc	tgacgggaagc	aaaacaccag	cagcagtttt	tccagttccg	2700
tttatccggg	caaaccatcg	aagtgaaccag	cgaataacctg	ttccgtcata	gcgataacga	2760
gctcctgcac	tgatggtg	cgctggatgg	taagccgctg	gcaagcgggtg	aagtgcctct	2820
ggatgtcgct	ccacaaggta	aacagttgat	tgaactgcct	gaactaccgc	agccggagag	2880
cgccgggcaa	ctctggctca	cagtacgcgt	agtgcaaccg	aacgcgaccg	catgggtcaga	2940
agccgggac	atcagcgcat	ggcagcagtg	gaggtaagtt	taaacaagat	cctactaact	3000
aactctacat	tgatgaattt	tcagactggc	ggaaaacctc	agtgtgacgc	tccccgccgc	3060
gtcccacgcc	atccgcgcat	tgaccaccag	cgaaatggat	ttttgcatcg	agctgggtaa	3120
taagcggttg	caatttaacc	gccagtcagg	ctttctttca	cagatgtgga	ttggcgataa	3180
aaaacaactg	ctgacgcgcg	tgcgcgatca	gttcacccgt	gcaccgctgg	ataacgacat	3240
tggcgtaagt	gaagcgaccc	gcattgaccc	taacgcctgg	gtcggtaagt	ttaaacaag	3300
ttgtactaac	taacgaagat	cttgataatt	ttcagaacgc	tggaaggcgg	cgggccatta	3360
ccaggccgaa	gcagcgttgt	tgacgtgcac	ggcagatata	cttgcgtgat	cggtgctgat	3420

tacgacogct cacgcgtggc agcatcaggg gaaaacctta tttatcagcc ggaaaacctta 3480
 ccggtattgat ggtagtggc aaatggcgat tacogttgat gttgaagtgg cgagcgatac 3540
 accgcatccg gcgcggattg gcctgaactg ccagctggcg caggtagcag agcgggtaaa 3600
 ctggctcgga ttaggccgc aagaaaacta tcccgaccgc cttactgccg cctgttttga 3660
 ccgctgggat ctgccattgt cagacatgta gtaagtttaa acttgatagt actaactaac 3720
 atgtttcatt taaattttca gtaccccgta cgtcttcccg agcgaaaacg gtctgcgctg 3780
 cgggacgcgc gaattgaatt atggcccaca ccagtgccgc ggcgacttcc agttcaacat 3840
 cagccgctac agtcaacagc aactgatgga aaccagccat cgccatctgc tgcacgcgga 3900
 agaaggcaca tggctgaata tcgacgggtt ccataatggg attggtggcg acgactcctg 3960
 gagcccgta gtatcggcgg aattccaact gagcgccggt cgctaccatt accaacttgt 4020
 ctggtgtcaa aaataatagg ggccgctgtc atcagagtaa gtttaaaactg agttctacta 4080
 actaacgagt aatattttaa ttttcagcat ctccgcgccg tgcctctgac ttctaagtcc 4140
 aattactctt caacatccct acatgctctt tctccctgtg ctcccacccc ctatttttgt 4200
 tattatcaaa aaaacttctt cttaatttct ttgtttttta gcttctttta agtcacctct 4260
 aacaatgaaa ttgtgtagat tcaaaaatag aattaattcg taataaaaaa tcgaaaaaaa 4320
 ttgtgctccc tccccccatt aataataatt ctatcccaa atctacaca tgttctgtgt 4380
 acacttctta tgtttttttt acttctgata aatttttttt gaaacatcat agaaaaaac 4440
 gcacacaaaa taccttatca tatgttacgt ttcagtttat gaccgcaatt tttatttctt 4500
 cgcacgtctg ggcctctcat gacgtcaaat catgctcatc gtgaaaaagt tttggagtat 4560
 ttttggaatt tttcaatcaa gtgaaagttt atgaaattaa ttttctgtct tttgcttttt 4620
 gggggtttcc cctattgttt gtcaagagtt tccgagacgg cgttttttctt gctaaaatca 4680
 caagtattga tgagcacgat gcaagaaaga tccgaagaag gtttgggttt gaggctcagt 4740
 ggaaggtgag tagaagttga taatttgaaa gtggagttag gtctatggg tttttgcctt 4800
 aaatgacaga atacattccc aataaccaca acataactgt ttcctactag tccgcccgtac 4860
 gggccctttc gtctcgcgcg tttcgggtgat gacggtgaaa acctctgaca catgcagctc 4920
 ccggagacgg tcacagcttg tctgtaagcg gatgccggga gcagacaagc ccgtcagggc 4980
 gcgtcagcgg gtgttgccgg gtgtcggggc tggcttaact atgcggcatc agagcagatt 5040
 gtactgagag tgcacatat gcggtgtgaa ataccgcaca gatgcgtaag gagaaaatac 5100
 cgcacagggc ggccttaagg gcctcgtgat acgcctattt ttataggtta atgtcatgat 5160
 aataatgggt tcttagacgt caggtggcac ttttcgggga aatgtgcgcg gaacccttat 5220
 ttgtttattt ttctaaatac attcaaatat gtatccgctc atgagacaat aaccctgata 5280
 aatgcttcaa taatattgaa aaaggaagag tatgagtatt caacatttcc gtgtcgcctt 5340
 tattcccttt tttgcggcat tttgccttcc tgtttttgct caccagaaa cgctggtgaa 5400
 agtaaaagat gctgaagatc agttgggtgc acgagtggtt tacatcgaa tggtatctaa 5460
 cagcggtaa atccttgaga gttttcgccc cgaagaacgt tttccaatga tgagcacttt 5520
 taaagttctg ctatgtggcg cggatttatc ccgtattgac gccgggcaag agcaactcgg 5580
 tcgcccata cactattctc agaattgactt ggttgagtac tcaccagtca cagaaaagca 5640
 tcttacggat ggcattgacag taagagaatt atgcagtgt gccataacca tgagtataa 5700
 cactgcggcc aacttacttc tgacaacgat cggaggaccg aaggagctaa ccgctttttt 5760
 gcacaacatg ggggatcatg taactcgcct tgatcgttgg gaaccggagc tgaatgaagc 5820
 cataccaaac gacgagcgtg acaccacgat gcctgtagca atggcaaca cgttgcgcaa 5880
 actattaact ggcaactac ttactctagc ttcggcgcaa caattaatag actggatgga 5940
 ggccgataaa gttgcaggac cacttctgct ctcggccctt ccggctggct ggtttattgc 6000
 tgataaatct ggagccggtg agcgtgggtc tcgcggtatc attgcagcac tggggccaga 6060
 tggttaagccc tcccgatatg tagttatcta cagcagcggg agtcaggcaa ctatggatga 6120
 acgaaataga cagatcgtg agataggtgc ctactgatt aagcatttgt aactgtcaga 6180
 ccaagtttac tcataatata tttagattga tttaaaactt catttttaat ttaaaaggat 6240
 ctaggatgaag atcctttttg ataattctcat gacaaaatc ccttaacgtg agttttcgtt 6300
 ccactgagcg tcagaccccg tagaaaagat caaaggatct tcttgagatc ctttttttct 6360
 gcgcgtaatc tgctgcttgc aaacaaaaaa accaccgcta ccagcggtgg tttgtttgcc 6420
 ggatcaagag ctaccaactc tttttccgaa ggttaactggc ttcagcagag cgcagatacc 6480
 aaatactgtc ctctagtgt agccgtagt aggccaccac ttcaagaact ctgtagcacc 6540
 gcctacatac ctgcctctgc taatcctgtt accagtggct gctgccagt gcgataagtc 6600
 gtgtcttacc ggttggact caagacgata gttaccggat aaggcgcagc ggtcgggctg 6660
 aacggggggg tcgtgcacac agcccagctt ggagcgaacg acctacaccg aactgagata 6720
 cctacagcgt gagcattgag aaagcgccac gcttcccga gggagaaagg cggacaggtg 6780
 tccggtaaagc ggcagggtcg gaacaggaga gcgcacgagg gagcttccag ggggaaacgc 6840

```

ctggtatctt tatagtcctg tcggggtttcg ccacctctga ottgagcgtc gattttttgtg 6900
atgctcgtca ggggggcgga gcctatggaa aaacgccagc aacgcggcct ttttacggtt 6960
cctggccttt tgctggcctt ttgctcacat gttctttcct gcgttatccc ctgattctgt 7020
ggataaccgt attaccgcct ttgagtgagc tgataccgct cgcgcgagcc gaacgaaccga 7080
gcgcagcgag tcagtgagcg aggaagcgga agagcgccca atacgcaaac cgctctccc 7140
cgcgcttgg ccgattcatt aatgcagctg gcacgacagg tttcccgact ggaaagcggg 7200
cagtgagcgc aacgcaatta atgtgagtta gctactcat taggcacccc aggcctttaca 7260
ctttatgctt ccggctcgta tggtgtgtgg aattgtgagc ggataacaat ttcacacagg 7320
aaacagctat gaccatgatt acgcca 7346

```

<210> 5

<211> 5991

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Plasmid pGQ3

<400> 5

```

cgcgccatga gtaaaggaga agaacttttc actggagttg tcccaattct tgttgaatta 60
gatggtgatg ttaatgggca caaattttct gtcagtggag aggggtgaagg tgatgcaaca 120
tacggaaaaa ttacccttaa atttatttgc actactggaa aactacctgt tccatgggta 180
agttaaaca tatatatact aactaaccct gattatttaa attttcagcc aacacttgct 240
actactttct gttatggtgt tcaatgcttc tcgagatacc cagatcatat gaaacggcat 300
gactttttca agagtgccat gcccgagggt tatgtacagg aaagaactat atttttcaaa 360
gatgacggga actacaagac acgtaagttt aaacagttcg gtactaacta accatacata 420
tttaaatttt caggtgctga agtcaagttt gaaggtgata cccttgttaa tagaatcgag 480
ttaaaaggta ttgatttttaa agaagatgga aacattcttg gacacaaatt ggaatacaac 540
tataactcac acaatgtata catcatggca gacaaacaaa agaatggaat caaagtgtga 600
agtttaaact tggacttact aactaacgga ttatatttaa attttcagaa cttcaaaatt 660
agacacaaca ttgaagatgg aagcgttcaa ctagcagacc attatcaaca aaatactcca 720
attggcgatg gcctgtcct tttaccagac aaccattacc tgtccacaca atctgccctt 780
tcgaaagatc ccaacgaaaa gagagaccac atgggtccttc ttgagtttgt aacagctgct 840
gggattacac atggcatgga tgaactatac aaatagggcc ggccgagctc cgcacggcc 900
gctgtcatca gatcgccatc tcgcgccgt gcctctgact tctaagtcca attactctc 960
aacatcccta catgctcttt ctccctgtgc tcccaccccc tatttttgtt attatcaaaa 1020
aaacttcttc ttaatttctt tgttttttag cttcttttaa gtcacctcta acaatgaaat 1080
tgtgtagatt caaaaataga attaatctgt aataaaaagt cgaaaaaat tgtgtctcct 1140
ccccccatta ataataattc tatcccaaaa tctacacaat gttctgtgta cacttcttat 1200
gtttttttta cttctgataa attttttttg aacatcata gaaaaaacog cacacaaaat 1260
accttatcat atgttacgtt tcagtttatg accgcaattt ttatttcttc gcacgtctgg 1320
gcctctcatg acgtcaaata atgctcatcg tgaaaaagtt ttggagtatt tttggaattt 1380
ttcaatcaag tgaaagttaa tgaaattaat tttcctgctt ttgctttttg ggggtttccc 1440
ctattgtttg tcaagagttt cgaggacggc gtttttcttg ctaaaatcac aagtattgat 1500
gagcacgatg caagaaagat cggaagaagg tttgggtttg aggtcagtg gaaggtgagt 1560
agaagttgat aatttgaaag tggagtagtg tctatggggt ttttgcccta aatgacagaa 1620
tacattccca atataccaaa cataactgtt tcctactagt cgccgtacg ggccctttcg 1680
tcctcgcgct ttcggtgatg acggtgaaaa cctctgacac atgcagctcc cggagacggg 1740
cacagcttgt ctgtaagcgg atgccgggag cagacaagcc cgtcagggcg cgtcagcggg 1800
tggtggcggg tgtcgggggt ggcttaacta tgccgcatca gagcagattg tactgagagt 1860
gcaccatatg cgtgtgtaaa taccgcacag atgcgtaagg agaaaatacc gcatcaggcg 1920
gccttaaggg cctcgtgata cgcctatttt tataggttaa tgctatgata ataattggtt 1980
cttagacgtc agtggtgcaact tttcggggaa atgtgcggcg aaccctatt tgtttatttt 2040
tctaaatata ttcaaataat tatccgctca tgagacaata accctgataa atgcttcaat 2100
aatattgaaa aaggaaagagt atgagtattc aacatttcoo gtgcgccctt attccctttt 2160
ttgcggcatt ttgccttctt gtttttgctc acccagaaac gctggtgaaa gtaaaagatg 2220
ctgaagatca gttgggtgca cgagtgggtt acatcgaaat ggatctcaac agcggtaaga 2280

```

tccttgagag ttttcgcccc gaagaacgtt ttccaatgat gagcactttt aaagttctgc 2340
tatgtggcgc ggtattatcc cgtattgacg cggggcaaga gcaactcggc cgccgcatac 2400
actattctca gaatgacttg gttgagtact caccagtcac agaaaagcat cttacggatg 2460
gcatgacagt aagagaatta tgcagtgcgt ccataaccat gagtgataac actgcccga 2520
acttacttct gacaacgatc ggaggaccga aggagctaac cgcttttttg cacaacatgg 2580
gggatcatgt aactcgcctt gatcggtggg aaccggagct gaatgaagcc ataccaaacg 2640
acgagcgtga caccacgatg cctgtagcaa tggcaacaac gttgcgcaaa ctattaactg 2700
gcgaactact tactctagct tcccggcaac aattaataga ctggatggag gcggataaag 2760
ttgcaggacc acttctgcgc tcggcccttc cggttggtg gtttattgct gataaatctg 2820
gagccggtga gcgtgggtct cgcggtatca ttgcagcact ggggccagat ggtaagccct 2880
ccggtatcgt agttatctac acgacgggga gtcaggcaac tatggatgaa cgaaatagac 2940
agatcgctga gataggtgcc tcaactgatta agcattggta actgtcagac caagtttact 3000
catatatact ttagattgat ttaaaacttc atttttaatt taaaaggatc taggtgaaga 3060
tcctttttga taatctcatg accaaaatcc cttaacgtga gttttcgttc cactgagcgt 3120
cagaccccggt agaaaagatc aaaggatcct cttgagatcc tttttttctg cgcgtaactc 3180
gctgcttgca aacaaaaaaa ccaccgctac cagcgggtgt ttgtttgccg gatcaagagc 3240
taccaactct ttttcogaag gtaactggct tcagcagagc gcagatacca aatactgtcc 3300
ttctagtgtg ccgtagttaa ggccaccact tcaagaactc tgtagcaccg cctacatacc 3360
tgctctgct aatcctgtta ccagtggctg ctgccagtgg cgataagtcg tgtcttaccg 3420
ggttggactc aagacgatag ttaccggata aggcgcagcg gtcgggctga acgggggggt 3480
cgtgcacaca gccagcttg gagcgaacga cctacaccga actgagatac ctacagcgtg 3540
agcattgaga aagcgccacg cttcccgaag ggagaaaagg gcagaggtat cggtaagcg 3600
gcagggtcgg aacaggagag cgcacgaggg agcttccagg gggaaaacgct tggatctctt 3660
atagtcctgt cgggtttcgc cactctgac ttgagcgtcg atttttgtga tgcctcgtcag 3720
gggggcggag cctatggaaa aacgccagca acgcggcctt tttacgggtc ctggcctttt 3780
gctggccttt tgctcacatg ttctttcctg cgttatcccc tgattctgtg gataaccgta 3840
ttaccgcctt tgagtgcgt gataccgctc gccgcagccg aacgaccgag cgcagcagat 3900
cagtgcgca ggaagcggaa gagcgcccaa tacgcaaac gcctctcccc gcgcgttggc 3960
cgattcatta atgcagctgg caagacaggt ttcccagctg gaaagcgggc agtgagcgca 4020
acgcaattaa tgtgagttag ctcaactcatt aggcacccca ggctttacac tttatgcttc 4080
cggctcgtat gttgtgtgga attgtgagcg gataacaatt tcacacagga aacagctatg 4140
accatgatta cgccaagctt gcatgcctgc agtgattcag agaggttgag aattattttc 4200
aaaaacattc aatgttttcc cttggagtga ctatgcaaat atgaaaatgt tttccaaaaa 4260
tatttggtg cctgataaaa aagtaggtga aatttcgcag gggaacatca tattaaaaatg 4320
ttgaattttt agaagaaatg gaaatgtttg tcggtgggtat gctcgaatat ttgagatatt 4380
atataattac tgttaaatcc gaaatttttg acaaacggaa aaaatttttg tcgaaatact 4440
acattttcga taacacaaaag gtacttccat aacacttata aaaactgttt gactatctta 4500
attgtgtttc catgaaggta ttgtgaatat ttttgacaaa ctgatagaat tttcaggaaa 4560
aaaaaatcca agaataaaca tttttcagaa ttggaacttt ctaatggctg attataaaaa 4620
caaagttata caactattca aagcagttgc tcaatctggc attttcttgt gttttttttt 4680
gaatatttca tcagcaagat gttgataatt ttgtgttaat tctaattgtt ttctacaatt 4740
tttcaaaccg aaaattgacc tttagacttg ttactttgt tctcgtgggt taactgttca 4800
ctgatttcta ttgctgttga tgaggtcttt gatcaaatgt gtattgtttt tatactgcat 4860
attgcttcaa ttctaaatca tctaataat tgtcaaaaca cttctgtttt tttttttcat 4920
tcaaaaactc tgcaaaaacg ttctcttaac aaaggttcac acaacaactc toctctccat 4980
ctctttctct caacaacaat gtgctggcct tgcatgtttg ccagtgcggg ttgtttacgc 5040
gttttcaaga tttttggtct cctatctaac gtcccgaat gcattttttc ctttcatttg 5100
gtttttttct gttcgagaaa agtgaccgtt tgtcaaatct tctaattttc agtgaataaa 5160
atgctgcaat ctactgctcg cactgcttca aagcttggtc aaccggttgc ggggtaagtc 5220
aaaatgaaat tttcgtttta aaattggttt tttttggtat tatagataaa acttatacca 5280
aaacaaaaa tatttagaaa aactttaata gagaataatt gttaataat taatttttgc 5340
aagctccttt taaattaaga catctaaaac agttttcagc ttgattgttt taatggttta 5400
gaaagcaata tttgtatttt gtgttaaaact gaaaatatct aggaataact acttttaaaa 5460
tatttgaaac ttgaaatttt aaaattccaa ataattttac tcatttcta aagtgtttga 5520
gtatttgtat cctgtgctga caccgaaatg ttctcaattt tggaaaaaaa agatttttat 5580
ccgtatcttc agtcttataa tttttttcac cttttttttc atttcagagt tctcgcctgc 5640
cgctccaagc acactctccc agatctccca ttcgactatg cagattttga acctgtaac 5700

```

agccatgaaa tcatgcagct tcatcatcaa aagcatcatg ccacctacgt gaacaatctc 5760
aatcagatcg aggagaaact tcacgaggct gtttcgaaag gttttttaat cagaagattt 5820
tgaaatgaat tttttttttg gtatataggg aatctaaaag aagcaattgc tctccaacca 5880
gcgctgaaat tcaatgggtg tggacacatc aatcattcta tctttctggac caacttggct 5940
aaggatggtg gagaaccttc aaaggagctg atggacacta ttaaggcttg g 5991

```

<210> 6

<211> 6980

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Plasmid pGQ4

<400> 6

```

gtgattcaga gaggttgaga attattttca aaaacattca atgttttccc ttggagtgc 60
tatgcaataa tgaaaatggt ttccaaaaat atttggatgc tgaaatttta gaagaaatgg 120
aaatgtttgt cgggtggtatg ctcgaaatatt tgagatatta tataatttact gttaaatccg 180
aaatttttga caaacggaaa aaatttgtgt cgaaatacta cattttcgat aacacaaagg 240
tacttccata tttaaacaca gctttatgat gtaaaagcta ttgtgtttcc atgaaggat 300
acacttataa aaactgtttg actatcttat ttcaggaaaa aaaaatccaa gaataaacat 360
ttttcagaat ttgaactttc taatggctga ttaataaaac aaagtatac aactattcaa 420
agcagttgct caatctggca ttttcttgtg tttttttttg aatatttcat cagcaagatg 480
ttgataattt tgtgttaatt ctaattgttt tctacaattt ttcaaaccga aaattgacct 540
ttgactttgt ttactttgtt ctctgtgggt aactgttcac tgatttctat tgctgttgat 600
gaggtctttg atcaaatttg tattgttttt atactgcata ttgcttcaat tctaaatcat 660
ctaataatatt gtcaaaacaac ttcttgtttt ttttttcatt caaaaacttct gcaaaaaacgt 720
tctcttaaca aaggttcaca caacaactct cctctccatc tctttctctc aacaacaatg 780
tgctggcctt gcatgtttgc cagtgcgggt tgtttacgcg ttttcaagat ttttggcttc 840
ctatctaacg tcccgaaatg cattttttcc tttcatattg ttttttctg ttcgagaaaa 900
gtgacgtttt gtcaaatctt ctaattttca gtgaataaaa tgctgcaatc tactgctcgc 960
actgcttcaa agcttgttca accggttgcg gggtaagtca aaatgaaatt ttcgttttaa 1020
aattggtttt ttttggattt atagataaaa cttataccaa aacaaaacat atttagaaaa 1080
actttaatag agaataattg tttaataatt aatttttgca agctcctttt aaattaagac 1140
atctaaaaca gttttcagct tgattgtttt aatgggttag aaagcaatat ttgtattttg 1200
tgttaaactg aaaaatatcta ggaaatacta cttttaaaaa atttgaaact tgaaatttta 1260
aaattccaaa taatttttact catttcctaa agtgtttgag tatttgtatc ctgtgctgac 1320
accgaaatgt tctcaatttt ggaaaaaaa gatttttata cgtatcttca gtcttacaat 1380
ttttttcacc ttttttttca tttcagagtt ctgcgcgtcc gctccaagca cactctccca 1440
gatctcccat tgcactatgc agatttgga cctgtaatca gccatgaaat catgcagctt 1500
catcatcaaa agcatcatgc cacctacgtg aacaatctca atcagatcga ggagaaactt 1560
cacgaggctg tttcgaaagg ttttttaatc agaagatttt gaaatgaatt ttttttttgg 1620
tatataggga atctaaaaga agcaattgct ctccaaccag cgctgaaatt caatggtggt 1680
ggacacatca atcattctat cttctggacc aacttggcta aggatggtg agaaccttca 1740
aaggagctga tggacactat taagccgagc tcagaaaaaa tgactgctcc aaagaagaag 1800
cgtaaggtag cggtagaaaa aatggaagac gccaaaaaca taaagaagg cccggcgcca 1860
ttctatccgc tggaagatgg aaccgcggga gagcaactgc ataaggctat gaagagatac 1920
gccctgggtc ctggaacaat tgcttttaca gatgcacata tcgaggtgga catcacttac 1980
gctgagtact tcgaaatgtc cgcttcggtg gcagaagcta tgaaacgata tgggctgaat 2040
acaaatcaca gaatcgtcgt atgcagtga aactctcttc aattctttat gccggtgttg 2100
ggcgcggtat ttatcggagt tgcagttgcg cccgcgaacg acatttataa tgaacgtgaa 2160
ttgctcaaca gtatgggcat ttgcagcct accgtggtgt tcgtttccaa aaaggggttg 2220
caaaaaattt tgaacgtgca aaaaaagctc ccaatcatcc aaaaaattat tatcatggat 2280
tctaaaacgg attaccaggg atttcagtcg atgtacacgt tcgtcacatc tcatctacct 2340
cccgttttta atgaatacga ttttgtgcca gagtccttcg atagggacaa gacaattgca 2400
ctgatcatga actcctctg atctactggt ctgcctaaag gtgtcgtctt gcctcataga 2460
actgcctgcg tgagattctc gcatgccaga gatcctattt ttggcaatca aatcattccg 2520

```

gatactgcga ttttaagtgt tgttccattc catcacgggt ttggaatggt tactacactc 2580
 ggatatttga tatgtggatt tgcagtcgtc ttaatgtata gatttgaaga agagctgttt 2640
 ctgaggagcc ttcaggatta caagattcaa agtgcgctgc tgggtgccaac cctatttctc 2700
 ttcttcgcca aaagcactct gattgacaaa tacgatttat ctaatttaca cgaaattgct 2760
 tctgggtggc ctcccccttc taaggaaagc ggggaagcgg ttgccaagag gttccatctg 2820
 ccaggatatca ggcaaggata tgggctcact gagactacat cagctattct gattacacc 2880
 gagggggatg ataaaccggg cgcggtcggt aaagtgttgc cattttttga agcgaagggt 2940
 gtggatctgg ataccgggaa aacgctgggc gttaatcaaa gaggcgaact gtgtgtgaga 3000
 ggtcctatga ttatgtccgg ttatgtaaac aatccggaag cgaccaacgc cttgattgac 3060
 aaggatggtt ggctacattc tggagacata gcttactggg acgaagacga acacttcttc 3120
 atcgttgacc gcctgaagtc tctgattaag taaaaaggct atcagggtgc tcccgtgaa 3180
 ttggaatcca tcttgctcca acaccccaac atcttcgacg cagggtgtcg aggtcttccc 3240
 gacgatgacg ccggtgaact tcccgccgcc gttgttgttt tggagcacgg aaagacgatg 3300
 acggaaaaag agatcgtgga ttacgtcgcc agtcaagtaa caaccgcgaa aaagtgtcgc 3360
 ggaggagttg tgtttgtgga cgaagtaccg aaaggtctta ccggaaaact cgacgcaaga 3420
 aaaatcagag agatcctcat aaaggccaag aaggcggaag agatcgccgt gtaattctag 3480
 gaattccaac tgagcgccgg tgcgtacctat taccaacttg tctgtgtgca aaaataatag 3540
 gggccgctgt catcagagta agtttaaaact gagttctact aactaacgag taatatttaa 3600
 attttcagca tctcgcgcc gtgcctctga cttctaagtc caattactct tcaacatccc 3660
 tacatgctct tctcctctgt gctcccacc cctatttttg ttattatcaa aaaaacttct 3720
 tcttaatttc tttgtttttt agcttctttt aagtcacctc taacaatgaa attgtgtaga 3780
 ttcaaaaata gaattaattc gtaataaaaa gtcgaaaaaa attgtgtctc ctcccccat 3840
 taataataat tctatcccaa aatctacaca atgttctgtg tacacttctt atgtttttt 3900
 tacttctgat aaattttttt tgaaacatca tagaaaaaac cgcacacaaa ataccttatc 3960
 atatgttacg ttccagttta tgaccgcaat ttttatttct tgcacgctct gggcctctca 4020
 tgacgtcaaa tcatgctcat cgtgaaaaag ttttgagta tttttggaat ttttcaatca 4080
 agtgaagttt tatgaaatta attttctgc ttttgctttt tgggggtttc cctattgtt 4140
 tgtcaagagt ttcgaggacg gcgtttttct tgctaaaatc acaagtattg atgagcacga 4200
 tgcaagaaag atcggaagaa ggtttgggtt tgaggctcag tggaaagtga gtagaagttg 4260
 ataatttgaa agtggagtag tgtctatggg gtttttgct taaatgacag aatacattcc 4320
 caataacca aacataactg tttcctacta tgcggccgta cgggcccttt cgtctcgcgc 4380
 gtttcggtga tgacggtgaa aacctctgac acatgcagct cccggagacg gtcacagctt 4440
 gtctgtaagc ggtgacggg agcagacaag cccgtcaggg cgcgtcagcg ggtgttggcg 4500
 ggtgtcgggg ctggcttaac tatgcgcat cagagcagat tgtactgaga gtgcaccata 4560
 tgcggtgtga aataccgcac agatgcgtaa ggagaaaata ccgcatcagg cggccttaag 4620
 ggccctgtga tacgcctatt tttatagggt aatgtcatga taataatggt ttcttagacg 4680
 tcagggtggca cttttcgggg aaatgtgcgc ggaaccctta tttgtttatt tttctaaata 4740
 cattcaaata tgtatccgct catgagacaa taaccctgat aaatgcttca ataatttga 4800
 aaaaggaaga gtatgagtat tcaacatttc cgtgtcgccc ttattccctt ttttgcgga 4860
 ttttgccctc ctgttttttc tcaaccagaa acgctggtga aagttaaaga tgctgaagat 4920
 cagttgggtg cacgagtggt ttacatcgaa ctggatctca acagcggtaa gatccttgag 4980
 agttttcgcc ccgaagaacg ttttccaatg atgagcaact ttaaagttct gctatgtggc 5040
 gcggtattat cccgtattga cgcggggcaa gagcaactcg gtcgcccgc acactattct 5100
 cagaatgact tgggtgagta ctcaaccagtc acagaaaagc atcttacgga tggcatgaca 5160
 gtaagagaat tatgcagtgc tgccataacc atgagtata acactgcggc caacttactt 5220
 ctgacaacga tcggaggacc gaaggagcta accgctttt tgcacaacat ggggatcat 5280
 gtaactcgcc ttgatcgttg ggaaccggag ctgaatgaag ccataccaaa cgacgagcgt 5340
 gacaccacga tgcctgtagc aatggcaaca acgttgcgca aactattaac tggcgacta 5400
 cttactctag cttccgggca acaattaata gactggatgg aggcggataa agttgcagga 5460
 ccacttctgc gctcggccct tccggctggc tgggtttatt ctgataaatc tggagccggt 5520
 gagcgtgggt ctgcgggtat cattgcagca ctggggccag atggtaagcc ctcccgatc 5580
 gtagttatct acacgacggg gagtcaggca actatggatg aacgaaatag acagatcgct 5640
 gagatagggt cctcactgat taagcattgg taactgtcag accaagttta ctcatatata 5700
 ctttagattg atttaaaact tcatttttaa tttaaaagga tctaggtgaa gatcctttt 5760
 gataatctca tgacaaaat cccttaacgt gagttttcgt tccactgagc gtcagacccc 5820
 gtagaaaaga tcaaaggatc ttcttgagat ccttttttgc tgcgcgtaat ctgctgctt 5880
 caaacaaaaa aaccaccgct accagcgggt gtttgtttgc cggatcaaga gctaccaact 5940


```

ctttttccga aggtaactgg cttcagcaga ggcagatac caaatactgt ccttctagtg 6000
tagccgtagt taggccacca cttcaagaac tctgtagcac cgcctacata cctcgctctg 6060
ctaatacctgt taccagtggc tgctgccagt ggcgataagt cgtgtcttac cgggttggac 6120
tcaagacgat agttaccgga taaggcgag cggtcgggt gaacggggg ttcgtgcaca 6180
cagcccagct tggagcgaac gacctacacc gaactgagat acctacagcg tgagcattga 6240
gaaagcgcca cgcttcccga agggagaaa ggcgacaggt atccggtaag cggcagggtc 6300
ggaacaggag agcgcacgag ggagcttcca gggggaacg cctggatatc ttatagtcct 6360
gtcgggtttc gccacctctg acttgagcgt cgatttttgt gatgctcgtc aggggggagg 6420
agcctatgga aaaacgccag caacgcggcc tttttacggt tcctggcctt ttgctggcct 6480
tttgctcaca tgttctttcc tgcgttatcc cctgattctg tggataaccg tattaccgcc 6540
tttgagttag ctgataccgc tcgcccagc cgaacgaccg agcgacgca gtcagttagc 6600
gaggaagcgg aagagcgccc aatacgcaaa ccgctctcc ccgcgcttg gccgattcat 6660
taatgcagct ggcacgacag gtttcccagc tggaaagcgg gcagttagcg caacgcaatt 6720
aatgtgagtt agctcactca ttaggcaccc caggctttac actttatgct tccggctcgt 6780
atgttgtgtg gaattgtgag cggataacaa tttcacacag gaaacagcta tgaccatgat 6840
tacgccaagc tgtaagttaa aacatgatct tactaactaa ctattctcat ttaaattttc 6900
agagcttaaa aatggctgaa atcactcaca acgatggata cgctaacaac ttggaaatga 6960
aataagcttg catgcctgca 6980

```

<210> 7

<211> 473

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Vit-2
promoter/NLS fragment

<400> 7

```

atgttttagaa cccctcattc aaaattaata gacagggctc tcaccgaatg ttgcaatttg 60
tttctgataa gggtcacaaa gcggagcgaa tgcttgaatg tgtccatcaa tgagcttatc 120
aatgcgctaa aacgtataaa cttccatatg aagtcaatcg aacatatgtc aatctttagc 180
cgtatataaa ggtgcactga aaacagtcca atcacgggtc agccatgagg tcgatccccg 240
gccgggattg gccaaaggac ccaaaggatg gtttcgaatg atactaacat aacatagaac 300
atthtcagga ggacccttgg agggtagcgg ggattggcca aaggacccaa aggtatgttt 360
cgaatgatac taacataaca tagaacattt tcaggaggac ccttgcttgg agggtagcga 420
gctcagaaaa aatgactgct ccaaagaaga agcgtaaggc accggtagaa aaa 473

```

INDICATIONS RELATING TO DEPOSITED MICROORGANISM OR OTHER BIOLOGICAL MATERIAL

(PCT Rule 13bis)

<p>A. The indications made below relate to the deposited microorganism or other biological material referred to in the description on page <u>21</u>, line <u>6-11</u></p>	
<p>B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/></p>	
<p>Name of depositary institution BELGIAN COORDINATED COLLECTION OF MICROORGANISMS</p>	
<p>Address of depositary institution (including postal code and country) Belgian Coordinated Collection of Microorganisms Laboratorium Voor Molecular Biology - Plasmidencollectie University of Ghent K.L. Ledeganckstraat 9000 Ghent, BELGIUM</p>	
<p>Date of deposit 01 JUNE 2001</p>	<p>Accession Number IMBP 5719CB</p>
<p>C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/></p>	
<p>D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)</p>	
<p>E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)</p> <p>The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")</p>	
<p>For receiving Office use only</p> <p><input type="checkbox"/> This sheet was received with the international application</p> <p>Authorized officer</p>	<p>For International Bureau use only</p> <p><input checked="" type="checkbox"/> This sheet was received by the International Bureau on: 10 AUG 2001</p> <p>Authorized officer Sylvaine DESCLOUX</p>

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
13 December 2001 (13.12.2001)

PCT

(10) International Publication Number
WO 01/094627 A3

(51) International Patent Classification⁷: **G01N 33/50**

(21) International Application Number: **PCT/IB01/01213**

(22) International Filing Date: **8 June 2001 (08.06.2001)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
0014009.5 **8 June 2000 (08.06.2000)** **GB**

(71) Applicant (for all designated States except US): **DEV-GEN NV [BE/BE];** Technologiepark 9, B-9052 Zwijnaarde (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **VERWAERDE, Philippe [FR/FR];** 72, résidence Du Château D'Eau, F-59960 Neuville En Ferrain (FR). **BOGAERT, Thierry [BE/BE];** Wolvendreef 26g, B-8500 Kortrijk (BE).

(74) Agents: **BALDOCK, Sharon, Claire et al.;** Boulton Watt Tennant, Verulam Gardens, 70 Gray's Inn Road, London WC1X 8BT (GB).

(81) Designated States (national): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.**

(84) Designated States (regional): **ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).**

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG)**
- of inventorship (Rule 4.17(iv)) for US only

Published:

- with international search report
- with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description

(88) Date of publication of the international search report:
3 October 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **ASSAY TECHNIQUES BASED ON GROWTH STAGE DEPENDENT EXPRESSION INC. ELEGANS**

(57) Abstract: This invention is directed to new methods to perform assays with nematodes, and more particularly with microscopic nematodes such as *C. elegans*. In particular, the invention provides methods based on the use of growth-stage specific promoters to drive growth-stage specific gene expression.

WO 01/094627 A3

INTERNATIONAL SEARCH REPORT

International Application No
PCT/IB 01/01213A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 G01N33/50

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
MEDLINE, EPO-Internal, WPI Data, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 98 51351 A (GEN HOSPITAL CORP) 19 November 1998 (1998-11-19) cited in the application the whole document	
A	LIU ZHONGCHI ET AL: "The Caenorhabditis elegans heterochronic gene pathway controls stage-specific transcription of collagen genes." DEVELOPMENT (CAMBRIDGE), vol. 121, no. 8, 1995, pages 2471-2478, XP002191574 ISSN: 0950-1991 abstract	
A	WO 99 01552 A (HESCHELER JUERGEN) 14 January 1999 (1999-01-14) claims 1,11-13	

☐ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

G document member of the same patent family

Date of the actual completion of the international search

27 February 2002

Date of mailing of the international search report

15/03/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Niemann, F

INTERNATIONAL SEARCH REPORT
Information on patent family members

International Application No
PCT/IB 01/01213

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9851351	A	19-11-1998	US 6225120 B1	01-05-2001
			AU 7494198 A	08-12-1998
			EP 1019092 A1	19-07-2000
			PL 336858 A1	17-07-2000
			WO 9851351 A1	19-11-1998
			HU 0002199 A2	28-09-2000
WO 9901552	A	14-01-1999	DE 19727962 A1	14-01-1999
			WO 9901552 A1	14-01-1999
			EP 1002080 A1	24-05-2000

THIS PAGE BLANK (USPTO)

Applicant(s): HOPPE, et al.

Serial No.: 10/766,339

Filing Date: 1/28/2004

Docket No.: DEAV2003/0005 US NP

PRIOR ART

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)